[{"ID": "CANIMM/1823", "Drug": "VS-4718- FAK/Pyk2 kinase inhibitor", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB15273", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "25073775", "STR_LINK_(SMILES)": "CNC(=O)C1=CC=CC=C1NC1=CC(NC2=C(OC)C=C(C=C2)N2CCOCC2)=NC=C1C(F)(F)F", "Single/Combination": "Single Drug", "PMID": "26406376", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin Cancer", "Animal_Strain_used": "FVB", "Cell_line_used_to_induce_tumor_in_mice": "SCC tumor cells", "Dose": "75 mg/kg for 24 hr", "Technique": "ELISA, FACS", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "total CD4+ T cells, effector CD4+CD44hiCD62Llow T cells, CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells; CD8+ T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4+CD25+FoxP3+ Treg cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD25 / IL2RA; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": "CD8+CD44hiCD62Llow T cells", "Controlled_Terms_Unaffected": "CD8; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1847", "Drug": "VS-4718- FAK/Pyk2 kinase inhibitor", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB15273", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "25073775", "STR_LINK_(SMILES)": "CNC(=O)C1=CC=CC=C1NC1=CC(NC2=C(OC)C=C(C=C2)N2CCOCC2)=NC=C1C(F)(F)F", "Single/Combination": "Single Drug", "PMID": "27376576", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Ductal Adenocarcinoma (PDA)", "Animal_Strain_used": "bearing orthotopic tumors derived from KI (Kras/INK4A)", "Cell_line_used_to_induce_tumor_in_mice": "KI tumors", "Dose": null, "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tumor-infiltrating myeloid-derived suppressor cells (MDSCs), CD206+ tumor-associated macrophages (TAMs), and CD4+FOXP3+ Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD206 / MRC1; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Tumor-associated macrophages / TAMs; Macrophages; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1848", "Drug": "VS-4718- FAK/Pyk2 kinase inhibitor", "Drug_category": "AKT inhibitor", "Drugbank_ID": "DB15273", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "25073775", "STR_LINK_(SMILES)": "CNC(=O)C1=CC=CC=C1NC1=CC(NC2=C(OC)C=C(C=C2)N2CCOCC2)=NC=C1C(F)(F)F", "Single/Combination": "Single Drug", "PMID": "27376576", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Ductal Adenocarcinoma (PDA)", "Animal_Strain_used": "KPC (p48-Cre/LSL-KrasG12D/p53Flox/+)", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": null, "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tumor-infiltrating F4/80+ and CD206+ macrophages and GR1+ granulocytes tumor cell p-STAT3 expression in PDAC tissue", "Controlled_Terms_Function_inhibited_Number_decreased": "CD206 / MRC1; Macrophages; Neutrophils / granulocytes; STAT3 signaling; Immune-cell infiltration; Pancreatic ductal adenocarcinoma context", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1650", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "14768038", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "Animal_Strain_used": "Syngeneic BD-IX strain rats", "Cell_line_used_to_induce_tumor_in_mice": "PROb", "Dose": "30 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD4+ CD25+ regulatory T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD25 / IL2RA; Regulatory T cells / Tregs; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1667", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "19746156", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Malignant Mesothelioma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "AB1-HA cells", "Dose": "(150 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8 T cells and NK cells IFN-γ TRAIL mediated apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; NK cells; T cells; CD8+ T cells; Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1682", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "21148486", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6 (H-2b ) and . Foxp3DTR", "Cell_line_used_to_induce_tumor_in_mice": "B16F10 cells", "Dose": "100 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IL-17 release increased specifically in CD4 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IL-17 / IL-17A; CD4; T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1683", "Drug": "Cyclophosphamide (CTX)", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "21156650", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "EG7 cells", "Dose": "Injected i.p. 100 mg/kg Cyclophosphamide (CTX)", "Technique": "Confocal Laser Scanning Microscopy (CLSM), qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Microscopy; Confocal microscopy", "Immune_System-Function_enhanced/numbers_increased": "CD11c+I-A+ tumor-infiltrating DC (TIDC ) CXCL10/CXCR3 CD11c , CD86 and MHC II", "Controlled_Terms_Function_enhanced_Number_increased": "CXCL10 / IP-10; CD86; CD11c / ITGAX; MHC class II; Dendritic cells; CXCR3; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1684", "Drug": "Cyclophosphamide (CTX)", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "21156650", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "EG7 cells", "Dose": "Injected i.p. 100 mg/kg Cyclophosphamide (CTX) + IFNy injected peritumorally (105 IU) daily for 4 days starting from day 1 post–CTX treatment", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "B220+ Dendritic cell precursors on day 3 post infection, CD135+ Dendritic cell precursors on day 3 post infection, CD11c+CFSElow cells IFN-α and IFN-β gene expression in the BM", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-α; IFN-β; CD11c / ITGAX; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": "conventional DC subsets (CD8α+ and CD8α−)", "Controlled_Terms_Function_inhibited_Number_decreased": "Dendritic cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1764", "Drug": "Metronomic Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "24965046", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Brain Tumor", "Animal_Strain_used": "ICR/Fox Chase immune deficient male scid", "Cell_line_used_to_induce_tumor_in_mice": "9L cells", "Dose": "140 or 160 mg CPA/kg body weight (BW)/injection (equal to doses of ~150 and 170 mg/kg, respectively, based on CPA-monohydrate", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ MDSC populations", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1815", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "26137402", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioma", "Animal_Strain_used": "C57BL/6 (B6)", "Cell_line_used_to_induce_tumor_in_mice": "GL261 glioma cells", "Dose": "140 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor-associated CD8+ cytotoxic T lymphocyte (CTL) cells, natural killer (NK) cells, macrophages,", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Macrophages; T cells; Cytotoxic T lymphocytes / CTLs", "Immune_System-Function_inhibited/numbers_decreased": "T regs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2024", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "31921384", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 colon carcinoma cells (CRL-2639)", "Dose": "40 mg/kg twice per week i.p. or 16 mg/kg five times per week p.o.", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": "T regs, TAMs, eosinophils", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2029", "Drug": "Cyclophosphamide", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Single Drug", "PMID": "32104586", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon-Cancer Liver Metastasis", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cell", "Dose": "20 mg/mL", "Technique": "Flow Cytometry + Immunohistochemistry + Enzyme-Linked Immunosorbent Assay", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD4+ and CD8+ T cells in the spleen", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4+CD25+FOXP3+ Treg cells IL-10- and TGF-β1-positive cells", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; TGF-β; CD4; CD25 / IL2RA; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2061", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Murine TNBC", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "EMT6", "Dose": "0.15 mg/kg IV, 1×/week", "Technique": "Mouse tumor model; tumor growth", "Controlled_Technique": "Tumor growth/survival analysis", "Immune_System-Function_enhanced/numbers_increased": "Less effective than combination therapy", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2062", "Drug": "Trabectedin", "Drug_category": "Alkylating agents", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Single", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Murine TNBC", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "0.15 mg/kg IV, 1×/week", "Technique": "Mouse tumor model; tumor growth and immune profiling", "Controlled_Technique": "Tumor growth/survival analysis; Immune-cell profiling/phenotyping", "Immune_System-Function_enhanced/numbers_increased": "Reduced MDSCs and M-MDSC/PMN-MDSC subsets", "Controlled_Terms_Function_enhanced_Number_increased": "Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / G-MDSCs", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1843", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug_ID": "D03899", "Drug_Pubchem": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "27345402", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Breast Tumor", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1 cells", "Dose": "5mg/kg", "Technique": "Flow cytometry,Real-time PCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSCs in the spleen", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "infiltration of lung by IL-4+IL-13+CD4+Th2 cells and MDSCs in the lungs", "Controlled_Terms_Negative_Regulation": "IL-4; IL-13; CD4; Myeloid-derived suppressor cells / MDSCs; Th2 cells; Immune-cell infiltration"}, {"ID": "CANIMM/1844", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug_ID": "D03899", "Drug_Pubchem": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "27345402", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Breast Tumor", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "E0771 cells", "Dose": "5mg/kg", "Technique": "Flow cytometry,Real-time PCR,ELISA", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "infiltration of lung by IL-4+IL-13+CD4+Th2 cells", "Controlled_Terms_Negative_Regulation": "IL-4; IL-13; CD4; Th2 cells; Immune-cell infiltration"}, {"ID": "CANIMM/1845", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug_ID": "D03899", "Drug_Pubchem": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "27345402", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Breast Tumor", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1 cells", "Dose": "5mg/kg", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-33", "Controlled_Terms_Negative_Regulation": "IL-33"}, {"ID": "CANIMM/1846", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug_ID": "D03899", "Drug_Pubchem": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "27345402", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Breast Tumor", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1 cells", "Dose": "5mg/kg", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "IL-33 in lung epithelial cells in lung", "Controlled_Terms_Negative_Regulation": "IL-33"}, {"ID": "CANIMM/1925", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis.", "KEGG_Drug_ID": "D03899", "Drug_Pubchem": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single Drug", "PMID": "29500278", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "NSG", "Cell_line_used_to_induce_tumor_in_mice": "MDA-MB-231", "Dose": "(DOXO; 4 mg/kg)", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CCL2 (MCP-1), CCL7 (MCP-3), and CCL8 (MCP-2)-cancer stem-like cell (CSC) phenotype and contributing to tumor relapse", "Controlled_Terms_Negative_Regulation": "CCL2 / MCP-1; CCL7 / MCP-3; CCL8 / MCP-2"}, {"ID": "CANIMM/2126", "Drug": "Doxorubicin", "Drug_category": "Anthracyclines", "Drugbank_ID": "DB00997", "Target/s_or_mechanism_of_action": "DNA intercalation; topoisomerase II inhibition", "KEGG_Drug_ID": "D03899", "Drug_Pubchem": "31703", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "Single/Combination": "Single", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "LLC", "Dose": "25 mg/kg", "Technique": "Flow cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+IFN-γ+ T cells, activated DCs,memory T cells (CD3+CD4+CD62L−)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD3; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD3+CD4+ or CD3+CD8+ T cells", "Controlled_Terms_Unaffected": "CD4; CD8; CD3; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1731", "Drug": "Bleomycin", "Drug_category": "Antibiotic", "Drugbank_ID": "DB00290", "Target/s_or_mechanism_of_action": "Acts by induction of DNA strand breaks", "KEGG_Drug_ID": "C06854", "Drug_Pubchem": "5360373", "STR_LINK_(SMILES)": "[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O", "Single/Combination": "Single Drug", "PMID": "23762310", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - (Colon Carcinoma)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 tumor cells", "Dose": "5 intraperitoneal injections (20 mg/kg) every other day", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "B cells, CD4+ T cells, CD8+ T cells, NK cells, dendritic cells, monocytes/macrophages or MDSC", "Controlled_Terms_Unaffected": "CD4; CD8; Myeloid-derived suppressor cells / MDSCs; Macrophages; Monocytes; Dendritic cells; NK cells; B cells; T cells; CD8+ T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Foxp3+ Treg TGFβ", "Controlled_Terms_Negative_Regulation": "TGF-β; FOXP3; Regulatory T cells / Tregs"}, {"ID": "CANIMM/1716", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "22934253", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "B16F10 cells", "Dose": "a chow diet containing 417 mg/kg PLX4720", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "T cells, B cells, NK cells, MDSCs or macrophages", "Controlled_Terms_Unaffected": "Myeloid-derived suppressor cells / MDSCs; Macrophages; NK cells; B cells; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1717", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "22934253", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "Tyr::CreERT2PTENF−/−BRAFF-V600E/+", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "a chow diet containing 417 mg/kg PLX4720", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD45+ leukocytes, CD8+ and CD4+ T cells in the melanomas ,frequency of NK-cells, myeloid derived suppressor cells (MDSCs), macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; CD45; Myeloid-derived suppressor cells / MDSCs; Macrophages; T cells; CD4+ T cells", "Immune_System_function_unaffected": "B220+CD19+ B-lymphocytes", "Controlled_Terms_Unaffected": "CD19; B cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1724", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "23454771", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1", "Dose": "20 mg/kg i.p.)", "Technique": "SDS-PAGE", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CCR2+ tumor-infiltrating\n leukocytes (TILs), NK cells (NK1.1+ TCRβ–), CD8+ T cells (CD8+ TCRβ+), CD8/Treg ratio DNAM-1 ligand, CD155;\n the nonclassical MHC, CD1d; and PD-L1,Fas and DR5", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD155 / PVR; PD-L1 / CD274; Regulatory T cells / Tregs; NK cells; T cells; CD8+ T cells; Tumor-infiltrating lymphocytes / TILs; Immune checkpoint pathway; CCR2; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "Tregs (CD4+ Foxp3+), pERK, CCL2", "Controlled_Terms_Function_inhibited_Number_decreased": "CCL2 / MCP-1; CD4; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": "total T cells (NK1.1– TCRβ+), CD4+ T cells\n (CD4+ TCRβ+), CD11b+ Gr-1+ myeloid cells", "Controlled_Terms_Unaffected": "CD4; CD11b / ITGAM; T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1754", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "24736544", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "Braf/Pten", "Cell_line_used_to_induce_tumor_in_mice": "1μl 4-hydroxytamoxifen (4-HT) (8mg/ml in ethanol) topically on the back skin and examined every week for melanoma growth", "Dose": "(417mg PLX4720/kg) for another 21 days", "Technique": "Flow Cytometry, Immunohistochemical Staining", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD4 and CD8 T lymphocytes infiltrating PLX4720-treated melanomas, maturation status of both TAMs and TIDCs CD4 T cells produced IFNγ (i.e., TH1 cells) CD40L on intratumoral CD4 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD40L / CD154; Tumor-associated macrophages / TAMs; Dendritic cells; T cells; Th1 / type 1 T-cell response; CD8+ T cells; CD4+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "intratumoral CD11b+/Gr-1+ cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM", "Immune_System_function_unaffected": "CD4 T cell production of IL-2 and TNFα.", "Controlled_Terms_Unaffected": "IL-2; TNF-α / TNF; CD4; T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-1+ CD4 T cells", "Controlled_Terms_Negative_Regulation": "CD4; PD-1 / PDCD1; T cells; CD4+ T cells"}, {"ID": "CANIMM/1755", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "24736544", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BrafV600E/Pten", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "417mg/kg PLX4720", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ and CD8+ T cells, FoxP3− CD4+ T cells, TH1 cells, CD40L+ CD4+ T cells, PD-1+ CD4+ T cells IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD40L / CD154; PD-1 / PDCD1; FOXP3; T cells; Th1 / type 1 T-cell response; CD8+ T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "FoxP3+ Treg CD4+ T cells and CD11b+/Gr-1+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD11b / ITGAM; FOXP3; Regulatory T cells / Tregs; T cells; CD4+ T cells", "Immune_System_function_unaffected": "IL-2 and TNFα.", "Controlled_Terms_Unaffected": "IL-2; TNF-α / TNF", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1766", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "24994118", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "Animal_Strain_used": "B6129SF1/J", "Cell_line_used_to_induce_tumor_in_mice": "TBP-3743", "Dose": "PLX4720-impregnated chow (417 mg/kg", "Technique": "Immunohistochemical Analysis", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cell infiltration was observed in tumors, infiltrating B220+ B cells, marker of monocytes and macrophages, F4/80 Caspase 3 cleavage- marker of apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Macrophages; Monocytes; B cells; T cells; CD8+ T cells; Apoptosis / caspase activation; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1767", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "24994118", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer - (Anaplastic)", "Animal_Strain_used": "B6129SF1/J syngeneic", "Cell_line_used_to_induce_tumor_in_mice": "105 TBP-3743 cells", "Dose": "PLX4720-impregnated\n chow (417 mg/kg),", "Technique": "Immunohistochemial Analysis", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1774", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "25183499", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "Tyr::CreER+/−BrafCA/+Ptenlox/lox(Braf/Pten) - bred onto a B6 background", "Cell_line_used_to_induce_tumor_in_mice": "intradermal injection of 4-hydroxy-tamoxifen (10μl of a 20 μM solution in DMSO)", "Dose": "(417 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8 T cells by proportion of CD45+ cells, but not by absolute number, CD4 T cells by the proportion of CD45+ cells but not the absolute number", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD45; T cells; CD8+ T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "Foxp3+ Tregs in the tumor microenvironment, myeloid-derived suppressor cells (MDSC)-CD11b+Gr1+ cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD4 T-cell expression of transcription factors T-bet, GATA3, and RORγt", "Controlled_Terms_Unaffected": "CD4; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1834", "Drug": "BRAFi PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "Animal_Strain_used": "B6129SF1/J", "Cell_line_used_to_induce_tumor_in_mice": "105 genetically engineered murine ATC; TBP 3743\n BRAFV600E/WT P53-/- cells", "Dose": "PLX4720-impregnated chow (417 mg/kg)", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1868", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "28123875", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "D4M.3A mouse melanoma cells", "Dose": "BRAFi [B] PLX4720 was provided in chow; MEKi [M] trametinib was dosed by daily oral gavage at 15 µg (on average 0.75 mg/kg); PI3Ki [P] BKM120 daily oral gavage at 400 µg (on average 20 mg/kg)", "Technique": "Flow Cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "intratumoral IFNγ positive CD8+ T cells The infiltrating CD8+ T cells expressed high levels of PD-1 in about 50% of the cells , a marker shown to be associated with tumor-antigen-specific T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; PD-1 / PDCD1; T cells; CD8+ T cells; Antigen-specific recognition; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1942", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "30327563", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid - Anaplastic Thyroid Cancer", "Animal_Strain_used": "B6129SF1/J", "Cell_line_used_to_induce_tumor_in_mice": "TBP-3743 cells(105)", "Dose": "PLX4720PLX4720-impregnated chow (417 mg/kg body weight), (n=\n 14, 7 for each timepoint at 1 week and 2 weeks)", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ cytotoxic T cells, granzyme B , and FoxP3+ T cells, NK cells, F4/80+CD206− cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD206 / MRC1; FOXP3; NK cells; T cells; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "monocytic MDSCs(CD11b+ Ly6G−Ly6C+)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs", "Immune_System_function_unaffected": "F4/80+CD206+IA/IE+ and F4/\n 80+CD206+IA/IE− cells (M2-polarised subsets) IFNγ", "Controlled_Terms_Unaffected": "IFN-γ; CD206 / MRC1; M2 macrophage phenotype", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1964", "Drug": "Trametinib", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Drug_Pubchem": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Single Drug", "PMID": "30771521", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "PKL (Lung tumors were induced by Ad-Cre in the transgenic mouse model)", "Cell_line_used_to_induce_tumor_in_mice": "3 × 105 PKL5–2 cells into the right flank of mice", "Dose": "trametinib for three days prior to initiation of combination or Single treatment+ trametinib (0.25, 0.5, and 1 mg/kg) continued for three weeks", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PMN-MDSCs, CD45+/CD11b+/Ly6Ghigh/Ly6Clow", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / granulocytic MDSCs", "Immune_System_function_unaffected": "percentage of CD4+ and CD8+ cells, monocytic-MDSCs CD45+/CD11b+/Ly6G-/Ly6Chigh,", "Controlled_Terms_Unaffected": "CD4; CD8; CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2007", "Drug": "PLX4720", "Drug_category": "BRAF inhibitor", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Single Drug", "PMID": "31702822", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "BRAFV600E/PTEN D4M-3A (RRID:CVCL_0P27)25 murine\n melanoma cell line", "Dose": "\"3 × 105 D4M cells injected subcutaneously (s.c.)+ after 8 days BRAFi containg Chow(417 mg PLX4720/kg) +2 mg/kg of\n the TLR7A at Day 19 (middle of sensitive phase)\"", "Technique": "Flow cytometry, qRT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD45+ immune cells, In BRAFi-sensitive tumors, more T\n and NK cells when compared to untreated tumors increased mRNA levels for chemokines CCL2, CCL3, CCL4, CXCL9, CXCL10 and cytokines IL-\n 12a, IL-12b, IL-15, IL-18 in BRAFi-sensitive tumors. IL-10 and TGF-β1 were also highly expressed in BRAFisensitive\n tumors, NK cells, CD4+ T cells and\n CD8+ T cells produced more IFN-γ in BRAFi-sensitive tumors, TNF-α+ cells CD4+ T cells and\n CD8+ T cells from BRAFi-sensitive tumors, granzyme B-positive\n cells CD69 in BRAFi-sensitive\n tumors on T cells, the inhibitory ligands PD-L1 as well as PD-L2 were\n expressed at higher levels in BRAFi-sensitive\n tumors gp100 and trp-2 in BRAFi-sensitive tumors, NKG2D+ cells were significantly higher on\n both NK and T cells in BRAFi-sensitive mice", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-10; IL-12; IL-18; TNF-α / TNF; TGF-β; CCL2 / MCP-1; CCL3 / MIP-1α; CCL4 / MIP-1β; CXCL9 / MIG; CXCL10 / IP-10; CD4; CD8; CD69; CD45; PD-L1 / CD274; PD-L2 / PDCD1LG2; NK cells; T cells; CD8+ T cells; CD4+ T cells; Granzyme B / GZMB; NKG2D ligand / receptor pathway; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "infiltrating NK cells were decreased in the\n BRAFi resistant tumors mRNA levels for CCL2, CCL3, CCL4, CXCL9 and\n CXCL10 and cytokines IL-\n 12a, IL-12b, IL-15, IL-18 in in BRAFi resistant tumors. IL-10 and TGF-β1 were also highly expressed in in BRAFi resistant tumors PD-1 Decreased in BRAFisensitive\n tumors gp100 and trp-2 in BRAFi resistant tumors, NKG2D+ cells were significantly higher on\n both NK and T cells in BRAFi-resistant mice", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; IL-12; IL-18; TGF-β; CCL2 / MCP-1; CCL3 / MIP-1α; CCL4 / MIP-1β; CXCL9 / MIG; CXCL10 / IP-10; PD-1 / PDCD1; NK cells; T cells; NKG2D ligand / receptor pathway; Immune-cell infiltration", "Immune_System_function_unaffected": "TNF-α secretion did not change in NK cells TIM-3", "Controlled_Terms_Unaffected": "TNF-α / TNF; NK cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2045", "Drug": "Abemaciclib", "Drug_category": "CDK4 protein kinase inhibitor", "Drugbank_ID": "DB12001", "Target/s_or_mechanism_of_action": "Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells", "KEGG_Drug_ID": "D10688", "Drug_Pubchem": "46220502", "STR_LINK_(SMILES)": "CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1", "Single/Combination": "Single Drug", "PMID": "32929370", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "ID8 (ID8-luc) cells", "Dose": "Abemaciclib (CDK4/6i)-(50 mg/kg)", "Technique": "Immunohistochemistry (IHC) and\n Immunofluorescence (IF)", "Controlled_Technique": "Immunohistochemistry (IHC); Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "CD45+ cells, CD8+ cells, CD19+ cells and PD-L1+ cells in ID8 tumors, IFN-y+ CD107 a+, CD8+ cells and IFN-y+ CD107 a+, CD4+foxp3- T cell, IFN-γ producing B cells, CD40+CD80+ CD86+ DCs, MHCII+ cells T bet CD69", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD69; CD80; CD86; CD40; CD45; CD19; PD-L1 / CD274; MHC class II; FOXP3; Dendritic cells; B cells; T cells; IFN-γ-producing cells; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "CD11B+Gr-1+ myeloid-derived suppressor cell\n (MDSC), IL-10 producing B cells, CD206+ cells", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; CD11b / ITGAM; CD206 / MRC1; Myeloid-derived suppressor cells / MDSCs; B cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1988", "Drug": "AZD5069 (αCXCR2)", "Drug_category": "CXCR2 antagonist", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "56645576", "STR_LINK_(SMILES)": "CC(C(CO)O)OC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F", "Single/Combination": "Single Drug", "PMID": "31433989", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "C57BL/6N", "Cell_line_used_to_induce_tumor_in_mice": "2.5x106 Pten−/−-TRAMP-C1 cells", "Dose": "αCXCR2 (AZD5069) 100mg/kg daily for a period of 3 weeks + neutralizing antibody for TNFα", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "p16 levels", "Controlled_Terms_Function_inhibited_Number_decreased": "p16 levels", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1989", "Drug": "AZD5069 (αCXCR2)", "Drug_category": "CXCR2 antagonist", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "56645576", "STR_LINK_(SMILES)": "CC(C(CO)O)OC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F", "Single/Combination": "Single Drug", "PMID": "31433989", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "C57BL/6N", "Cell_line_used_to_induce_tumor_in_mice": "2.5x106 Pten−/−-TRAMP-C1 cells", "Dose": "αCXCR2 (AZD5069) 100mg/kg daily for a period of 3 weeks", "Technique": "Flow cytometry, Q-PCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "F4/80+CD11c+CD206− pro-inflammatory TAMs, CD4+ CD25high T regulatory cells TNFα p16, pH2AX foci, and GATA4", "Controlled_Terms_Function_enhanced_Number_increased": "TNF-α / TNF; CD4; CD11c / ITGAX; CD206 / MRC1; Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1990", "Drug": "AZD5069 (αCXCR2)", "Drug_category": "CXCR2 antagonist", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "56645576", "STR_LINK_(SMILES)": "CC(C(CO)O)OC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F", "Single/Combination": "Single Drug", "PMID": "31433989", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "Ptenpc−/−", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "αCXCR2 (AZD5069) 100mg/kg daily for a period of 3 weeks", "Technique": "Flow cytometry, Q-PCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "F4/80+CD11c+CD206− pro-inflammatory TAMs, CD4+ and CD8+ T cells in the treated tumors, CD4+ CD25high T regulatory cells TNFα, granzyme B GATA4, pHP1γ and p16", "Controlled_Terms_Function_enhanced_Number_increased": "TNF-α / TNF; CD4; CD8; CD11c / ITGAX; CD206 / MRC1; Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs; T cells; CD8+ T cells; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "F4/80+CD11c+/−CD206+ cells arginase and CD206 levels Ki-67 staining ,", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11c / ITGAX; CD206 / MRC1; Cell proliferation / Ki-67", "Immune_System_function_unaffected": "CD45+CD11b+LY6G−F4/80+macrophages", "Controlled_Terms_Unaffected": "CD11b / ITGAM; CD45; Macrophages", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1991", "Drug": "AZD5069 (αCXCR2)", "Drug_category": "CXCR2 antagonist", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "56645576", "STR_LINK_(SMILES)": "CC(C(CO)O)OC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F", "Single/Combination": "Single Drug", "PMID": "31433989", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "Ptenpc−/−; Trp53pc−/−", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "αCXCR2 (AZD5069) 100mg/kg daily for a period of 3 weeks", "Technique": "Flow cytometry, Q-PCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "F4/80+CD11c+CD206− pro-inflammatory TAMs, CD4+ and CD8+ T cells in the treated tumors, CD4+ CD25high T regulatory cells TNFα, granzyme B GATA4, pHP1γ and p16", "Controlled_Terms_Function_enhanced_Number_increased": "TNF-α / TNF; CD4; CD8; CD11c / ITGAX; CD206 / MRC1; Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs; T cells; CD8+ T cells; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "F4/80+CD11c+/−CD206+ cells arginase and CD206 levels Ki-67 staining ,", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11c / ITGAX; CD206 / MRC1; Cell proliferation / Ki-67", "Immune_System_function_unaffected": "CD45+CD11b+LY6G−F4/80+macrophages", "Controlled_Terms_Unaffected": "CD11b / ITGAM; CD45; Macrophages", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1892", "Drug": "NU7441", "Drug_category": "DNA-dependent protein kinase (DNA-PK) Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor", "KEGG_Drug_ID": null, "Drug_Pubchem": "11327430", "STR_LINK_(SMILES)": "C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56", "Single/Combination": "Single Drug", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "B16-F1", "Dose": "NU7026 (6 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2032", "Drug": "VPA (valpromide)", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug_ID": "D00399", "Drug_Pubchem": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "32158627", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "B16-F10", "Dose": "VPA (500 mg/kg) untill day 15", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells (CD3ɛ−NK1.1+) and CD8+ T-cells\n (CD3ɛ+CD4−CD8α+) in tumors, CD69hi cells in CD8+ T -cells (CD3ɛ+CD8α+CD4−) and NK cells (CD3ɛ−NK1.1+) CCR2 on monocytic (M)-MDSCs", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; Myeloid-derived suppressor cells / MDSCs; NK cells; T cells; CCR2", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs (CD11b+Gr-1+),PMN-MDSCs (CD11b+Ly6int), M-MDSCs (CD11b+Ly-6Chi)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / granulocytic MDSCs", "Immune_System_function_unaffected": "TAMs (CD11b+Ly-6C−Ly-6G−F4/80+),Tregs (CD4+CD8α−CD25+)", "Controlled_Terms_Unaffected": "CD4; CD25 / IL2RA; CD11b / ITGAM; Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2033", "Drug": "VPA (valpromide)", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug_ID": "D00399", "Drug_Pubchem": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "32158627", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "EL4", "Dose": "VPA (500 mg/kg) untill day 13", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells (CD3ɛ−NK1.1+) and CD8+ T-cells\n (CD3ɛ+CD4−CD8α+) in tumors, CD69hi cells in CD8+ T -cells (CD3ɛ+CD8α+CD4−) and NK cells (CD3ɛ−NK1.1+) CCR2 on monocytic (M)-MDSCs", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; Myeloid-derived suppressor cells / MDSCs; NK cells; T cells; CCR2", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs (CD11b+Gr-1+),", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "TAMs (CD11b+Ly-6C−Ly-6G−F4/80+),Tregs (CD4+CD8α−CD25+)", "Controlled_Terms_Unaffected": "CD4; CD25 / IL2RA; CD11b / ITGAM; Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2034", "Drug": "VPA (valpromide)", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug_ID": "D00399", "Drug_Pubchem": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "32158627", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "EL4", "Dose": "VPA (500 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2035", "Drug": "VPA (valpromide)", "Drug_category": "Fatty acid derivatives", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug_ID": "D00399", "Drug_Pubchem": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Single Drug", "PMID": "32158627", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "B16-F10", "Dose": "VPA(500 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1703", "Drug": "Entinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "22303460", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "Animal_Strain_used": "BALB/c mouse", "Cell_line_used_to_induce_tumor_in_mice": "RENCA", "Dose": "entinostat (5 mg/kg, daily, 5 d/wk by oral gavage)", "Technique": "Flow Cytometry,Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Foxp3 levels in Tregs, Tregs infiltrating the tumors", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1705", "Drug": "Entinostat", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "22303460", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer -Castration Resistant Prostate Cancer", "Animal_Strain_used": "male FVB", "Cell_line_used_to_induce_tumor_in_mice": "CR Myc-CaP tumors", "Dose": "entinostat (5 days/wk, 5 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Foxp3 level in Tregs of tumor-bearing mice", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1740", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug_ID": "D10019", "Drug_Pubchem": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "23963286", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL6 or immunodeficient B6.129S7-Rag1tm1Mom/J", "Cell_line_used_to_induce_tumor_in_mice": "B16", "Dose": "25mg/kg LBH589", "Technique": "Survival Analysis", "Controlled_Technique": "Survival analysis (Kaplan–Meier)", "Immune_System-Function_enhanced/numbers_increased": "adaptive immune system", "Controlled_Terms_Function_enhanced_Number_increased": "adaptive immune system", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1946", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D06320", "Drug_Pubchem": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "Female nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "NCI-H460 (lung)", "Dose": "vorinostat (150 mg/kg, p.o.).", "Technique": "Immunofluorescence, Fluorescent Image Intensity", "Controlled_Technique": "Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1743", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "24203492", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Fibrosarcoma Lung Metastasis", "Animal_Strain_used": "NOD.Cg-Rag1tm1MomPrf1tm1Sdz/SzJ", "Cell_line_used_to_induce_tumor_in_mice": "HT1080.eGFP-FFLuc tumor cells", "Dose": "752 ng entinostat via intraperitoneal administration (in 0.1 mL PBS), or 8 × 106 IL-2-activated NK cells (in 0.2 mL PBS) by tail-vein injection", "Technique": "In Vivo Bioluminescent Imaging", "Controlled_Technique": "Bioluminescence/luciferase assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell significantly lower tumor burden", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1792", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug_ID": null, "Drug_Pubchem": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "25745993", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "EL4 lymphoma cells", "Dose": "1μM/kg TSA", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ CD62L− activated T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1793", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug_ID": null, "Drug_Pubchem": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "25745993", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6 and nude ,Rag1−/−,β2m−/− , CIITA−/−,gld/gld", "Cell_line_used_to_induce_tumor_in_mice": "B16F0 cells", "Dose": "1 μm/kg or 3 μm/kg TSA was injected i.p. every 2 days", "Technique": "Flow Cytometry, Immunohistochemistry,Real-Time Pcr", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD4+ CD62L− activated T cells,effector memory T cells interleukin-2 (IL-2), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and granulocyte-macrophage colony stimulating factor (GM-CSF)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; TNF-α / TNF; GM-CSF / CSF2; CD4; Macrophages; Neutrophils / granulocytes; T cells", "Immune_System-Function_inhibited/numbers_decreased": "FasL-mediated AICD of tumor-infiltrating CD4+ T", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1810", "Drug": "Nexturastat A", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "71462653", "STR_LINK_(SMILES)": "CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6 /Nexturastat A", "Cell_line_used_to_induce_tumor_in_mice": "B16–F10", "Dose": "25 mg/kg", "Technique": "Blocking Antibodies", "Controlled_Technique": "Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": "delayed tumor growth-Anti‐tumor activity in vivo is dependent on intact immunity", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1811", "Drug": "Tubastatin A", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "HDAC6 inhibitor", "KEGG_Drug_ID": null, "Drug_Pubchem": "49850262", "STR_LINK_(SMILES)": "CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO", "Single/Combination": "Single Drug", "PMID": "25957812", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "B16–F10", "Dose": "25 mg/kg", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "delayed tumor growth", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1817", "Drug": "LBH589 (Panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug_ID": "D10019", "Drug_Pubchem": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26176219", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Wilms Tumor ( Embryonic Kidney Cancer)", "Animal_Strain_used": "nude", "Cell_line_used_to_induce_tumor_in_mice": "SK-NEP-1 cells", "Dose": "LBH589 10mg/kg and 20mg/kg dose three times per wee", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1821", "Drug": "LBH589 (panobinostat)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug_ID": "D10019", "Drug_Pubchem": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "B16F10", "Dose": "LBH589 (15mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1, PD-L2 expression in melanoma cell", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1837", "Drug": "Romidepsin", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug_ID": "D06637", "Drug_Pubchem": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Single Drug", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "129S4/SvJaeJ", "Cell_line_used_to_induce_tumor_in_mice": "LKR cells", "Dose": "(2mg/kg on days 14,16,18)", "Technique": "RT-PCR, Flow cytometry,Microarray studies", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "T cell, CD8 T cell infiltration of tumor T cell chemokines-Ccl5 and Cxcl9/10", "Controlled_Terms_Function_enhanced_Number_increased": "CCL5 / RANTES; CXCL9 / MIG; CD8; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1882", "Drug": "Ricolinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug_ID": "D10661", "Drug_Pubchem": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "28408401", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Animal_Strain_used": "Genetically engineered harboring Kras+/LSL-G12DTrp53L/L (KP) or EGFRLSL-T790M/L858R (TL)", "Cell_line_used_to_induce_tumor_in_mice": "For lung tumor induction, mice received 1 × 106 CFU Cre-encoding adenovirus intranasally at 5–6 weeks of age", "Dose": "50 mg/kg daily", "Technique": "Flow cytometry, Single cell RNA sequencing", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis; Single-cell RNA sequencing", "Immune_System-Function_enhanced/numbers_increased": "tumor-infiltrating CD8+ T cells IFN-γ activation marker CD69-on tumor-infiltrating CD8+ T cells, Cd69, Cd44, Cd247, and Zap70- -on tumor-infiltrating T cells, MHC class II as well as co-stimulatory molecule CD86on TAMs", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; CD69; MHC class II; Tumor-associated macrophages / TAMs; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "CD4+Foxp3+ Treg cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1902", "Drug": "Trichostatin A (TSA)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug_ID": null, "Drug_Pubchem": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Single Drug", "PMID": "28871002", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "BALB/c nude", "Cell_line_used_to_induce_tumor_in_mice": "Hepa1-6 carcinoma", "Dose": "TSA (30 mg/kg) was administered every day for 18 days via an intraperitoneal (i.p.) route", "Technique": "Blocking Antibodies To Deplete NK Cells, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells, infiltrated NK cells in the tumor reduced the Hepa1-6 tumor size", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1945", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "Female nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "NCI-H460 (lung)", "Dose": "entinostat (20 mg/kg, p.o.)", "Technique": "Immunofluorescence, Fluorescent Image Intensity", "Controlled_Technique": "Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2167", "Drug": "NextA", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Promotes M1 macrophage polarization and decreases M2 macrophages", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38414061", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Murine melanoma", "Animal_Strain_used": "C57BL/6 mice", "Cell_line_used_to_induce_tumor_in_mice": "SM1 melanoma cells", "Dose": "20 mg/kg every other day", "Technique": "In vivo melanoma model; immune-cell analysis", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "M1 macrophages", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages", "Immune_System-Function_inhibited/numbers_decreased": "M2 macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1947", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "Female nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "DU145 (prostate)", "Dose": "entinostat (20 mg/kg, p.o.)", "Technique": "Immunofluorescence, Fluorescent Image Intensity", "Controlled_Technique": "Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1948", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "Female nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "PC-3 (prostate)", "Dose": "entinostat (20 mg/kg, p.o.)", "Technique": "Immunofluorescence, Fluorescent Image Intensity", "Controlled_Technique": "Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1949", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D06320", "Drug_Pubchem": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "Female nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "DU145 (prostate)", "Dose": "vorinostat (150 mg/kg, p.o.).", "Technique": "Immunofluorescence, Fluorescent Image Intensity", "Controlled_Technique": "Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1950", "Drug": "Vorinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D06320", "Drug_Pubchem": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30377559", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "Female nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "PC-3 (prostate)", "Dose": "vorinostat (150 mg/kg, p.o.).", "Technique": "Immunofluorescence, Fluorescent Image Intensity", "Controlled_Technique": "Immunofluorescence assay; Immunostaining/image analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "PD-L1 expression", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1951", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "30423192", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "Immunocompetent C57BL/6 , Rag1 knockout", "Cell_line_used_to_induce_tumor_in_mice": "ID8 cells", "Dose": "14 days of treatment with entinostat 20 mg/kg", "Technique": "NanoString® assay,Flow cytometry", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "intratumoral accumulation of cytotoxic CD8+ T cells interferon gamma (IFNγ) granzyme B, CXCL10, PD-L1, MHCI alpha chains as well as CIITA, MHCII expression on tumor/stromal cells reduce ovarian tumor size and prolong survival", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL10 / IP-10; CD8; PD-L1 / CD274; MHC class II; MHC class I; CIITA; T cells; CD8+ T cells; Granzyme B / GZMB; Immune checkpoint pathway; Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": "FoxP3 expression, LAG3 and BTLA", "Controlled_Terms_Function_inhibited_Number_decreased": "LAG-3; BTLA; FOXP3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1952", "Drug": "Vorinostat (SAHA)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D06320", "Drug_Pubchem": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "30537988", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastric Cancer (GC)", "Animal_Strain_used": "615", "Cell_line_used_to_induce_tumor_in_mice": "MFC cells", "Dose": "daily dose of 20 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "infiltrating CD8+ T cells slower tumor growth", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells; Immune-cell infiltration; Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": "B7-H1-positive tumor cells", "Controlled_Terms_Function_inhibited_Number_decreased": "B7-H1 (PD-L1)-positive tumor cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1985", "Drug": "ACY1215", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug_ID": "D10661", "Drug_Pubchem": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Single Drug", "PMID": "31311810", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "ARID1Aflox/flox/PIK3CAH1047R OCCC mouse model", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "ACY1215 (50 mg/kg, daily)", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD69+ activated CD4 and CD8 T cells, IFNγ+ CD4 and CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD69; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "Granzyme B+ CD8 T cells or Foxp3+ regulatory T cells", "Controlled_Terms_Unaffected": "CD8; FOXP3; Regulatory T cells / Tregs; T cells; CD8+ T cells; Granzyme B / GZMB", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2016", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "TS/A tumor cells", "Dose": "20 mg/kg ENT", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells in TME granzyme B and IFNγ MHCII-expressing on tumor cells, CIITA, CD74, and MHCII (IAα and IEβ1) , surface expression of MHCI and FAS on CD45neg cells, PD-L1 on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; PD-L1 / CD274; MHC class II; MHC class I; CIITA; T cells; CD8+ T cells; Granzyme B / GZMB; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2018", "Drug": "Panobinostat (LBH589)", "Drug_category": "Histone deacetylase inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug_ID": "D10019", "Drug_Pubchem": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Single Drug", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "TS/A tumor cells", "Dose": null, "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "MHCII-expressing on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2055", "Drug": "Domatinostat (4SC-202)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Class I HDAC inhibition; modulation of tumor immune microenvironment", "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Single", "PMID": "31703604", "Cancer_Type": "Adenocarcinoma", "Cancer_Type_Description": null, "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "C38 murine colon carcinoma", "Dose": "20 mg/kg twice daily", "Technique": "Flow cytometry; immune-cell phenotyping", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Intratumoral CTLs increased to approximately 22%; effector-memory CTL (CD44+CD62L−)phenotype increased; Ki67+ CTLs increased; activated/proliferating CTLs increased; IFN-gamma-associated activity increased", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; T cells; Cell proliferation / Ki-67", "Immune_System-Function_inhibited/numbers_decreased": "NR", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "NR", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-1/LAG3 double-positive CTLs increased; indicates compensatory inhibitory regulation", "Controlled_Terms_Negative_Regulation": "PD-1 / PDCD1; LAG-3"}, {"ID": "CANIMM/2064", "Drug": "B102", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PARP1/PARP2 + HDAC inhibition; DNA damage → cGAS-STING → type-I IFN signaling; promotes antigen presentation", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38182579", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Triple-negative breast cancer", "Animal_Strain_used": "Female M-NSG", "Cell_line_used_to_induce_tumor_in_mice": "MDA-MB-436", "Dose": "15 mg/kg", "Technique": "Immunofluorescence ,western blotting; RT-qPCR", "Controlled_Technique": "Immunofluorescence assay; Western blot/immunoblot analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "IFNβ, CCL5, CXCL10, activation of the cGAS–STING signaling pathway", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-β; CCL5 / RANTES; CXCL10 / IP-10; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 ↑", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2065", "Drug": "B102", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PARP1/PARP2 + HDAC inhibition; DNA damage → cGAS-STING → type-I IFN signaling; promotes antigen presentation", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38182579", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Triple-negative breast cancer", "Animal_Strain_used": "Female BALB/c nude", "Cell_line_used_to_induce_tumor_in_mice": "MDA-MB-231", "Dose": "15 mg/kg", "Technique": "Immunofluorescence ,western blotting; RT-qPCR", "Controlled_Technique": "Immunofluorescence assay; Western blot/immunoblot analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "IFNβ, CCL5, CXCL10, activation of the cGAS–STING signaling pathway", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-β; CCL5 / RANTES; CXCL10 / IP-10; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 ↑", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2066", "Drug": "B302", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PARP1/PARP2 + HDAC inhibition; DNA damage → cGAS-STING → IFNβ/JAK-STAT signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38182579", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Triple-negative breast cancer", "Animal_Strain_used": "Female M-NSG", "Cell_line_used_to_induce_tumor_in_mice": "MDA-MB-436", "Dose": "50 mg/kg", "Technique": "Immunofluorescence ,western blotting; RT-qPCR", "Controlled_Technique": "Immunofluorescence assay; Western blot/immunoblot analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "IFNβ, CCL5, CXCL10, activation of the cGAS–STING signaling pathway", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-β; CCL5 / RANTES; CXCL10 / IP-10; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 ↑", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2067", "Drug": "B302", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PARP1/PARP2 + HDAC inhibition; DNA damage → cGAS-STING → IFNβ/JAK-STAT signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38182579", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Triple-negative breast cancer", "Animal_Strain_used": "Female BALB/c nude", "Cell_line_used_to_induce_tumor_in_mice": "MDA-MB-231", "Dose": "50 mg/kg", "Technique": "Immunofluorescence ,western blotting; RT-qPCR", "Controlled_Technique": "Immunofluorescence assay; Western blot/immunoblot analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "IFNβ, CCL5, CXCL10, activation of the cGAS–STING signaling pathway", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-β; CCL5 / RANTES; CXCL10 / IP-10; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 ↑", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2068", "Drug": "B302", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PARP1/PARP2 + HDAC inhibition; DNA damage → cGAS-STING → IFNβ/JAK-STAT signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38182579", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Triple-negative breast cancer", "Animal_Strain_used": "Female BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "50 mg/kg", "Technique": "Immunofluorescence ,western blotting; RT-qPCR", "Controlled_Technique": "Immunofluorescence assay; Western blot/immunoblot analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "IFNβ, CCL5, CXCL10, activation of the cGAS–STING signaling pathway", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-β; CCL5 / RANTES; CXCL10 / IP-10; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 ↑", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2069", "Drug": "Entinostat (ENT/MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibitors", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "TS/A", "Dose": "20 mg/kg/day", "Technique": "Nanostring, RT-qPCR, flow cytometry, TCR repertoire sequencing, T-cell restimulation", "Controlled_Technique": "Gene expression/sequencing analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-II , MHC-I , CD74 , class II transcriptional activator (CIITA), granzyme B (GZMB), perforin (PRF-1), interferon-γ\n(IFNG), and l-selectin (SELL),CXCL10, CXCL13, CD8/Treg ratio", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL10 / IP-10; CXCL13; CD8; Regulatory T cells / Tregs; Granzyme B / GZMB; Perforin / PRF1; MHC class I; MHC class II; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "Treg cells, FOXP3 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1, PD-L2, inhibitory immune-ligand expression", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L2"}, {"ID": "CANIMM/2070", "Drug": "Panobinostat (PAN/LBH589)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "HDAC inhibitors", "KEGG_Drug_ID": "D10319", "Drug_Pubchem": "6918837", "STR_LINK_(SMILES)": "CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO", "Single/Combination": "Single", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "TS/A", "Dose": "20 mg/kg/day", "Technique": "Nanostring, RT-qPCR, flow cytometry, TCR repertoire sequencing, T-cell restimulation", "Controlled_Technique": "Gene expression/sequencing analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-II , MHC-I , CD74 , class II transcriptional activator (CIITA), granzyme B (GZMB), perforin (PRF-1), interferon-γ\n(IFNG), and l-selectin (SELL),CXCL10, CXCL13, CD8/Treg ratio", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL10 / IP-10; CXCL13; CD8; Regulatory T cells / Tregs; Granzyme B / GZMB; Perforin / PRF1; MHC class I; MHC class II; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "Treg cells, FOXP3 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1, PD-L2, inhibitory immune-ligand expression", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L2"}, {"ID": "CANIMM/2071", "Drug": "Panobinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Pan-HDAC inhibition → epigenetic modulation, apoptosis and growth inhibition", "KEGG_Drug_ID": "D10319", "Drug_Pubchem": "6918837", "STR_LINK_(SMILES)": "CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO", "Single/Combination": "Single", "PMID": "34531855", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "Animal_Strain_used": "C57BL/6 mice", "Cell_line_used_to_induce_tumor_in_mice": "RMA-S (4 X 105 cells/mice)", "Dose": "Panobinostat (10 mg/kg) three times a week", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK-cell numbers, CD69+ NK cells, CD107A+ NK cells, activating receptors NKG2D and CD226 NK", "Controlled_Terms_Function_enhanced_Number_increased": "CD69; CD107a; NK cells", "Immune_System-Function_inhibited/numbers_decreased": "inhibitory receptors PD-1, NKG2A and Ly49I/C", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2072", "Drug": "B102", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "PARP1/PARP2 + HDAC inhibition; DNA damage → cGAS-STING → type-I IFN signaling; promotes antigen presentation", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "38182579", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Triple-negative breast cancer", "Animal_Strain_used": "Female BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "15 mg/kg", "Technique": "Immunofluorescence ,western blotting; RT-qPCR", "Controlled_Technique": "Immunofluorescence assay; Western blot/immunoblot analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "Type-I IFN signaling", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 ↑", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2090", "Drug": "HBI-8000 (chidamide/tucidinostat)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Inhibits class I HDACs, particularly HDAC1/2/3; modulates tumor immune microenvironment and immune-related gene expression", "KEGG_Drug_ID": "D10993", "Drug_Pubchem": "12136798", "STR_LINK_(SMILES)": "C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N", "Single/Combination": "Single", "PMID": "34461854", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Murine colon carcinoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "50 mg/kg orally, daily", "Technique": "Syngeneic tumor model; NanoString nCounter PanCancer Immune Profiling", "Controlled_Technique": "Gene expression/sequencing analysis; Immune-cell profiling/phenotyping", "Immune_System-Function_enhanced/numbers_increased": "dendritic-cell score, macrophage score, NK-cell score, cytotoxic-cell score, CD45-cell score, antigen-presentation/MHC expression, immune effector genes", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD45; Macrophages; NK cells; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2116", "Drug": "FK228 (Romidepsin)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "HDAC inhibitor; reported to directly inhibit HDAC1, HDAC2, HDAC4 and HDAC6. In this study, FK228 induces ER-stress-associated necroptosis in tumor cells, producing immunogenic cell death and remodeling the tumor immune microenvironment.", "KEGG_Drug_ID": "D06637", "Drug_Pubchem": "5352062", "STR_LINK_(SMILES)": "C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C", "Single/Combination": "Single", "PMID": "40940553", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": null, "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "FK228 (0.5 mg/kg) via the tail vein every 2 days (5 times\nin total) and FK228 treated dead CT26 cells", "Technique": "In-vivo vaccination assay, immunohistochemistry/immunofluorescence, flow cytometry, single-cell RNA sequencing (scRNA-seq), pySCENIC transcription-factor analysis.", "Controlled_Technique": "In-vivo/in-vitro immunological assay; Immunohistochemistry (IHC); Immunofluorescence assay; Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ T-cell infiltration increased,CD8⁺ T-cell activation increased, GZMB- and IFN-γ-expressing CD8⁺ T cells increased, NK-cell infiltration increased, macrophages shifted toward a pro-inflammatory phenotype, neutrophils increased in the combination-treatment tumor microenvironment.", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; Macrophages; NK cells; T cells; Neutrophils / granulocytes; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression increased on cancer cells and macrophages; PD-1 expression increased on total T cells and CD8⁺ T cells following FK228 treatment. Tregs also increased", "Controlled_Terms_Negative_Regulation": "CD8; PD-L1 / CD274; PD-1 / PDCD1; Regulatory T cells / Tregs; Macrophages; T cells"}, {"ID": "CANIMM/2174", "Drug": "Entinostat (MS-275)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC1/HDAC3 inhibition; increases MHC-I and immunogenicity", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "39438988", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "9464D murine neuroblastoma", "Animal_Strain_used": "Female C57BL/6 mice, 6–8 weeks", "Cell_line_used_to_induce_tumor_in_mice": "9464D", "Dose": "5 mg/kg/day i.p. ×14 days", "Technique": "Flow cytometry, IHC, immunofluorescence, cytokine/chemokine analysis", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC); Immunofluorescence assay; Cytokine/chemokine analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC-I, CD8⁺ T cells, CD4⁺ T cells, NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; NK cells; T cells; MHC class I; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2117", "Drug": "FK228 (Romidepsin)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "HDAC inhibitor; reported to directly inhibit HDAC1, HDAC2, HDAC4 and HDAC6. In this study, FK228 induces ER-stress-associated necroptosis in tumor cells, producing immunogenic cell death and remodeling the tumor immune microenvironment.", "KEGG_Drug_ID": "D06637", "Drug_Pubchem": "5352062", "STR_LINK_(SMILES)": "C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C", "Single/Combination": "Single", "PMID": "40940553", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": null, "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "FK228 (0.5 mg/kg) via the tail vein every 2 days (5 times\nin total) and FK228 treated dead 4T1 cells", "Technique": "In-vivo vaccination assay, immunohistochemistry/immunofluorescence, flow cytometry, single-cell RNA sequencing (scRNA-seq), pySCENIC transcription-factor analysis.", "Controlled_Technique": "In-vivo/in-vitro immunological assay; Immunohistochemistry (IHC); Immunofluorescence assay; Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ T-cell infiltration increased,CD8⁺ T-cell activation increased, GZMB- and IFN-γ-expressing CD8⁺ T cells increased, NK-cell infiltration increased, macrophages shifted toward a pro-inflammatory phenotype, neutrophils increased in the combination-treatment tumor microenvironment.", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; Macrophages; NK cells; T cells; Neutrophils / granulocytes; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression increased on cancer cells and macrophages; PD-1 expression increased on total T cells and CD8⁺ T cells following FK228 treatment. Tregs also increased", "Controlled_Terms_Negative_Regulation": "CD8; PD-L1 / CD274; PD-1 / PDCD1; Regulatory T cells / Tregs; Macrophages; T cells"}, {"ID": "CANIMM/2118", "Drug": "Domatinostat (4SC-202)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Class I HDAC inhibition; epigenetic modulation; increases antigen processing/presentation, MHC-I/MHC-II expression and T-cell-mediated antitumor immunity", "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Single", "PMID": "31703604", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": null, "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "CT26 murine colorectal carcinoma", "Dose": "20 mg/kg twice daily", "Technique": "Flow cytometry; tumor immune-cell profiling", "Controlled_Technique": "Flow cytometry; Immune-cell profiling/phenotyping", "Immune_System-Function_enhanced/numbers_increased": "Intratumoral CTLs increased approximately 8-fold; CD4+ T cells increased approximately 3-fold; CTL/Treg ratio increased; antigen-processing machinery genes increased; MHC-I/MHC-II increased; IFNG increased; IFN-gamma response increased", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; Regulatory T cells / Tregs; T cells; MHC class I; MHC class II; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "Intratumoral MDSCs slightly decreased", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "Tumor-infiltrating B cells; NK cells; peripheral-blood immune-cell populations largely unaffected", "Controlled_Terms_Unaffected": "NK cells; B cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Regulatory T cells increased; PD-1/LAG3-positive CTLs increased, representing inhibitory feedback", "Controlled_Terms_Negative_Regulation": "PD-1 / PDCD1; LAG-3; Regulatory T cells / Tregs; T cells"}, {"ID": "CANIMM/2123", "Drug": "OBP-801", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB12279", "Target/s_or_mechanism_of_action": "Potent class-I HDAC inhibitor", "KEGG_Drug_ID": null, "Drug_Pubchem": "11178958", "STR_LINK_(SMILES)": "CC(C)[C@H]1NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C)C(=O)N2)OC(=O)C[C@@H]1O", "Single/Combination": "Single", "PMID": "39682244", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Clear cell renal cell carcinoma", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "RENCA", "Dose": "10 mg/kg IV, days 1,4,7,11 in tumor-growth experiment; days 1,4,7 in TIL experiment", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MHC-I presentation; LMP2/PSMB9; CD45⁺CD3e⁺ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD3; CD45; T cells; MHC class I; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD8a⁺CD8b⁺ T-cell", "Controlled_Terms_Unaffected": "CD8; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2129", "Drug": "Citarinostat (ACY241)", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB15449", "Target/s_or_mechanism_of_action": "Selective HDAC6 inhibition; increases α-tubulin acetylation and modulates tumor immunity", "KEGG_Drug_ID": "D10918", "Drug_Pubchem": "53340426", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "35223194", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC / lung adenocarcinoma", "Animal_Strain_used": "Kras+/LSL-G12D; Trp53L/L (KP) mice", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "25 mg/kg i.p., 3×/week; efficacy studies up to 6 weeks", "Technique": "Flow cytometery, transcriptomics", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CD4+Foxp3− T cells, CD8+ T cells, NK cells, CD69/Ki-67, memory T cells, CD107a/granzyme B, tumor-associated macrophages (TAMs; CD11b+CD11c-Gr1-) have high expression of MHC-I/MHC-II, CD80, CD86, CD40", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD11b / ITGAM; CD11c / ITGAX; CD40; CD69; CD80; CD86; CD107a; FOXP3; Macrophages; Tumor-associated macrophages / TAMs; NK cells; T cells; Granzyme B / GZMB; MHC class I; MHC class II; Cell proliferation / Ki-67; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "CD4+ CD25hiFoxp3+ regulatory T cells,  lung tumor-infiltrating CD8 + T cells expressed lower levels of the inhibitory receptors BTLA, PD-1, and CTLA-4, TAMs (tumour associated macroohages) have reduced PD-L1/PD-L2, CTLA4, VSIR, TIGIT, LGALS9, ARG1", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; CD25 / IL2RA; PD-L1 / CD274; PD-L2; PD-1 / PDCD1; CTLA-4; TIGIT; BTLA; VSIR; LGALS9; FOXP3; Regulatory T cells / Tregs; T cells; Arginase-1 / ARG1", "Immune_System_function_unaffected": "tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSC), and dendritic cells (DC)", "Controlled_Terms_Unaffected": "Myeloid-derived suppressor cells / MDSCs; Macrophages; Tumor-associated macrophages / TAMs; Dendritic cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2130", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibition", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "35764364", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "MHC-I/APM-deficient murine lung cancer", "Animal_Strain_used": "Female C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "CMT.64", "Dose": "6 mg/kg/day, oral diet", "Technique": "flow cytometry, immune profiling, RNA-seq", "Controlled_Technique": "Flow cytometry; Immune-cell profiling/phenotyping; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC-I/APM-related immune recognition", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2131", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC1/HDAC3 inhibition; systemic immune modulation", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "42515717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Syngeneic murine NSCLC", "Animal_Strain_used": "C57BL/6 mice", "Cell_line_used_to_induce_tumor_in_mice": "KPN1.1", "Dose": "7.5 mg/kg orally, 5×/week; 8 doses over 10 days", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4⁺ T cells, CD8⁺ T cells, systemic T-cell populations expanded", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4⁺ IFN-γ production unchanged after gp33/gp66 stimulation", "Controlled_Terms_Unaffected": "IFN-γ; CD4", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2142", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Inhibits HDACs; promotes MHC-I/APM expression and immune-response gene programs", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "35764364", "Cancer_Type": "Lung Cancer; Hpv16-Expressing Tumors", "Cancer_Type_Description": "MHC-I-deficient, HPV16 E6/E7+ lung tumor model", "Animal_Strain_used": "Female C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "TC-1/a9", "Dose": "6 mg/kg/day, oral diet for 10 days", "Technique": "Flow cytometry; RNA-seq; pathway analysis", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC-I/APM-related immune recognition", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2150", "Drug": "CN133", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "NR", "Target/s_or_mechanism_of_action": "Potent class-I HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3", "KEGG_Drug_ID": "NR", "Drug_Pubchem": "NR", "STR_LINK_(SMILES)": "CN(Cc1ccc(/C=C/C(=O)NO)cc1)CC12CC3CC(CC(C3)C1)C2", "Single/Combination": "Single", "PMID": "37880708", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Subcutaneous prostate-cancer allograft", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "RM1 prostate cancer cells", "Dose": "1 mg/kg, intraperitoneally, twice/week", "Technique": "flow cytometry, RNA-seq/microarray, RT-qPCR", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD4⁺ T cells, CD8⁺ T cells, CD8⁺ T-cell granzyme B, perforin", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells; Granzyme B / GZMB; Perforin / PRF1", "Immune_System-Function_inhibited/numbers_decreased": "PMN-MDSCs (CD11b⁺Ly6G⁺), Arg-1, iNOS, HGF, CCL5, IL-6 and CCL12", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; CCL5 / RANTES; CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / G-MDSCs; Arginase-1 / ARG1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2155", "Drug": "Entinostat", "Drug_category": "Histone Deacetylase Inhibitors", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibition and epigenetic modulation of immune-response pathways", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Single", "PMID": "35764364", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "MHC-I-deficient, IFN-γ-resistant sarcoma", "Animal_Strain_used": "Female C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "RVP3", "Dose": "6 mg/kg/day, oral diet", "Technique": "Tumor growth; immune profiling by flow cytometry", "Controlled_Technique": "Tumor growth/survival analysis; Flow cytometry; Immune-cell profiling/phenotyping", "Immune_System-Function_enhanced/numbers_increased": "MHC-I/APM-related immune recognition", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1644", "Drug": "CC-4047/ACTIMID/ Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug_ID": "D08976", "Drug_Pubchem": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "11994441", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal -Ectopic Colorectal Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": null, "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-y, IL-2", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1669", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Drug_Pubchem": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "19965642", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "A20 tumor cells", "Dose": "(gavage, 300 mg/kg, twice daily for 7 days)", "Technique": "ELISA, Flow cytometery", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ and CD8+ T lymphocytes IFN-γ was produced by both CD4+ and CD8+ T lymphocytes", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1732", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Drug_Pubchem": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "23765229", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - A20 Murine Lymphoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "5mg/kg/day", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "anti-Id antibodies", "Controlled_Terms_Unaffected": "Anti-idiotype (anti-Id) antibodies", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1733", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Drug_Pubchem": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "23765229", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - A20 Murine Lymphoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": null, "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": "splenic MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1824", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Drug_Pubchem": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "26447613", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Animal_Strain_used": "C57BL/KaLwRij", "Cell_line_used_to_induce_tumor_in_mice": "5TGM1 cells", "Dose": "(25 mg/kg/day) for 21 consecutive days", "Technique": "Depleting Studies, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells, including IFN-γ-secreting and IL-4-secreting NK cells, decreased on ex vivo stimulation, CD25+Foxp3+CD4+ regulatory T (Treg) cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-4; CD4; CD25 / IL2RA; FOXP3; Regulatory T cells / Tregs; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1842", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Drug_Pubchem": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "27287425", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "Animal_Strain_used": "C57/BL6", "Cell_line_used_to_induce_tumor_in_mice": "EL4 T-cell lymphoma", "Dose": "1 mg/kg for 5 consecutive days", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1934", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells.", "KEGG_Drug_ID": "D08976", "Drug_Pubchem": "134780", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "29780393", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "Animal_Strain_used": "NSG xenografted with human primary AML blasts", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "5mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1954", "Drug": "Lenalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Drug_Pubchem": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Single Drug", "PMID": "30619281", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "WEHI-3", "Dose": "1 mg/kg for 5 consecutive days", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2091", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Inhibits IFN-γ-induced PD-L1 expression and transcription", "KEGG_Drug_ID": "D08976", "Drug_Pubchem": "134780", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N", "Single/Combination": "Single", "PMID": "30315115", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "MC38 — mouse colon cancer", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "50 mg/kg intraperitoneally in mice", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor-infiltrating CD3⁺ cells; CD8⁺/CD4⁺ ratio", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD3", "Immune_System-Function_inhibited/numbers_decreased": "Inducible PD-L1; PD-1/PD-L1-mediated suppression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-1 / PDCD1", "Immune_System_function_unaffected": "Constitutive PD-L1 largely unaffected", "Controlled_Terms_Unaffected": "PD-L1 / CD274", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2098", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Binds cereblon (CRBN); modulates ubiquitin-ligase substrate specificity and immunomodulates T-cell and NK-cell activity", "KEGG_Drug_ID": "D08976", "Drug_Pubchem": "134780", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N", "Single/Combination": "Single", "PMID": "19009291", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "CT26 syngeneic murine colorectal carcinoma model", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "50 mg/kg intraperitoneally once daily for 6 days in mice", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "40% reduction in CD4+CD25+CTLA-4+FOXP3+ Tregs in draining lymph nodes versus control", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD25 / IL2RA; CTLA-4; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": "CD4+/CD25+/CTLA-4/FOXP3+ T regulatory cells in the spleens", "Controlled_Terms_Unaffected": "CD4; CD25 / IL2RA; CTLA-4; FOXP3; Regulatory T cells / Tregs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2145", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Cereblon (CRBN); immunomodulation via STAT1 activation and STAT6 inactivation", "KEGG_Drug_ID": "D08976", "Drug_Pubchem": "134780", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N", "Single/Combination": "Single", "PMID": "23940785", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Intracranial human B-cell lymphoma xenograft", "Animal_Strain_used": "Female athymic mice (8–10 weeks old)", "Cell_line_used_to_induce_tumor_in_mice": "Raji-luciferase", "Dose": "0.3, 3, 10, 30 mg/kg orally once daily for 28 days", "Technique": "Bioluminescence imaging; immunohistochemistry; immunofluorescence", "Controlled_Technique": "Bioluminescence/luciferase assay; Immunohistochemistry (IHC); Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "Increased macrophages, M1-polarized macrophages and NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; NK cells", "Immune_System-Function_inhibited/numbers_decreased": "Decreased M2-polarized tumor-associated macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages; Tumor-associated macrophages / TAMs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2146", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Cereblon (CRBN); immunomodulation via STAT1 activation and STAT6 inactivation", "KEGG_Drug_ID": "D08976", "Drug_Pubchem": "134780", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N", "Single/Combination": "Single", "PMID": "23940785", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Intracranial human B-cell lymphoma xenograft", "Animal_Strain_used": "Female athymic mice (8–10 weeks old)", "Cell_line_used_to_induce_tumor_in_mice": "OCI-LY10-luciferase", "Dose": "3, 10, 30 mg/kg orally once daily for 28 days", "Technique": "Bioluminescence imaging; immunohistochemistry; immunofluorescence", "Controlled_Technique": "Bioluminescence/luciferase assay; Immunohistochemistry (IHC); Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "Increased macrophages, M1-polarized macrophages and NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; NK cells", "Immune_System-Function_inhibited/numbers_decreased": "Decreased M2-polarized tumor-associated macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages; Tumor-associated macrophages / TAMs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2168", "Drug": "Pomalidomide", "Drug_category": "Immunomodulatory Agents (IMiDs)", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Inhibits IFN-γ-induced PD-L1 expression", "KEGG_Drug_ID": "D08976", "Drug_Pubchem": "134780", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N", "Single/Combination": "Single", "PMID": "30315115", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "B16-OVA — mouse melanoma expressing ovalbumin", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "B16-OVA", "Dose": "mg/kg intraperitoneally in mice", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "OT-1 CTL-mediated tumor killing; antitumor T-cell response", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "Inducible PD-L1; tumor immune evasion", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274", "Immune_System_function_unaffected": "Constitutive PD-L1 largely unaffected", "Controlled_Terms_Unaffected": "PD-L1 / CD274", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1725", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug_ID": null, "Drug_Pubchem": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "Animal_Strain_used": "athymic nude", "Cell_line_used_to_induce_tumor_in_mice": "KCNR", "Dose": "30 mg/kg QD per mouse", "Technique": "Western Blot Analyses,H & E Staining", "Controlled_Technique": "Western blot/immunoblot analysis; Hematoxylin and eosin (H&E)/histology; Hematoxylin and eosin (H&E)/histology", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tyrosine phosphorylated STAT3 as well as of STAT3 downstream targets (CyclinD1,-3, Bcl-2 and Survivin)", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT3 signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1726", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug_ID": null, "Drug_Pubchem": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "Animal_Strain_used": "athymic nude", "Cell_line_used_to_induce_tumor_in_mice": "SY5Y", "Dose": "30 mg/kg QD per mouse", "Technique": "Western Blot Analyses,H & E Staining", "Controlled_Technique": "Western blot/immunoblot analysis; Hematoxylin and eosin (H&E)/histology; Hematoxylin and eosin (H&E)/histology", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tyrosine phosphorylated STAT3 as well as of STAT3 downstream targets (CyclinD1,-3, Bcl-2 and Survivin)", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT3 signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1727", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug_ID": null, "Drug_Pubchem": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Rhabdomyosarcoma", "Cancer_Type_Description": "Rhabdomyosarcoma", "Animal_Strain_used": "SCID/Beige", "Cell_line_used_to_induce_tumor_in_mice": "Rh18", "Dose": "30 mg/kg BID per mouse", "Technique": "Western Blot Analyses,H & E Staining", "Controlled_Technique": "Western blot/immunoblot analysis; Hematoxylin and eosin (H&E)/histology; Hematoxylin and eosin (H&E)/histology", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tyrosine phosphorylated STAT3 as well as of STAT3 downstream targets (CyclinD1,-3, Bcl-2 and Survivin)", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT3 signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1728", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug_ID": null, "Drug_Pubchem": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "23531921", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Ewing Sarcoma", "Animal_Strain_used": "SCID/Beige", "Cell_line_used_to_induce_tumor_in_mice": "TC32", "Dose": "30 mg/kg BID per mouse", "Technique": "Western Blot Analyses,H & E Staining", "Controlled_Technique": "Western blot/immunoblot analysis; Hematoxylin and eosin (H&E)/histology; Hematoxylin and eosin (H&E)/histology", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tyrosine phosphorylated STAT3 as well as of STAT3 downstream targets (CyclinD1,-3, Bcl-2 and Survivin)", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT3 signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1772", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug_ID": null, "Drug_Pubchem": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "25149535", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "AZD1480", "Dose": "AZD1480 at 30 mg/kg or with vehicle by oral gavage twice a day for 7 days", "Technique": "Western Blot Analysis", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD4+ and CD8+ T cells, tumor-infiltrating CD4+ and CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "monocytic MDSCs (moMDSC; CD11b+Ly6C+Ly6G−) and granulocytic MDSCs (grMDSC; CD11b+Ly6ClowLy6G+,tumor-infiltrating DCs, moMDSCs and grMDSCs within the tumor microenvironment complete inhibition of P-STAT3 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / granulocytic MDSCs; Dendritic cells; STAT3 signaling; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1830", "Drug": "AZD1480", "Drug_category": "JAK2 inhibitor", "Drugbank_ID": "DB12588", "Target/s_or_mechanism_of_action": "AZD1480 blocks cell proliferation and induces apoptosis of myeloma cell lines. These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.", "KEGG_Drug_ID": null, "Drug_Pubchem": "16659841", "STR_LINK_(SMILES)": "C[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1", "Single/Combination": "Single Drug", "PMID": "26660519", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Carcinoma Cells", "Animal_Strain_used": "MISIIR-TAg", "Cell_line_used_to_induce_tumor_in_mice": "spontaneous development", "Dose": "30 mg/kg AZD1480.", "Technique": "Immunoblot And Electro Chemiluminescent Elisa Analysis", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pSTAT3Y705 levels", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1776", "Drug": "PD184352 (\n CI-1040)", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB12429", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "6918454", "STR_LINK_(SMILES)": "FC1=C(F)C(NC2=CC=C(I)C=C2Cl)=C(C=C1)C(=O)NOCC1CC1", "Single/Combination": "Single Drug", "PMID": "25256614", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57J/B6", "Cell_line_used_to_induce_tumor_in_mice": "BRafV600E-4434", "Dose": "25 mg/kg/day PD184352", "Technique": "Immunohistochemistry,Quantitative real time PCR analysis", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "pan macrophage marker CD68in tumors, monocyte and macrophage marker F4/80 M1 macrophage marker CD86, the M2 marker CD163 and TNFα in tumors", "Controlled_Terms_Function_enhanced_Number_increased": "TNF-α / TNF; CD86; CD163; Macrophages; Monocytes; M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1864", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "27803104", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Mammary Tumor", "Animal_Strain_used": "WT C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Brpkp110 tumors", "Dose": "1.0 mg/kg trametinib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD11b+MHC-II−Ly6ChiLy6G− monocytic-MDSCs (M-MDSCs)-M-MDSCs expressed high levels of Arginase and Nos2 and were capable of suppressing the proliferation of activated T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; MHC class II; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; T cells; Cell proliferation / Ki-67", "Immune_System_function_unaffected": "CD8+ or CD4+ T cells at tumor beds, PD-1+ intratumoral CD8+ or CD4+ T cells, Foxp3+ Tregs and differentiated (MHC-II+) macrophages, CD11b+MHC-II−Ly6ClowLy6G+ polymorphonuclear-MDSCs (PMN-MDSCs)", "Controlled_Terms_Unaffected": "CD4; CD8; CD11b / ITGAM; PD-1 / PDCD1; MHC class II; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / granulocytic MDSCs; Macrophages; T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1898", "Drug": "MEK inhibitor selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug_ID": "D09666", "Drug_Pubchem": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "28807001", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "25 mg/kg, twice daily", "Technique": "Immunohistochemical Staining,Flow Cytometry Analysis", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD4+ T-cells, intratumoral MHC-II+ Ly6C+ intermediary differentiating monocytes", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; MHC class II; Monocytes; T cells", "Immune_System-Function_inhibited/numbers_decreased": "tumor-infiltrating gMDSC/neutrophil p-ERK levels", "Controlled_Terms_Function_inhibited_Number_decreased": "PMN-MDSCs / granulocytic MDSCs; Neutrophils / granulocytes; MAPK signaling; Immune-cell infiltration", "Immune_System_function_unaffected": "CD8+ T-cells or CD4+ Foxp3+", "Controlled_Terms_Unaffected": "CD4; CD8; FOXP3; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1904", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "28928458", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "AT3ova", "Dose": "trametinib (1 mg/kg/daily)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD8+, CD4+ FOXP3−, and CD4+ FOXP3+ cells reduced IFNγ production of CD8+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; CD4; CD8; FOXP3; T cells; CD8+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1905", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": "28928458", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "AT3ova", "Dose": "trametinib (1 mg/kg/daily)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD8+ T cells and both populations of CD4+ T cells; helper (FOXP3−) and T regulatory cells CD8+ and CD4+ T-cell cytokine production (IFNγ)", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; CD4; CD8; FOXP3; Regulatory T cells / Tregs; T cells; CD8+ T cells; CD4+ T cells", "Immune_System_function_unaffected": "innate immune subsets such as NK cells and NK T cells revealed no changes in frequency (CD3+ NK1.1+, CD3− NK1.1+), maturation (CD11b+ CD27−), or effector function (Granzyme B+)", "Controlled_Terms_Unaffected": "CD3; CD11b / ITGAM; NK cells; T cells; Granzyme B / GZMB", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1972", "Drug": "Selumetinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug_ID": "D09666", "Drug_Pubchem": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Single Drug", "PMID": "30995478", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Animal_Strain_used": "HKP1 lung-cancer-bearing", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "Pulsative selumetinib (0-1uM)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "pERK expression in CD4+ and CD8+ T cells T-bet in both CD4+ and CD8+ T cells from lung tumors CTLA-4 and PD-1 expression on CD8+ T cells, PD-1 and CTLA -4 expression on CD4+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; PD-1 / PDCD1; CTLA-4; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2039", "Drug": "MEKi GDC-0623", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11982", "Target/s_or_mechanism_of_action": "Not Available", "KEGG_Drug_ID": null, "Drug_Pubchem": "42642654", "STR_LINK_(SMILES)": "OCCONC(=O)C1=C(NC2=C(F)C=C(I)C=C2)N2C=NC=C2C=C1", "Single/Combination": "Single Drug", "PMID": "32358491", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Murine Colon Carcinoma", "Animal_Strain_used": "C57BL/6-Ly5.1", "Cell_line_used_to_induce_tumor_in_mice": "MC-38", "Dose": null, "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "M2 CD206+ phenotype", "Controlled_Terms_Function_inhibited_Number_decreased": "CD206 / MRC1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2042", "Drug": "MEKi GDC-0623", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB11982", "Target/s_or_mechanism_of_action": "Not Available", "KEGG_Drug_ID": null, "Drug_Pubchem": "42642654", "STR_LINK_(SMILES)": "OCCONC(=O)C1=C(NC2=C(F)C=C(I)C=C2)N2C=NC=C2C=C1", "Single/Combination": "Single Drug", "PMID": "32358491", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Tumor", "Animal_Strain_used": "C57BL/6-Ly5.1", "Cell_line_used_to_induce_tumor_in_mice": "PDA30364", "Dose": null, "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "M2 CD206+ phenotype,MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD206 / MRC1; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2051", "Drug": "Trametinib", "Drug_category": "MEK inhibitor", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Single Drug", "PMID": null, "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "Animal_Strain_used": "WT C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Lewis Lung Carcinoma cells (LLC1)", "Dose": "1.0 mg/kg trametinib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "monocytic-MDSCs (M-MDSCs)", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2073", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitor/ MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "MEK1/MEK2 inhibition", "KEGG_Drug_ID": "D10405", "Drug_Pubchem": "16222096", "STR_LINK_(SMILES)": "C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O", "Single/Combination": "Single", "PMID": "42183887", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "4T1, murine TNBC xenograft", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "10 mg/kg orally, once daily (QD), 22 days", "Technique": "IHC, flow cytometry of splenocytes, immunofluorescence", "Controlled_Technique": "Immunohistochemistry (IHC); Flow cytometry; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "activated caspase-8, Bax, Bak, CRT, and HMGB1, CD8+ T cells increased; naïve CD8+ T cells increased; effector CD4+ T cells increased; intratumoral CD4+ and CD8+ T cells increased; CD8+Granzyme-B+ cells increased; CD80+CD86+ (mature) and MHC-IIhigh (antigen-presenting) DCs", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD80; CD86; T cells; Granzyme B / GZMB; Calreticulin / CRT; HMGB1; Apoptosis / caspase activation; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "inactivated ERK,  Foxp3+ Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs; MAPK signaling", "Immune_System_function_unaffected": "Total body weight did not show progressive loss; splenocyte/T-cell effects differed in non-tumor-bearing mice", "Controlled_Terms_Unaffected": "T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2099", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitor/ MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "Inhibits MEK1/2 → suppresses MAPK/ERK signaling", "KEGG_Drug_ID": "D10405", "Drug_Pubchem": "16222096", "STR_LINK_(SMILES)": "CN1CCN(CC1)C(=O)C2=C(C=C(C=C2F)F)NC3=C(C=C(C=C3)F)I", "Single/Combination": "Single", "PMID": "34389557", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "Animal_Strain_used": "Balb/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "Cobimetinib 7.5 mg/kg M/W/F", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells and T regulatory cells, IFNγ and GZMB in MEK1-KO tumors, CD4+ central memory and effector memory cells, CD8+ central memory and effector memory cells, proliferating CD8+ T cells and CD4+ T cells, CD86+ CD19+ and MHCII+ CD19+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD19; CD86; Regulatory T cells / Tregs; T cells; Granzyme B / GZMB; MHC class I; MHC class II; Cell proliferation / Ki-67; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4+ T cells", "Controlled_Terms_Unaffected": "CD4; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2100", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitor/ MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "Inhibits MEK1/2 → suppresses MAPK/ERK signaling", "KEGG_Drug_ID": "D10405", "Drug_Pubchem": "16222096", "STR_LINK_(SMILES)": "CN1CCN(CC1)C(=O)C2=C(C=C(C=C2F)F)NC3=C(C=C(C=C3)F)I", "Single/Combination": "Single", "PMID": "34389557", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "Animal_Strain_used": "Balb/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 MEK1-KO cells", "Dose": "Cobimetinib 7.5 mg/kg M/W/F", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells and T regulatory cells, IFNγ and GZMB in MEK1-KO tumors, CD4+ central memory and effector memory cells, CD8+ central memory and effector memory cells, proliferating CD8+ T cells and CD4+ T cells, CD86+ CD19+ and MHCII+ CD19+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD19; CD86; Regulatory T cells / Tregs; T cells; Granzyme B / GZMB; MHC class I; MHC class II; Cell proliferation / Ki-67; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4+ T cells", "Controlled_Terms_Unaffected": "CD4; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2169", "Drug": "PD0325901", "Drug_category": "MEK inhibitor/ MEK inhibitors", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MEK1/2 inhibition; reduces ERK1/2 phosphorylation", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "32661093", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "BRAF V600E-mutant, PTEN-loss melanoma", "Animal_Strain_used": "C57BL/6; NSG", "Cell_line_used_to_induce_tumor_in_mice": "D4M3.A", "Dose": "7 ppm in chow", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "Increased tumor immunogenicity and CD8⁺ T-cell infiltration", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "No significant changes reported in CD4⁺ T cells, FOXP3⁺ regulatory T cells or NK cells in the reported comparison", "Controlled_Terms_Unaffected": "CD4; FOXP3; Regulatory T cells / Tregs; NK cells; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2101", "Drug": "Cobimetinib + anti-PD-1 + anti-4-1BB", "Drug_category": "MEK inhibitor/ MEK inhibitors; Monoclonal Antbody", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "Inhibits MEK1/2 → suppresses MAPK/ERK signaling", "KEGG_Drug_ID": "D10405", "Drug_Pubchem": "16222096", "STR_LINK_(SMILES)": "CN1CCN(CC1)C(=O)C2=C(C=C(C=C2F)F)NC3=C(C=C(C=C3)F)I", "Single/Combination": "Single", "PMID": "34389557", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "Animal_Strain_used": "Balb/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "Cobimetinib 7.5 mg/kg M/W/F + anti-PD-1 0.25 mg/mouse + anti-4-1BB 0.025 mg/mouse", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ, GZMB, TNFα, and CD69; increase in CD8+ T cells;percentage of both GZMB+ CD8+ T and Ki67+ CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; TNF-α / TNF; CD8; CD69; T cells; Granzyme B / GZMB; Cell proliferation / Ki-67", "Immune_System-Function_inhibited/numbers_decreased": "significant decrease in PD-1+ Lag3+ double positive CD8+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; PD-1 / PDCD1; LAG-3; T cells", "Immune_System_function_unaffected": "percentage of CD4+ T cells", "Controlled_Terms_Unaffected": "CD4; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2006", "Drug": "Cobimetinib", "Drug_category": "MEK inhibitors", "Drugbank_ID": "DB05239", "Target/s_or_mechanism_of_action": "MEK inhibitor Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway.", "KEGG_Drug_ID": "D10405", "Drug_Pubchem": "16222096", "STR_LINK_(SMILES)": "OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1", "Single/Combination": "Single Drug", "PMID": "31671149", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "1x105\n CT26 colon cancer cells", "Dose": "7.5 mg/kg of cobimetinib(MEKi) three times weekly via intraperitoneal injection", "Technique": "Flow Cytometry, Quantitative Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ and CD4+ T cells increased in MEK treated tumors", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "B 10 cells , T2-MZP Bregs, Tim1+ Bregs in the tumor draining nodes of the\n cobimetinib-treated mice", "Controlled_Terms_Function_inhibited_Number_decreased": "B10 cells; T2-MZP B regulatory cells (Bregs); TIM-1-positive B regulatory cells (Bregs)", "Immune_System_function_unaffected": "anti-tumor IgG", "Controlled_Terms_Unaffected": "Antitumor immunoglobulin G (IgG)", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1689", "Drug": "Trastuzumab (4D5)", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21321106", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "1 × 106 CT-26HER2/neu cells", "Dose": "1 mg/kg 4D5", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-y, RANTES IL-8", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-8 / CXCL8; CCL5 / RANTES", "Immune_System-Function_inhibited/numbers_decreased": "MIP-1α was minimal", "Controlled_Terms_Function_inhibited_Number_decreased": "CCL3 / MIP-1α", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1691", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21387286", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "NOD/SCID", "Cell_line_used_to_induce_tumor_in_mice": "HCC1569 cells (5.0 × 106)", "Dose": "human PBMCs (5.0 × 106 cells/mouse, i.p.) injections + trastuzumab (0.005 mg/g, intraperitoneally [i.p.])", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "human lymphocytes were invaded intercellular and stroma in tumor tissue.", "Controlled_Terms_Function_enhanced_Number_increased": "lymphocytes", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1692", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21387286", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "NOD/SCID", "Cell_line_used_to_induce_tumor_in_mice": "HCC1569 cells (5.0 × 106)", "Dose": "human PBMCsKLRG1(−) (5.0 × 106 cells/mouse, i.p.) injections + trastuzumab (0.005 mg/g, intraperitoneally [i.p.])", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "human lymphocytes were invaded intercellular and stroma in tumor tissue.", "Controlled_Terms_Function_enhanced_Number_increased": "lymphocytes", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1693", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21387286", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "NOD/SCID", "Cell_line_used_to_induce_tumor_in_mice": "HCC1569 cells (5.0 × 106)", "Dose": "human PBMCsKLRG1(−) (5.0 × 106 cells/mouse, i.p.) injections", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1694", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21387286", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "NOD/SCID", "Cell_line_used_to_induce_tumor_in_mice": "HCC1569 cells (5.0 × 106)", "Dose": "trastuzumab (0.005 mg/g, intraperitoneally [i.p.])", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1711", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Drug_Pubchem": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22922885", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Pleural Mesothelioma", "Animal_Strain_used": "C.B-17 SCID", "Cell_line_used_to_induce_tumor_in_mice": "MSTO-211H cells", "Dose": "cetuximab (0.05 mg/mouse i.t. on day 7), IL-2 (30 IU/ml i.t. on day 7)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "improved survival-suggestive of ADCC", "Controlled_Terms_Function_enhanced_Number_increased": "ADCC / antibody-dependent cytotoxicity; Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1712", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Drug_Pubchem": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22927667", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "Animal_Strain_used": "Athymic (nu/nu)", "Cell_line_used_to_induce_tumor_in_mice": "SCC-1 cells", "Dose": "(5 mg/kg i.p. twice weekly × 3 weeks)", "Technique": "ELISA,Immunoblot Assays", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "tumor cells with higher autonomous expression of TGF-β TGF-β–dependent activation of AKT and EMT", "Controlled_Terms_Negative_Regulation": "TGF-β; AKT signaling; Epithelial-mesenchymal transition"}, {"ID": "CANIMM/1713", "Drug": "Cetuximab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Drug_Pubchem": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22927667", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "Animal_Strain_used": "Athymic (nu/nu)", "Cell_line_used_to_induce_tumor_in_mice": "1CC8", "Dose": "(5 mg/kg i.p. twice weekly × 3 weeks)", "Technique": "ELISA,Immunoblot Assays", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "tumor cells with higher autonomous expression of TGF-β TGF-β–dependent activation of AKT and EMT", "Controlled_Terms_Negative_Regulation": "TGF-β; AKT signaling; Epithelial-mesenchymal transition"}, {"ID": "CANIMM/1714", "Drug": "Anti-CTLA-4", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22934253", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "Tyr::CreERT2PTENF−/−BRAFF-V600E/+", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "Mice were injected intraperitoneal with the anti-CTLA-4 mAbs dissolved in HBSS. Dosing per injection was 200 μg for the hamster-derived anti-CTLA-4 mAb clone 9H10 (BioXcell, BE0131) and 100 μg for the mouse-derived anti-CTLA-4 mAb clone 9D9 (BioXcell, BE0164)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD45+ leukocytes, CD8+ T cells, CD4+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD45; T cells; CD8+ T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "regulatory T cells", "Controlled_Terms_Unaffected": "Regulatory T cells / Tregs; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1753", "Drug": "Anti-CD40 antibody (FGK45)", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "24736544", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "Braf/Pten", "Cell_line_used_to_induce_tumor_in_mice": "1μl 4-hydroxytamoxifen (4-HT) (8mg/ml in ethanol) topically on the back skin and examined every week for melanoma growth", "Dose": "(250μg/mouse) every three days from weeks 6-8", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "maturation status of both TAMs and TIDCs", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor-associated macrophages / TAMs; Dendritic cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "intratumoral CD4 and CD8 T cells or CD11b+/Gr-1+ myeloid cells", "Controlled_Terms_Unaffected": "CD4; CD8; CD11b / ITGAM; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "splenic and intratumoral Tregs", "Controlled_Terms_Negative_Regulation": "Regulatory T cells / Tregs"}, {"ID": "CANIMM/1833", "Drug": "Anti PD-L1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "Animal_Strain_used": "B6129SF1/J", "Cell_line_used_to_induce_tumor_in_mice": "105 genetically engineered murine ATC; TBP 3743\n BRAFV600E/WT P53-/- cells", "Dose": "anti PD-L1 200ug/mouse/I.P dose every other day (4 total doses)", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1856", "Drug": "Anti-PD-1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27622011", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1", "Dose": "4 doses of 200 ug of PD-1", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD3+CD8+ cells in the tumors,CD3+CD4+ cells in the tumors,", "Controlled_Terms_Unaffected": "CD4; CD8; CD3", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1896", "Drug": "Anti-CTLA-4", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28807001", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "Anti-CTLA-4 (10 mg/kg)", "Technique": "Flow Cytometry Analysis", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor-infiltrating CD8+ T-cell", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "tumor-infiltrating Tregs, MHCIIlo/− TAMs and pDCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1931", "Drug": "Trastuzumab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29746929", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J hmHER2 transgenic", "Cell_line_used_to_induce_tumor_in_mice": "B16-BL6 melanoma cells", "Dose": "100 μg/mouse of trastuzumab (", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-I (H-2Db),CD80 and CD86", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; CD86; MHC class I", "Immune_System-Function_inhibited/numbers_decreased": "HER2", "Controlled_Terms_Function_inhibited_Number_decreased": "HER2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; Immune checkpoint pathway"}, {"ID": "CANIMM/1757", "Drug": "PLX4720+anti CD40L", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "24736544", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BrafV600E/Pten", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "417mg/kg PLX4720+anti-CD40L ab (250μg/mouse)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "FoxP3+ Treg CD4+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; FOXP3; Regulatory T cells / Tregs; T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4+ and CD8+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; T cells; CD8+ T cells", "Immune_System_function_unaffected": "CD11b+/Gr-1+", "Controlled_Terms_Unaffected": "CD11b / ITGAM", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1962", "Drug": "Anti-PD-1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30771521", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "PKL (Lung tumors were induced by Ad-Cre in the transgenic mouse model)", "Cell_line_used_to_induce_tumor_in_mice": "3 × 105 PKL5–2 cells into the right flank of mice", "Dose": "trametinib for three days prior to initiation of combination or single treatment+ anti-PD-1 (200ug twice a week) continued for three weeks", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "percentage of CD4+ and CD8+ cells, monocytic-MDSCs CD45+/CD11b+/Ly6G-/Ly6Chigh,PMN-MDSCs, CD45+/CD11b+/Ly6Ghigh/Ly6Clow", "Controlled_Terms_Unaffected": "CD4; CD8; CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / granulocytic MDSCs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1963", "Drug": "Anti-PD-L1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30771521", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "PKL (Lung tumors were induced by Ad-Cre in the transgenic mouse model)", "Cell_line_used_to_induce_tumor_in_mice": "3 × 105 PKL5–2 cells into the right flank of mice", "Dose": "trametinib for three days prior to initiation of combination or single treatment+ anti-PD-L1 (200ug twice a week) continued for three weeks", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PMN-MDSCs, CD45+/CD11b+/Ly6Ghigh/Ly6Clow", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / granulocytic MDSCs", "Immune_System_function_unaffected": "percentage of CD4+ and CD8+ cells, monocytic-MDSCs CD45+/CD11b+/Ly6G-/Ly6Chigh,", "Controlled_Terms_Unaffected": "CD4; CD8; CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1970", "Drug": "Anti-PD-1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30992475", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1 murine melanoma tumor cells", "Dose": "15 mg/kg anti-PD-1", "Technique": "QRT-PCR, immunoblot", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "IFNγ in the TME", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 and PD-L2 in tumor cells", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-L2 / PDCD1LG2; Immune checkpoint pathway"}, {"ID": "CANIMM/1997", "Drug": "Anti -PD-1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31661001", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38 (1 × 106)", "Dose": "murine anti-PD-1 [RMP1–14] (5 mg/kg, twice week for 2 weeks)", "Technique": "Immunostaining, Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC); Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "Granzyme B (GRZB) positive immune cells", "Controlled_Terms_Function_enhanced_Number_increased": "Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "FoxP3 positive Treg cells PD-L1 reduction", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; FOXP3; Regulatory T cells / Tregs; Immune checkpoint pathway", "Immune_System_function_unaffected": "PD-1 expression", "Controlled_Terms_Unaffected": "PD-1 / PDCD1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2001", "Drug": "Anti Human PD-1 (nivolumab)", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": "DB09035", "Target/s_or_mechanism_of_action": "The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response", "KEGG_Drug_ID": "D10316", "Drug_Pubchem": "348000000", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31661001", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "Athymic Nude-Foxn1nu", "Cell_line_used_to_induce_tumor_in_mice": "PES43 (2.5 × 106) melanoma cells", "Dose": "anti-human PD-1/(CD279) IgG4 (S228P) (nivolumab) monoclonal antibody (5 mg/kg ip, twice week/3 weeks)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Granzyme B (GRZB) positive immune cells", "Controlled_Terms_Function_enhanced_Number_increased": "Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "DTC-PES43 cells", "Controlled_Terms_Unaffected": "DTC-PES43 cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2002", "Drug": "Anti PD-1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31661001", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - B16 Melanoma", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "B16-hCXCR4 (5 × 105)", "Dose": "murine anti-PD-1 [RMP1–14] (5 mg/kg, twice week for 2 weeks)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Granzyme B (GRZB) positive immune cells, tumor-infiltrating Tregs", "Controlled_Terms_Function_enhanced_Number_increased": "Regulatory T cells / Tregs; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "FoxP3 positive Treg cells, pDC (CD 45+ cells) CXCR4 decreased in tumors", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs; CXCR4", "Immune_System_function_unaffected": "PD-1 expression", "Controlled_Terms_Unaffected": "PD-1 / PDCD1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2030", "Drug": "Anti-PD-1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32158627", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "EL4", "Dose": "anti-PD1(200 μg/\n mouse on day 4, 7 and 8)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2031", "Drug": "Anti-PD-1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32158627", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "B16-F10", "Dose": "anti-PD1 (200 μg/\n mouse on days 7, 10 and 13)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2038", "Drug": "Anti-CD40 Ab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32358491", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Murine Colon Carcinoma", "Animal_Strain_used": "C57BL/6-Ly5.1", "Cell_line_used_to_induce_tumor_in_mice": "MC-38", "Dose": null, "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "M1- Macrophages", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages", "Immune_System-Function_inhibited/numbers_decreased": "M2- Macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2041", "Drug": "Anti-CD40 Ab", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32358491", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Tumor", "Animal_Strain_used": "C57BL/6-Ly5.1", "Cell_line_used_to_induce_tumor_in_mice": "PDA30364", "Dose": null, "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "M1- Macrophages", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages", "Immune_System-Function_inhibited/numbers_decreased": "M2- Macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2047", "Drug": "Anti-PD-1", "Drug_category": "Monoclonal Antbody", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32929370", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "ID8 (ID8-luc) cells", "Dose": "anti-PD-1 mAb (200 μg)", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "increased infiltration of CD8+ T cells expressing CD69, CD107a or IFN-γ, CD4+ T cells expressing CD69, CD107a or IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD69; T cells; CD8+ T cells; CD4+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1826", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug_ID": "D00753", "Drug_Pubchem": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Tumors", "Animal_Strain_used": "dox-exposed FVB mEGFRþ /CC10þ littermates", "Cell_line_used_to_induce_tumor_in_mice": "doxycycline administration", "Dose": null, "Technique": "Immunohistochemical Staining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1827", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug_ID": "D00753", "Drug_Pubchem": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Tumors", "Animal_Strain_used": "A/J mouse", "Cell_line_used_to_induce_tumor_in_mice": "exposed to the tobacco-carcinogen NNK", "Dose": null, "Technique": "Immunohistochemical Staining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1828", "Drug": "MTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug_ID": "D00753", "Drug_Pubchem": "5284616", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "Single/Combination": "Single Drug", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Tumors", "Animal_Strain_used": "C57BL/6 KRAS LA2", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": null, "Technique": "Immunohistochemical Staining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2059", "Drug": "TAK-228 (sapanisertib)", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "ATP-competitive inhibitor of mTORC1 and mTORC2; inhibits mTOR signaling and increases PD-L1 expression", "KEGG_Drug_ID": "D11183", "Drug_Pubchem": "45375953", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Human bladder cancer xenograft-derived explants generated from CAL-29 cells", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CAL-29", "Dose": "20 × 10⁶ cells injected to generate tumor; after excision, tumor fragments treated ex vivo with TAK-228.", "Technique": "PD-L1 IHC", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 increased in CAL-29 xenograft-derived tumor fragments following TAK-228 treatment", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2060", "Drug": "TAK-228 (sapanisertib)", "Drug_category": "mTOR inhibitor", "Drugbank_ID": "DB11836", "Target/s_or_mechanism_of_action": "ATP-competitive inhibitor of mTORC1 and mTORC2; inhibits mTOR signaling and increases PD-L1 expression", "KEGG_Drug_ID": "D11183", "Drug_Pubchem": "45375953", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Single", "PMID": "39258533", "Cancer_Type": "Bladder cancer", "Cancer_Type_Description": "Human bladder cancer xenograft-derived explants generated from T24 cells", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "T24", "Dose": "20 × 10⁶ cells injected to generate tumor; after excision, tumor fragments treated ex vivo with TAK-228.", "Technique": "PD-L1 IHC", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 decreased in T24 xenograft-derived fragments following TAK-228 treatment", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/1651", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02371", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "16166452", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "not mentioned", "Cell_line_used_to_induce_tumor_in_mice": "TC-1 tumors", "Dose": "120 mg/kg", "Technique": "Winn Assay", "Controlled_Technique": "Cytotoxicity/release assay; Cellular cytotoxicity/function assay", "Immune_System-Function_enhanced/numbers_increased": "CD8(+) T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1652", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02370", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "16166452", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "TC-1 lung cancer tumors", "Dose": "120 mg/kg", "Technique": "51Cr Release Assay", "Controlled_Technique": "Cytotoxicity/release assay", "Immune_System-Function_enhanced/numbers_increased": "NK cell", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1653", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "16166452", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "L1C2 (lung cancer)", "Dose": "120 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+ /CD11b+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD4+ T cells and CD8+ T cells", "Controlled_Terms_Unaffected": "CD4; CD8; T cells; CD8+ T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1654", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "16166452", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "large Lewis lung carcinoma (lung cancer)", "Dose": "120 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+ /CD11b+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD4+ T cells and CD8+ T cells", "Controlled_Terms_Unaffected": "CD4; CD8; T cells; CD8+ T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1655", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "16166452", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "C57Bl/6 and BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "TC-1 lung cancer tumors", "Dose": "120 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+ /CD11b+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD4+ T cells, CD8+ T cells, or B cells.", "Controlled_Terms_Unaffected": "CD4; CD8; B cells; T cells; CD8+ T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1656", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02369", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "16166452", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Mesothelioma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "AB12 (mesothelioma)", "Dose": "120 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+ /CD11b+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD4+ T cells and CD8+ T cells", "Controlled_Terms_Unaffected": "CD4; CD8; T cells; CD8+ T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1657", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "16166452", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Mesothelioma", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "AE-17", "Dose": "120 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+ /CD11b+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD4+ T cells and CD8+ T cells", "Controlled_Terms_Unaffected": "CD4; CD8; T cells; CD8+ T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1658", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "16252259", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BALB/c nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "Mel 195", "Dose": "0.75 mg/kg", "Technique": "RT-PCR, IIF\n analysis, western blotting", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HLA class I antigens and of HLA-A1 and -A2 alleles CTA MAGE-1, -2, -3, -10, GAGE 1-6,", "Controlled_Terms_Function_enhanced_Number_increased": "HLA-A1; MHC class I; Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1659", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "16252259", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BALB/c nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "NY-ESO-1-negative Mel 275", "Dose": "0.75 mg/kg", "Technique": "RT-PCR, IIF\n analysis, western blotting", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "HLA class I antigens and of HLA-A1 and -A2 alleles CTA MAGE-1, -2, -3, -4, -10, GAGE 1-6, NY-ESO-1,", "Controlled_Terms_Function_enhanced_Number_increased": "HLA-A1; MHC class I; Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1660", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "16252259", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BALB/c nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "Mel 313", "Dose": "0.75 mg/kg", "Technique": "RT-PCR\n , western blotting", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "HLA class I antigens CTA MAGE-1, -2, -3, -4, -10, GAGE 1-6, NY-ESO-1,", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1661", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "16252259", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "Mel 275", "Dose": "0.75 mg/kg", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "anti-NY-ESO-1 antibodies", "Controlled_Terms_Function_enhanced_Number_increased": "Cancer-testis antigens", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1670", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02372", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "19997099", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Animal_Strain_used": "nude", "Cell_line_used_to_induce_tumor_in_mice": "HCT116", "Dose": "50 mg/ kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Human leucocyte antigen class 1 on tumors", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1671", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00545", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00585", "Drug_Pubchem": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "20388795", "Cancer_Type": "Thymoma", "Cancer_Type_Description": "Thymoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "EL4 cells", "Dose": "5FU (50 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor-specific CD8(+) T cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1672", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00584", "Drug_Pubchem": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "20388795", "Cancer_Type": "Thymoma", "Cancer_Type_Description": "Thymoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "EL4 cells", "Dose": "5FU (50 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1673", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "20388795", "Cancer_Type": "Thymoma", "Cancer_Type_Description": "Thymoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "EL4 cells", "Dose": "gemcitabine (120 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1719", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": null, "PMID": "23221383", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "Animal_Strain_used": "bearing Kras-INK tumors", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "50 mg/kg", "Technique": "Flow cytometry, mRNA analysis", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "TAMs-tumor-infiltrating macrophages myeloid cell receptors colony-stimulating factor-1 receptor (CSF1R) or chemokine (C-C motif) receptor 2 (CCR2)", "Controlled_Terms_Negative_Regulation": "Tumor-associated macrophages / TAMs; Macrophages; CSF1R; CCR2; Immune-cell infiltration"}, {"ID": "CANIMM/1729", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "23671644", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "EL4 tumors", "Dose": "(1.0 mg/kg body weight)", "Technique": "Flow cytometry, cDNA microarray analyses", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ producing CD8+ T and CD4+ T cells IFN-γ CD80 expression in EL4 cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD80; T cells; CD4+ T cells; IFN-γ-producing cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1744", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "24281006", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "mouse ovarian surface epithelial cells (ID8 cells)", "Dose": "120 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1745", "Drug": "Reovirus with gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "24281006", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "mouse ovarian surface epithelial cells (ID8 cells)", "Dose": "120 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1746", "Drug": "Reovirus with gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "24281006", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "mouse ovarian surface epithelial cells (ID8 cells)", "Dose": "120 mg/kg", "Technique": "Quantitative real-time PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "TGF-β, IL-1β, IDO-1, and COX2", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; TGF-β; IDO1; COX-2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1750", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "24582211", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Cancer", "Animal_Strain_used": "a C3H/HeN mouse", "Cell_line_used_to_induce_tumor_in_mice": "SCCVII cells", "Dose": "60 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD80, CD83, CD40, and MHC-class I and MHC-class II molecules on dendritic cells +upregulated tumor-cell surface expressions of several immune accessory molecules and adhesion molecules, including CD80, CD86, CD40, ICAM-1, VCAM-1, and P-selectin induces apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "CD80; CD83; CD86; CD40; Dendritic cells; Apoptosis / caspase activation; VCAM-1; ICAM-1 / CD54", "Immune_System-Function_inhibited/numbers_decreased": "B cells and MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs; B cells", "Immune_System_function_unaffected": "CD4+ T cells and CD8+ T cells", "Controlled_Terms_Unaffected": "CD4; CD8; T cells; CD8+ T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1775", "Drug": "5-fluorouracil (5-FU)", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00584", "Drug_Pubchem": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "25209187", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "C57BL/6 and BALB/c", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "50 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSCs (by promoting apoptosis) NO production", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs; Apoptosis / caspase activation", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1851", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "27416831", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1 cells", "Dose": "15 μg decitabine daily for 4 days", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "splenic and circulating CD11b + Gr1 + cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1854", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "27471652", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Mesothelioma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "AE17", "Dose": "120 µg/g", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "tumor-associated M3 and MDSCs, but not M2 macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs; Macrophages; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1863", "Drug": "5-fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00584", "Drug_Pubchem": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "27645787", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "5-FU (40 mg/kg) was injected intraperitoneally (i.p.) every other day for a total of three injections for the first cycle treatment (C1). A week after the last 5-FU injection, 5-FU 40 mg/kg was injected every day for a total of four injections for the second cycle (C2) treatment. The third cycle (C3) and fourth cycle (C4) were as same as C2.", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8 T cells and CD45-PD-L1 + cells in tumor", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD45; PD-L1 / CD274; T cells; CD8+ T cells; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "CD4 T-cells and B cells in spleen, CD45+ cells in tumor", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD45; B cells; T cells", "Immune_System_function_unaffected": "CD8 T-cells , NK cells, MDSCs and Tregs in spleen; NK cells in tumor IL-10, IL-6 and TGF-β", "Controlled_Terms_Unaffected": "IL-6; IL-10; TGF-β; CD8; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; NK cells; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1890", "Drug": "Fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00584", "Drug_Pubchem": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "28637493", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Oral Squamous Cell Carcinoma (OSCC).", "Animal_Strain_used": "BALB/c nude", "Cell_line_used_to_induce_tumor_in_mice": "WSU-HN6 or CAL27 cells", "Dose": "20 mg/kg every 4 days for 3 weeks", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "pro-IL-1β in OSCC tissues NLRP3 in OSCC tissues", "Controlled_Terms_Negative_Regulation": "IL-1 family"}, {"ID": "CANIMM/1926", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "29622799", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c mouse", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "20 μg DAC for 5 consecutive days", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD4+ T lymphocytes and CD8+ T lymphocytes in the TME IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; T cells; CD8+ T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1927", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "29622799", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c mouse", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "20 μg DAC for 5 consecutive days + PD-1 blockade -500 μg", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "T lymphocytes", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1955", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "30657234", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Ductal Adenocarcinoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "PAN02 cells", "Dose": "50 mg/kg GEM", "Technique": "Flow Cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD4+ cells and CD8+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8", "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr‐1+ myeloid cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1992", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02372", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "31488209", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "60 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ in spleen and lungs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2020", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "31776206", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Murine Mammary Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "one million E0771 tumor cells", "Dose": "GEM (60 mg/kg body weight) four times on days 10, 14,\n 18, and 22 or a single treatment on day 22", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "monocytic MDSC (CD11b+Ly6G-Ly6Chigh) GM-CSF,sICAM-1 PD-L1 and IDO1", "Controlled_Terms_Function_enhanced_Number_increased": "GM-CSF / CSF2; CD11b / ITGAM; PD-L1 / CD274; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; Immune checkpoint pathway; IDO1", "Immune_System-Function_inhibited/numbers_decreased": "IFN-g–producing CD4 and\n CD8 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; T cells; CD8+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2025", "Drug": "5-fluorouracil", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00584", "Drug_Pubchem": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "50 mg/kg", "Technique": "Immunoblotting,Immunohistochemistry", "Controlled_Technique": "Western blot/immunoblot analysis; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2026", "Drug": "Decitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "20 μg", "Technique": "Immunoblotting,immunohistochemistry,qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "Ifng, Ifngr1, (Tnfaip3, Ifit3b, Il1a, Isg15, Il1rn, Mx2), chemokine-associated genes (Ccl6, Ccl2, Cx3cl1, Cxcl1, Cxcl10, Cxcl2, Ccl7, Cxcl9), Cd274 (Pdl1) and Pdcd1lg2 (Pdl2),immune response genes (Sbno2, Icam1, Pf4, Lilrb4a, Spib, Rsad2) tumor programmed cell death 1 ligand 1 (PD-L1) level, phosphorylation of STAT1 and its downstream transcription factor IRF1", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-1 family; CCL2 / MCP-1; CCL7 / MCP-3; CXCL9 / MIG; CXCL10 / IP-10; CXCL1; PD-L1 / CD274; PD-L2 / PDCD1LG2; Immune checkpoint pathway; STAT1; ICAM-1 / CD54", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2053", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Inhibition of DNA polymerase", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": null, "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Panc02 cells", "Dose": "120 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2132", "Drug": "Gemcitabine", "Drug_category": "Nucleoside Analogue", "Drugbank_ID": "DB00441", "Target/s_or_mechanism_of_action": "Ribonucleotide reductase inhibition; DNA synthesis inhibition; induces ICD", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung cancer", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "LLC", "Dose": "25 mg/kg", "Technique": "Flow cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+IFN-γ+ T cells, activated DCs,memory T cells (CD3+CD4+CD62L−)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD3; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD3+CD4+ or CD3+CD8+ T cells", "Controlled_Terms_Unaffected": "CD4; CD8; CD3; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1646", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "others/combination", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Combination", "PMID": "12907617", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Fibrosarcoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "C3", "Dose": "ATRA pellets (21-day release, 5 mg)", "Technique": "ELISPOT assay", "Controlled_Technique": "ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "antigenspecific IFN-γ -producing T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1648", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "others/combination", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Combination", "PMID": "12907617", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "MethA sarcoma", "Dose": "ATRA pellets (21-day release, 5 mg)", "Technique": "ELISPOT assay, Flow cytometry", "Controlled_Technique": "Flow cytometry; ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "antigenspecific T cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+CD11b+ ImCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1649", "Drug": "Gemcitabine plus anti-CD40 antibody, FGK45 alone", "Drug_category": "others/combination", "Drugbank_ID": "DB00515 (APRD00359), DB00441", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation, Inhibition of DNA polymerase", "KEGG_Drug_ID": "D00275,D02368", "Drug_Pubchem": "5702198, 60750", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Combination", "PMID": "12907622", "Cancer_Type": "Mesothelioma", "Cancer_Type_Description": "Mesothelioma", "Animal_Strain_used": "BALB/c (H-2d)", "Cell_line_used_to_induce_tumor_in_mice": "AB1-HA tumor", "Dose": "120 μg/gram gemcitabine i.p. q3dx5 and/or 100 μg of FGK45 i.p. three times over 6 days", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD4 and CD8 cells infilteration of tumor", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1662", "Drug": "CHAP31++tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "16818655", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "Animal_Strain_used": ". Wild type B6", "Cell_line_used_to_induce_tumor_in_mice": "CLL cells ( splenocytes from leukemic Eμ-TCL1\n transgenic mice)", "Dose": "ibrutinib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "No significant change in circulating T cell numbers before and after ibrutinib treatment", "Controlled_Terms_Unaffected": "T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1663", "Drug": "Trichostatin A +tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)", "Drug_category": "others/combination", "Drugbank_ID": "DB04297", "Target/s_or_mechanism_of_action": "TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones (histone deacetylases, HDAC) and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin", "KEGG_Drug_ID": null, "Drug_Pubchem": "444732", "STR_LINK_(SMILES)": "C[C@H](\\C=C(/C)\\C=C\\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C", "Single/Combination": "Combination", "PMID": "16818655", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Chronic Lymphocytic Leukaemia (CLL)", "Animal_Strain_used": "HckKO", "Cell_line_used_to_induce_tumor_in_mice": "MC38 CRC cell line", "Dose": "RK20449 (30mg/kg) for 7 days", "Technique": "Quantitative RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD206+ cells,proliferating BrdU+ cells, and CD31+ endothelial cells AAM genes Il4, Il10, Il13, Arg1, and Ym1, but minimal effects on the CAM genes Il1β, Tnfα, and Nos2 inhibition of Hck", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; IL-4; IL-10; IL-13; TNF-α / TNF; CD31 / PECAM-1; CD206 / MRC1; Arginase-1 / ARG1; Cell proliferation / Ki-67", "Immune_System_function_unaffected": "CD45+ cells or F4/80+ macrophages", "Controlled_Terms_Unaffected": "CD45; Macrophages", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1664", "Drug": "IL-2 with the HDAC inhibitor MS-275(Entinostat)", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "17671140", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal - Metastatic Renal Cell Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "RENCA luciferase-expressing cells", "Dose": "150,000 IU of IL-2 twice daily by i.p. injections (twice weekly), 5 mg/kg of MS-275 daily by oral gavage (5 d/wk),", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "regulatory T cells (CD4+ Foxp3+)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; FOXP3; Regulatory T cells / Tregs; T cells", "Immune_System_function_unaffected": "CD8+, natural killer, and natural killer T cells", "Controlled_Terms_Unaffected": "CD8; NKT cells; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1677", "Drug": "Carboplatin +paclitaxel", "Drug_category": "others/combination", "Drugbank_ID": "DB00958, DB01229", "Target/s_or_mechanism_of_action": "1. Carboplatin undergoes activation inside cells and forms reactive platinum complexes that cause the intra- and inter-strand cross-linkage of DNA molecules within the cell. 2.Pacilitaxel-Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "1. D01363, 2. D00491", "Drug_Pubchem": "38904, 36314", "STR_LINK_(SMILES)": "carboplatin-[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], pacilitaxel- [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Combination", "PMID": "20683396", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "Female athymic nude (nu/nu)", "Cell_line_used_to_induce_tumor_in_mice": "MA-148 cells", "Dose": "(10 mg/kg) and carboplatin (32.5 mg/kg)", "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1680", "Drug": "Oxaliplatin + interleukin 12", "Drug_category": "others/combination", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug_ID": "D01790", "Drug_Pubchem": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Combination", "PMID": "20855451", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal - Metastatic Colorectal Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38Luc1 cells", "Dose": "5 mg/kg", "Technique": "ELISA, Flow cytometery", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+/T regulatory cell ratio IFNg", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; Regulatory T cells / Tregs", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1681", "Drug": "IL-12 +cyclophosphamide", "Drug_category": "others/combination", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Combination", "PMID": "21148040", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "125 mg/kg", "Technique": "Immunohistochemisrry ,Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "infiltration by CD8+ T cells and tumor Ag-specific CD8+ T cells ,Ly6Chigh myeloid cells-Ly6C(high)Ly6G(low) inflammatory monocytes and Ly6G(high)Ly6C(+) neutrophils(inflammatory myeloid cells (IMC)) IL-1, IL-6, IL-12, CCL5, and CCL3", "Controlled_Terms_Function_enhanced_Number_increased": "IL-1 family; IL-6; IL-12; CCL3 / MIP-1α; CCL5 / RANTES; CD8; Monocytes; Neutrophils / granulocytes; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "CD4+ Foxp3+ T cells ,Mo-MDSC\n infiltration", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; FOXP3; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; T cells; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1686", "Drug": "IL-12+ Trastuzumab (4D5)", "Drug_category": "others/combination", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "21321106", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "1 × 106 CT-26HER2/neu cells", "Dose": "1 μg murine IL-12, 1 mg/kg 4D5", "Technique": "ELISA, Flow cytometery", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD69+ cells IFN-y, RANTES CD335", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CCL5 / RANTES; CD69", "Immune_System-Function_inhibited/numbers_decreased": "IL-8 MIP-1α was minimal", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8; CCL3 / MIP-1α", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1687", "Drug": "IL-12+ Trastuzumab+ anti-asialo GM1 Ab", "Drug_category": "others/combination", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "21321106", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "1 × 106 CT-26HER2/neu cells", "Dose": "1 μg murine IL-12, 1 mg/kg 4D5 +anti-asialo GM1 Ab", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IFN-y", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1688", "Drug": "IL12", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "21321106", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "1 × 106 CT-26HER2/neu cells", "Dose": "1 μg murine IL-12", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IFN-y, RANTES IL-8", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-8 / CXCL8; CCL5 / RANTES", "Immune_System-Function_inhibited/numbers_decreased": "MIP-1α was minimal", "Controlled_Terms_Function_inhibited_Number_decreased": "CCL3 / MIP-1α", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1697", "Drug": "Imatinib and CTLA-4", "Drug_category": "others/combination", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Drug_Pubchem": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Combination", "PMID": "21873989", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "Animal_Strain_used": "(KitV558Δ/+)", "Cell_line_used_to_induce_tumor_in_mice": "spontaneous", "Dose": "1.12 mg i.p. twice daily based on an established dose of 45 mg kg−1+CTLA-4 blocking antibodies (BioXCell) for induction by injecting 200 µg clone 9H10 i.p. on day 3, 100 ug clone 9H10 i.p. on days 6, 9, and 12, followed by 100 µg of clone 9D9 every 3 d thereafter for long term studies.", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "IFN-γ producing CD8+ T cells. IFN-γ producing CD8+ T cells.", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; T cells; CD8+ T cells; IFN-γ-producing cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1698", "Drug": "Cyclophosphamide (CY) 1 d + IL-12/GM-CSF therapy", "Drug_category": "others/combination", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Combination", "PMID": "21908736", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Spontaneous Mammary Tumors", "Animal_Strain_used": "FVBneuN", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "200 mg/kg", "Technique": "Flow Cytometry, Real Time Pcr", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD8(+) CTL IFNγ and Granzyme B", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; Cytotoxic T lymphocytes / CTLs; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "CD4+ Foxp3+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; FOXP3", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1699", "Drug": "SGI-1776(inhibitor of PIM kinase activity) and sunitinib", "Drug_category": "others/combination", "Drugbank_ID": "DB12494, DB01268", "Target/s_or_mechanism_of_action": "SGI-1776 has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias, Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "24795070, 5329102", "STR_LINK_(SMILES)": "CN1CCC(CNC2=NN3C(C=C2)=NC=C3C2=CC=CC(OC(F)(F)F)=C2)CC1, CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "22015557", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "Animal_Strain_used": "nude (BALB/c background)", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "sunitinib (40 mg kg–1 PO), SGI-1776 (200 mg kg–1 free base PO)", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Bad phosphorylation(induces apoptosis), c-Myc levels and decreases tumour cell proliferation", "Controlled_Terms_Function_inhibited_Number_decreased": "Apoptosis / caspase activation; Cell proliferation / Ki-67", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1700", "Drug": "SGI-1776(inhibitor of PIM kinase activity) and sunitinib", "Drug_category": "others/combination", "Drugbank_ID": "DB12494, DB01268", "Target/s_or_mechanism_of_action": "SGI-1776 has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias, Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "24795070, 5329102", "STR_LINK_(SMILES)": "CN1CCC(CNC2=NN3C(C=C2)=NC=C3C2=CC=CC(OC(F)(F)F)=C2)CC1, CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "22015557", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "Animal_Strain_used": "nude (BALB/c background)", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "sunitinib (40 mg kg–1 PO), SGI-1776 (200 mg kg–1 free base PO)", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Bad phosphorylation(induces apoptosis), c-Myc levels and decreases tumour cell proliferation", "Controlled_Terms_Function_inhibited_Number_decreased": "Apoptosis / caspase activation; Cell proliferation / Ki-67", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1704", "Drug": "IL-2 and entinostat", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "22303460", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "Animal_Strain_used": "BALB/c mouse", "Cell_line_used_to_induce_tumor_in_mice": "RENCA", "Dose": "IL-2 (Prometheus, 150,000 IU, twice a day, 2 d/wk, i.p.), entinostat (5 mg/kg, daily, 5 d/wk by oral gavage)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ induction-by CD8", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1706", "Drug": "Entinostat + survivin peptide vaccine SVN53-67/M57-KLH (SurVaxM)", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "22303460", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer -Castration Resistant Prostate Cancer", "Animal_Strain_used": "male FVB", "Cell_line_used_to_induce_tumor_in_mice": "CR Myc-CaP tumors", "Dose": "entinostat (5 days/wk, 5 mg/kg), SurVaxM (1 dose/wk)", "Technique": "Flow Cytometry,Mhc Class I Tetramer Binding Assay", "Controlled_Technique": "Flow cytometry; MHC class I tetramer-binding assay", "Immune_System-Function_enhanced/numbers_increased": "CD8+IFN-γ+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8", "Immune_System-Function_inhibited/numbers_decreased": "Foxp3 level in Tregs of tumor-bearing mice", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1707", "Drug": "Decitabine + Vorinostat", "Drug_category": "others/combination", "Drugbank_ID": "DB01262, DB02546", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses.\n Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D03665, D06320", "Drug_Pubchem": "451668, 5311", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "22461695", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "Animal_Strain_used": "BALB/c and Fasgld", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "Decitabine (0.1 mg/kg body weight), Vorinostat (25 mg/kg body weight)", "Technique": "Flow cytometry, RT PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "tumor-infiltrating CD8+ T cell and CD8− lung cells expressed FasL FasL, FasL-mediated tumor suppression", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1756", "Drug": "PLX4720+agonistic anti CD40", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "24736544", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BrafV600E/Pten", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "417mg/kg PLX4720+agonistic anti-CD40 Ab (250μg/mouse)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "FoxP3+ Treg CD4+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; FOXP3; Regulatory T cells / Tregs; T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4+ and CD8+ T cells, CD11b+/Gr-1+", "Controlled_Terms_Unaffected": "CD4; CD8; CD11b / ITGAM; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1709", "Drug": "Combined vaccine + axitinib therapy", "Drug_category": "others/combination", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug_ID": "D03218", "Drug_Pubchem": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Combination", "PMID": "22504156", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MO5 (B16.OVA) tumor cells", "Dose": "s.c. vaccine (syngenic DC.IL12 pulsed with the OVA257–264 and OVA323–339 peptides on days 7 and 14), axitinib alone (0.5 mg/day provided via oral gavage on days 7–13) or the combination of vaccine + axitinib", "Technique": "Flow Cytometry, Rt-Pcr And Fluorescence Microscopy", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Microscopy", "Immune_System-Function_enhanced/numbers_increased": "bulk CD8+ T cells IFN-γ,CXCR3,CXCL12 CD31+ vascular endothelial cells in treated melanomas appeared activated based on their enhanced expression of VCAM-1 Tbet", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL12 / SDF-1; CD8; CD31 / PECAM-1; T cells; CD8+ T cells; VCAM-1; CXCR3", "Immune_System-Function_inhibited/numbers_decreased": "MDSC and Treg populations", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1710", "Drug": "Vaccine -syngenic DC.IL12 pulsed with the OVA257–264 and OVA323–339 peptides", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "22504156", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MO5 (B16.OVA) tumor cells", "Dose": "s.c. vaccine (syngenic DC.IL12 pulsed with the OVA257–264 and OVA323–339 peptides on days 7 and 14)", "Technique": "Flow Cytometry, Rt-Pcr And Fluorescence Microscopy", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Microscopy", "Immune_System-Function_enhanced/numbers_increased": "bulk CD8+ T cells IFN-γ,CXCR3,CXCL11 CD31+ Tbet", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL11 / I-TAC; CD8; CD31 / PECAM-1; T cells; CD8+ T cells; CXCR3", "Immune_System-Function_inhibited/numbers_decreased": "Treg (CD4+Foxp3+) phenotypes in the TME", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1715", "Drug": "Anti-CTLA-4 + PLX4720", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "22934253", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "Tyr::CreERT2PTENF−/−BRAFF-V600E/+", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "a chow diet containing 417 mg/kg PLX4720 + Mice were injected intraperitoneal with the anti-CTLA-4 mAbs dissolved in HBSS. Dosing per injection was 200 μg for the hamster-derived anti-CTLA-4 mAb clone 9H10 (BioXcell, BE0131) and 100 μg for the mouse-derived anti-CTLA-4 mAb clone 9D9 (BioXcell, BE0164)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD45+ leukocytes, CD8+ and CD4+ T cells in the melanomas ,frequency of NK-cells, myeloid derived suppressor cells (MDSCs), macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; CD45; Myeloid-derived suppressor cells / MDSCs; Macrophages; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1730", "Drug": "AR-42 and/or DNA vaccine (DNA encoding CRT/E7)", "Drug_category": "others/combination", "Drugbank_ID": "DB12707", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "6918848", "STR_LINK_(SMILES)": "CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "23715898", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "TC-1 cells", "Dose": "AR-42 was given daily at a dose of 30 mg/kg body weight via oral gavage. The DNA vaccine (2 μg/mouse) was given at 3-day intervals via gene gun", "Technique": "Kaplan-Meier Survival Analysis, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Survival analysis (Kaplan–Meier)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells IFN-γ(IFN-γ-producing CD8+ T cells ) Improved survival", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; T cells; CD8+ T cells; IFN-γ-producing cells; Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1734", "Drug": "Lenalidomide and cyclophosphamide", "Drug_category": "others/combination", "Drugbank_ID": "DB00480, DB00531", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. \n Inhibition of protein synthesis", "KEGG_Drug_ID": "D04687, D07760", "Drug_Pubchem": "216326, 2907", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Combination", "PMID": "23765229", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - A20 Murine Lymphoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": null, "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "splenic Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1735", "Drug": "Lenalidomide and lymphoma Id DNA fusion vaccine", "Drug_category": "others/combination", "Drugbank_ID": "DB00480", "Target/s_or_mechanism_of_action": "In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.", "KEGG_Drug_ID": "D04687", "Drug_Pubchem": "216326", "STR_LINK_(SMILES)": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "Single/Combination": "Combination", "PMID": "23765229", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - A20 Murine Lymphoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "5mg/kg/day", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "anti-Id antibodies", "Controlled_Terms_Function_enhanced_Number_increased": "anti-Id antibodies", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1736", "Drug": "Lymphoma Id DNA fusion vaccine", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "23765229", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - A20 Murine Lymphoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "5mg/kg/day", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "anti-Id antibodies", "Controlled_Terms_Function_enhanced_Number_increased": "anti-Id antibodies", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1739", "Drug": "Ad5-OVA plus low-dose 5-fluorouracil (5-FU)", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "23840786", "Cancer_Type": "Thymoma", "Cancer_Type_Description": "Thymoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "E.G7", "Dose": "10^8 pfu (2.7×10^9 virus particles) of Ad5-OVA ± i.p. administration of 40 mg/kg 5-FU", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8(+) T lymphocytes", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "MDSCs", "Controlled_Terms_Negative_Regulation": "Myeloid-derived suppressor cells / MDSCs"}, {"ID": "CANIMM/1741", "Drug": "Α-lactalbumin vaccine and Sunitinib", "Drug_category": "others/combination", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "24105638", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Mammary Carcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1 mouse mammary carcinoma", "Dose": null, "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ myeloid derived suppressor cells (MDSCs), T regulatory cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1748", "Drug": "Sorafenib and YC-1, a soluble guanylyl cyclase (sGC) activator", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "24418169", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "nude", "Cell_line_used_to_induce_tumor_in_mice": "HCCLM3", "Dose": "sorafenib (30 mg/kg/day) and YC-1 (10 mg/kg/day)", "Technique": "Immunohistochemistry Assay", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": "p-STAT3, cyclin D1, and survivin,p-STAT3, cyclin D1, and survivin", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT3 signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1749", "Drug": "Sorafenib and YC-1, a soluble guanylyl cyclase (sGC) activator", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "24418169", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "nude", "Cell_line_used_to_induce_tumor_in_mice": "HepG2 cell", "Dose": "sorafenib (30 mg/kg/day) and YC-1 (10 mg/kg/day)", "Technique": "Immunohistochemistry Assay", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "Apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": "p-STAT3, cyclin D1, and survivin,p-STAT3, cyclin D1, and survivin", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT3 signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1752", "Drug": "Dasatinib + OVA peptide-based dendritic cell vaccination therapy", "Drug_category": "others/combination", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Drug_Pubchem": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Combination", "PMID": "24734217", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "M05 melanoma cells", "Dose": "0.01–1 mg/day", "Technique": "Immunofluorescence Staining And Fluorescence Microscopy,Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Microscopy; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "Type1 CD8+ effector T cell and DC infiltration", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Dendritic cells; T cells; Th1 / type 1 T-cell response; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ myeloid-derived suppressor cells (MDSC) and CD4+Foxp3+ regulatory T (Treg)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD11b / ITGAM; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1758", "Drug": "PLX4720+Anti IFN-y", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "24736544", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BrafV600E/Pten", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "417mg/kg PLX4720+IFNγ(250μg/mouse)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD11b+/Gr-1+", "Controlled_Terms_Function_enhanced_Number_increased": "CD11b / ITGAM", "Immune_System-Function_inhibited/numbers_decreased": "CD4+ and CD8+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; T cells; CD8+ T cells", "Immune_System_function_unaffected": "TAMs or TIDCs", "Controlled_Terms_Unaffected": "Tumor-associated macrophages / TAMs; Dendritic cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1759", "Drug": "PLX4720+GK1.5 mAbs", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "24736544", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BrafV600E/Pten", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "417mg/kg PLX4720+GK1.5 mAbs", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD8+ or CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1760", "Drug": "PLX4720+TIB210", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "24736544", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "BrafV600E/Pten", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "417mg/kg PLX4720 + TIB210", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD8+ or CD4+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD8; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1761", "Drug": "Cyclophosphamide + adoptive transfer (AT) of tumor-specific CD4+ T cells", "Drug_category": "others/combination", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Combination", "PMID": "24780756", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "B-Cell Lymphoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "B-cell lymphoma cell line A20 (A20HA)", "Dose": null, "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "inflammatory myeloid cells consisting of monocytic and granulocytic subsets", "Controlled_Terms_Unaffected": "inflammatory myeloid cells consisting of monocytic and granulocytic subsets", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1762", "Drug": "PLX4720 + anti-mouse PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "24903021", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "BP cells", "Dose": "BRAFi (200 ppm) was initiated at day 0. 100μg of anti-PD-1 (29F.1A12) antibody was administered i.p. at days 1, 3, and 5", "Technique": "Flow Cytometry, Immunohistochemical Staining", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD3+ T cells, CD8+ T cells in the tumor , The CD8/Treg ratio, polyfunctional CD8+ T cells producing both IFNγ and TNFα in the mice treated with anti-PD-1 and BRAFi", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; TNF-α / TNF; CD8; CD3; PD-1 / PDCD1; Regulatory T cells / Tregs; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1763", "Drug": "PLX4720 + anti-mouse PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "24903021", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "BP cells", "Dose": "BRAFi (200 ppm) was initiated at day 0. ), 200μg anti-PD-L1 (10F.9G2), or isotype antibody was administered i.p. at days 1, 3, and 5", "Technique": "Flow Cytometry, Immunohistochemical Staining", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD3+ T cells, The CD8/Treg ratio", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD3; Regulatory T cells / Tregs; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1768", "Drug": "PLX4720 +dasatinib", "Drug_category": "others/combination", "Drugbank_ID": "DB06999, DB01254", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf,\n Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Drug_Pubchem": "24180719, 3062316", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F,\n CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Combination", "PMID": "24994118", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "Animal_Strain_used": "B6129SF1/J", "Cell_line_used_to_induce_tumor_in_mice": "TBP-3743", "Dose": "PLX4720-impregnated chow (417 mg/kg) and 50 mg/kg dasatinib", "Technique": "Immunohistochemical Analysis", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cell infiltration was observed in tumors, infiltrating B220+ B cells, marker of monocytes and macrophages, F4/80 Caspase 3 cleavage- marker of apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Macrophages; Monocytes; B cells; T cells; CD8+ T cells; Apoptosis / caspase activation; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1769", "Drug": "PLX4720+Dasatinib", "Drug_category": "others/combination", "Drugbank_ID": "DB06999, DB01254", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf,\n Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Drug_Pubchem": "24180719, 3062316", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F,\n CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Combination", "PMID": "24994118", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer - (Anaplastic)", "Animal_Strain_used": "B6129SF1/J syngeneic", "Cell_line_used_to_induce_tumor_in_mice": "105 TBP-3743 cells", "Dose": "PLX4720-impregnated\n chow (417 mg/kg), orally gavaged with 50 mg/kg dasatinib five days per week", "Technique": "Immunohistochemial Analysis", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1770", "Drug": "Pmel-ACT+ LBH589 (Panobinostat)", "Drug_category": "others/combination", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug_ID": "D10019", "Drug_Pubchem": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "25054063", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "B16-F10", "Dose": "LBH589 (Panobinostat): 5 mg/kg+ \"5 × 106 gp100-specific Pmel\n T cells\"+ \"gp10025-33 peptide pulsed dendritic\n cell vaccination\"", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Pmel T cells (CD8+ Thy1.1+) IFN-γ ,TNF, and IL-10, IL-6 CD25, OX-40", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-6; IL-10; TNF-α / TNF; CD8; CD25 / IL2RA; T cells", "Immune_System-Function_inhibited/numbers_decreased": "T regulatory cells (CD3+ CD4+ FoxP3+)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD3; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": "CD40L, 4-1BB, or CD27", "Controlled_Terms_Unaffected": "CD40L / CD154", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1773", "Drug": "PLX4720", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": null, "PMID": "25183499", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6 (Braf/Pten model)", "Cell_line_used_to_induce_tumor_in_mice": "Braf/Pten tumors", "Dose": "PLX4720 (417 mg/kg) for 10 days", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "increased CD8+ T cells by proportion of CD45+ cells but not the absolute number, increased CD4 +T cells by proportion of CD45+ cells but not the absolute number,", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD45; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "Foxp3+ Tregs,CD11b+Gr1+", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": "T-bet, GATA3, and RORγt", "Controlled_Terms_Unaffected": "T-bet, GATA3, and RORγt", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1777", "Drug": "PD184352 and BMS-345541", "Drug_category": "others/combination", "Drugbank_ID": "DB12429", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "6918454", "STR_LINK_(SMILES)": "FC1=C(F)C(NC2=CC=C(I)C=C2Cl)=C(C=C1)C(=O)NOCC1CC1", "Single/Combination": "Combination", "PMID": "25256614", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57J/B6", "Cell_line_used_to_induce_tumor_in_mice": "BRafV600E-4434", "Dose": "25 mg/kg/day PD184352 and 40 mg/kg/day BMS-345541", "Technique": "Immunofluorescence Staining", "Controlled_Technique": "Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "pan macrophage marker CD68, and also the M1 and M2 macrophage markers CD86 and CD163, in the tumors from mice treated with the MEKi/IKKi combination when compared to the MEKi and IKKi only treatment", "Controlled_Terms_Function_inhibited_Number_decreased": "CD86; CD68; CD163; Macrophages; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1778", "Drug": "5-fluorouracil (5-FU)+IFN-a", "Drug_category": "others/combination", "Drugbank_ID": "DB00544", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA", "KEGG_Drug_ID": "D00584", "Drug_Pubchem": "3385", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O", "Single/Combination": "Combination", "PMID": "25368252", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Cancer", "Animal_Strain_used": "C57BL/6 (B6)", "Cell_line_used_to_induce_tumor_in_mice": "Panc02 cells", "Dose": "5-FU (35 mg/g/d; IP from day 5 to day 9)+murine IFN-a on days 5, 7, 9 (500 IU/g, SC).", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8 T cells, infiltrating NK cells, dendritic cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Dendritic cells; NK cells; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1862", "Drug": "Trametinib + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "27622011", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1", "Dose": "0.6mg/kg of trametinib + 4 doses of 200 ug of PD-1", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD3+CD8+ cells in the tumors,CD3+CD4+ cells in the tumors,", "Controlled_Terms_Unaffected": "CD4; CD8; CD3", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1781", "Drug": "Golvatinib + lenvatinib", "Drug_category": "others/combination", "Drugbank_ID": "DB11977, DB09078", "Target/s_or_mechanism_of_action": "An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. Golvatinib binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of various tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.\n Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET", "KEGG_Drug_ID": "D09919", "Drug_Pubchem": "16118392, 9823820", "STR_LINK_(SMILES)": "CN1CCN(CC1)C1CCN(CC1)C(=O)NC1=CC(OC2=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C(F)=C2)=CC=N1,\n COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O", "Single/Combination": "Combination", "PMID": "25458359", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid -Human Thyroid Cancer", "Animal_Strain_used": "Nude (CAnN.Cg-Foxn1nu/CrlCrlj; female, 5–6 weeks old)", "Cell_line_used_to_induce_tumor_in_mice": "K1/angiopoietin-2 (Ang2)", "Dose": "golvatinib 100 mg/kg + lenvatinib 10 mg/kg", "Technique": "Immunohistochemical Analysis, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "myeloid cells (CD11b+), macrophages (F4/80+ in Flow cytometry, CD11b+F4/80+ in immunohistochemistry)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1784", "Drug": "Golvatinib + lenvatinib", "Drug_category": "others/combination", "Drugbank_ID": "DB11977, DB09078", "Target/s_or_mechanism_of_action": "An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. Golvatinib binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of various tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.\n Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET", "KEGG_Drug_ID": "D09919", "Drug_Pubchem": "16118392, 9823820", "STR_LINK_(SMILES)": "CN1CCN(CC1)C1CCN(CC1)C(=O)NC1=CC(OC2=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C(F)=C2)=CC=N1,\n COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O", "Single/Combination": "Combination", "PMID": "25458359", "Cancer_Type": "Uterus", "Cancer_Type_Description": "Endometrial - Human Endometrial Cancer", "Animal_Strain_used": "Nude (CAnN.Cg-Foxn1nu/CrlCrlj; female, 5–6 weeks old)", "Cell_line_used_to_induce_tumor_in_mice": "AN3CA tumors", "Dose": "golvatinib 100 mg/kg + lenvatinib 10 mg/kg", "Technique": "Immunohistochemical Analysis, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "macrophage population", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1788", "Drug": "Sorafenib + AMD3100", "Drug_category": "others/combination", "Drugbank_ID": "DB00398, DB06809", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.\n Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered. Filgrastim, a granulocyte-colony stimulating factor, is added to enhance CD34+ cell mobilization, thus increasing the yield of stem cells- an important determinant of graft adequacy.", "KEGG_Drug_ID": "D08524,\n D08971", "Drug_Pubchem": "216239, \n 65015", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,\n C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Combination", "PMID": "25529917", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C3H", "Cell_line_used_to_induce_tumor_in_mice": "HCA-1 tumors", "Dose": "sorafenib at a dose of 50mg/kg (in PBS/1%Tween80, MGH Pharmacy), and with the CXCR4 inhibitor AMD3100 (10mg/kg bodyweight, s.c. by osmotic minipumps, Sigma)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "F4/80+ TAMs, and CD11b+Gr-1+ and CD45+CXCR4+ myeloid cells, CD4+CD25+FoxP3+ Tregs in HCA-1 tumors, M2-type markers in TAMs without affecting that of M1-type markers", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD25 / IL2RA; CD11b / ITGAM; CD45; FOXP3; Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs; CXCR4", "Immune_System_function_unaffected": "CD4+ and CD8+ T-lymphocytes", "Controlled_Terms_Unaffected": "CD4; CD8", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1789", "Drug": "Sorafenib + AMD3100 + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB00398, DB06809", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.\n Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered. Filgrastim, a granulocyte-colony stimulating factor, is added to enhance CD34+ cell mobilization, thus increasing the yield of stem cells- an important determinant of graft adequacy.", "KEGG_Drug_ID": "D08524,\n D08971", "Drug_Pubchem": "216239, \n 65015", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,\n C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Combination", "PMID": "25529917", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "Mst1–/– Mst2F/–", "Cell_line_used_to_induce_tumor_in_mice": "induced liver fibrosis with carbon tetrachloride (CCl4) treatment (20%v/v in olive oil, 150µL gavage, 3 times per week) for 12 weeks", "Dose": "sorafenib at a dose of 50mg/kg (in PBS/1%Tween80, MGH Pharmacy), and with the CXCR4 inhibitor AMD3100 (10mg/kg bodyweight, s.c. by osmotic minipumps, Sigma), PD-1 (100μg i.p. every 3 days, for a total of 5 times).", "Technique": "Immunoflorescence staining, immunohistochemistry, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "intratumoral penetration and activation of CD8+ T-lymphocytes in HCC IFN-γ, IL-2 and TNF-α apoptosis- cleaved caspase 3", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; TNF-α / TNF; CD8; Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1790", "Drug": "Sorafenib + AMD3100 + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB00398, DB06809", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.\n Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered. Filgrastim, a granulocyte-colony stimulating factor, is added to enhance CD34+ cell mobilization, thus increasing the yield of stem cells- an important determinant of graft adequacy.", "KEGG_Drug_ID": "D08524,\n D08971", "Drug_Pubchem": "216239, \n 65015", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,\n C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Combination", "PMID": "25529917", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C3H", "Cell_line_used_to_induce_tumor_in_mice": "HCA-1 tumors", "Dose": "sorafenib at a dose of 50mg/kg (in PBS/1%Tween80, MGH Pharmacy), and with the CXCR4 inhibitor AMD3100 (10mg/kg bodyweight, s.c. by osmotic minipumps, Sigma), PD-1 (100μg i.p. every 3 days, for a total of 5 times).", "Technique": "Immunoflorescence staining, immunohistochemistry, ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "intratumoral penetration and activation of CD8+ T-lymphocytes in HCC IFN-γ, IL-2 and TNF-α apoptosis- cleaved caspase 3", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; TNF-α / TNF; CD8; Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1791", "Drug": "Bortezomib( a proteasome inhibitor) and SAHA( Vorinostat)", "Drug_category": "others/combination", "Drugbank_ID": "DB00188, DB02546", "Target/s_or_mechanism_of_action": "Bortezomib is a reversible inhibitor of the 26S proteasome, which is made up of a 20S core complexed with a 19S regulatory complex. Individual β-subunits allow specific catalytic action of the 20S core.\n Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D03150,D06320", "Drug_Pubchem": "387447, 5311", "STR_LINK_(SMILES)": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,\n ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "25591912", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "TC-1 tumor cells", "Dose": "bortezomib (1 mg/kg, once every 3 days), SAHA (30 mg/kg, once per day)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "E7-specific CD8+ T cells, CD8+ T cells in the tumor IFN-γ by CD8+ T cells significantly lower tumor volume", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; T cells; CD8+ T cells; Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1794", "Drug": "Dabrafenib+ACT", "Drug_category": "others/combination", "Drugbank_ID": "DB08912", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene.", "KEGG_Drug_ID": "D10064", "Drug_Pubchem": "44462760", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1", "Dose": "three million gp10025-33 peptide activated pmel-1 splenocytes+ 30 mg/kg of dabrafenib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+Thy1.1+ (adoptively transferred pmel-1 effector) and CD3+CD8+ (both endogenous and adoptively transferred effector) cells MHC expression, PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD3; PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "decreased percentage of MO-MDSC in spleen", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "tumour-associated macrophages (TAMs, F4/80+CD11b+), increased MO-MDSCs (Ly6ChighLy6GlowCD11b+) and decreased PMN-MDSCs (Ly6ClowLy6GhighCD11b+) in tumors", "Controlled_Terms_Negative_Regulation": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / granulocytic MDSCs; Tumor-associated macrophages / TAMs; Macrophages"}, {"ID": "CANIMM/1795", "Drug": "Dabrafenib+trametinib+ACT", "Drug_category": "others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Drug_Pubchem": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1", "Dose": "three million gp10025-33 peptide activated pmel-1 splenocytes+ 0.6mg/kg of trametinib+30 mg/kg of dabrafenib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+Thy1.1+ (adoptively transferred pmel-1 effector) and CD3+CD8+ (both endogenous and adoptively transferred effector) cells MHC expression, PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD3; PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD11b+ cells in spleen", "Controlled_Terms_Unaffected": "CD11b / ITGAM", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "tumour-associated macrophages (TAMs, F4/80+CD11b+), T regulatory cells (Tregs, CD4+CD25+FOXp3+) showed significantly increased percentage in the tumours, increased MO-MDSCs (Ly6ChighLy6GlowCD11b+) and decreased PMN-MDSCs (Ly6ClowLy6GhighCD11b+) in tumors", "Controlled_Terms_Negative_Regulation": "CD4; CD25 / IL2RA; CD11b / ITGAM; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / granulocytic MDSCs; Tumor-associated macrophages / TAMs; Macrophages"}, {"ID": "CANIMM/1796", "Drug": "Dobrafenib+ Trametinib", "Drug_category": "others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Drug_Pubchem": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "dabrafenib (30 mg/kg) and trametinib(0.15mg/kg)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1797", "Drug": "Pmel-1 ACT+Dabrafenib", "Drug_category": "others/combination", "Drugbank_ID": "DB08912", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene.", "KEGG_Drug_ID": "D10064", "Drug_Pubchem": "44462760", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "ACT (3 million)+Dobrafenib (30 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+Thy1.1+, CD3+CD8+\n (both endogenous and adoptively transferred\n effector) cells, Ly6CHiLy6GLoCD11b+, F4/80+CD11b+, T regulatory cells (Tregs; CD4+CD25+FOXp3+)", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD3; CD25 / IL2RA; CD11b / ITGAM; FOXP3; Regulatory T cells / Tregs", "Immune_System-Function_inhibited/numbers_decreased": "Ly6CLoLy6GHiCD11b+", "Controlled_Terms_Function_inhibited_Number_decreased": "Ly6CLoLy6GHiCD11b+", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1798", "Drug": "Pmel-1 ACT+Dabrafenib", "Drug_category": "others/combination", "Drugbank_ID": "DB08912", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene.", "KEGG_Drug_ID": "D10064", "Drug_Pubchem": "44462760", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "ACT (3 million)+Dobrafenib (30 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+Thy1.1+ IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1799", "Drug": "Pmel-1 ACT+Dabrafenib +anti PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB08912", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene.", "KEGG_Drug_ID": "D10064", "Drug_Pubchem": "44462760", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "ACT (3 million)+Dobrafenib (30 mg/kg)+anti PD-1 (200 ug)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1800", "Drug": "Pmel-1 ACT+dabrafenib+trametinib", "Drug_category": "others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Drug_Pubchem": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "ACT (3 million)+dabrafenib(30 mg/kg) and trametinib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+Thy1.1+ IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1801", "Drug": "Pmel-1 ACT+dabrafenib+trametinib+ anti PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Drug_Pubchem": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "ACT (3 million)+dabrafenib(30 mg/kg) +trametinib+ anti PD-1(200 ug)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1802", "Drug": "Pmel-1 ACT+Dobrafenib+ Trametinib", "Drug_category": "others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Drug_Pubchem": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "ACT of gp10025-33 peptide–activated\n splenocytes obtained from pmel-1mice (3 million)+dabrafenib(30 mg/kg) and trametinib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+Thy1.1+, CD3+CD8+\n (both endogenous and adoptively transferred\n effector) cells, Ly6CHiLy6GLoCD11b+, F4/80+CD11b+ IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; CD3; CD11b / ITGAM", "Immune_System-Function_inhibited/numbers_decreased": "Ly6CLoLy6GHiCD11b+", "Controlled_Terms_Function_inhibited_Number_decreased": "Ly6CLoLy6GHiCD11b+", "Immune_System_function_unaffected": "T regulatory cells (Tregs; CD4+CD25+FOXp3+)", "Controlled_Terms_Unaffected": "CD4; CD25 / IL2RA; FOXP3; Regulatory T cells / Tregs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1803", "Drug": "Pmel-1 ACT+Trametinib", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "ACT (3 million)+Trametinib(0.6 mg/kg)", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+Thy1.1+, CD3+CD8+\n (both endogenous and adoptively transferred\n effector) cells, Ly6CHiLy6GLoCD11b+, F4/80+CD11b+", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD3; CD11b / ITGAM", "Immune_System-Function_inhibited/numbers_decreased": "Ly6CLoLy6GHiCD11b+", "Controlled_Terms_Function_inhibited_Number_decreased": "Ly6CLoLy6GHiCD11b+", "Immune_System_function_unaffected": "T regulatory cells (Tregs; CD4+CD25+FOXp3+)", "Controlled_Terms_Unaffected": "CD4; CD25 / IL2RA; FOXP3; Regulatory T cells / Tregs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1804", "Drug": "Pmel-1 ACT+Trametinib", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "ACT (3 million)+Trametinib(0.6 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+Thy1.1+ IFN-y", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD3", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1805", "Drug": "Pmel-1 ACT+Trametinib+ anti PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "murine melanoma SM1", "Dose": "ACT (3 million)+Trametinib(0.6 mg/kg)+ anti PD-1 (200 ug)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1806", "Drug": "Trametinib+ACT", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "25787767", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1", "Dose": "three million gp10025-33 peptide activated pmel-1 splenocytes+ 0.6mg/kg of trametinib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+Thy1.1+ (adoptively transferred pmel-1 effector) and CD3+CD8+ (both endogenous and adoptively transferred effector) cells MHC expression, PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD3; PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD11b+ cells in spleen", "Controlled_Terms_Unaffected": "CD11b / ITGAM", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "increased MO-MDSCs (Ly6ChighLy6GlowCD11b+) and decreased PMN-MDSCs (Ly6ClowLy6GhighCD11b+) in tumors", "Controlled_Terms_Negative_Regulation": "Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / granulocytic MDSCs"}, {"ID": "CANIMM/1807", "Drug": "Sorafenib + anti-CTLA-4", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "25845968", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "RENCA cells", "Dose": "Sorafenib (10 mg/kg) and anti-CTLA-4 Ab (100 g/mouse)", "Technique": "Immunohostochemistry", "Controlled_Technique": "Immunohostochemistry", "Immune_System-Function_enhanced/numbers_increased": "CD4- cells and CD8-cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1809", "Drug": "Sunitinib + SFVeE6,7 immunization", "Drug_category": "others/combination", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "25949902", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "TC-1 tumor cells", "Dose": "20 or 40 mg/kg body weight i.p", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs,Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1812", "Drug": "Metronomic Cyclophosphamide + DepoVax vaccine containing HPV16E749–57 peptide antigen", "Drug_category": "others/combination", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Combination", "PMID": "25960932", "Cancer_Type": "Hpv16-Expressing Tumors", "Cancer_Type_Description": "Hpv16-Expressing Tumors", "Animal_Strain_used": "C57BL6", "Cell_line_used_to_induce_tumor_in_mice": "C3 tumor line", "Dose": "(20 mg/kg/day) CPA in combination with a 10 μg R9F-PADRE antigen (DPX-R9F) DepoVax vaccine containing HPV16E749-57 (R9F) peptide antigen (DPX-R9F).", "Technique": "IFNγ ELISPOT assay +Flow cytometry+RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells,increased T-cell infiltration IFNγ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1814", "Drug": "Cyclophosphamide + lysate/CpG oligodeoxynucleotide (ODN)", "Drug_category": "others/combination", "Drugbank_ID": "DB00531", "Target/s_or_mechanism_of_action": "Inhibition of protein synthesis", "KEGG_Drug_ID": "D07760", "Drug_Pubchem": "2907", "STR_LINK_(SMILES)": "ClCCN(CCCl)P1(=O)NCCCO1", "Single/Combination": "Combination", "PMID": "26082836", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "Neuroblastoma", "Animal_Strain_used": "Male A/J", "Cell_line_used_to_induce_tumor_in_mice": "AgN2a", "Dose": "100 mg/kg", "Technique": "ELISPOT assay, Flow cytometry", "Controlled_Technique": "Flow cytometry; ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "CD4 and CD8 T cells, DC activation IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; Dendritic cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1818", "Drug": "A-GITR", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "26239999", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal - Metastatic Renal Cell Cancer", "Animal_Strain_used": "B6", "Cell_line_used_to_induce_tumor_in_mice": "RENCA cells", "Dose": "a-GITR (100 µg, i.p.)", "Technique": "Flow cytometry, real-time quantitative\n PCR (q-PCR)", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD69 and NKG2D CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD69; T cells; CD8+ T cells; NKG2D ligand / receptor pathway", "Immune_System-Function_inhibited/numbers_decreased": "CD41FoxP3 Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1849", "Drug": "CD40 monoclonal antibody (mAb) therapy + sunitinib", "Drug_category": "others/combination", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "27385210", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Fibrosarcoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "T241 fibrosarcoma cells", "Dose": "30 μg agonistic rat-anti-mouse CD40 antibody +sunitinib- dose of 50 mg/kg", "Technique": "Flow cytometry,Immunofluorescence Staining", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "CD86 on cDCs (B220−CD11b+/−CD11c+), intratumoral CD8+ T-cells ICAM-1 and VCAM-1", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD86; CD11b / ITGAM; CD11c / ITGAX; T cells; VCAM-1; ICAM-1 / CD54", "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1999", "Drug": "Peptide R", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31661001", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38 (1 × 106)", "Dose": "Pep R (2 mg/kg, 5 days per week for 2 weeks)", "Technique": "Immunostaining, Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC); Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "Granzyme B (GRZB) positive immune cells", "Controlled_Terms_Function_enhanced_Number_increased": "Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "FoxP3 positive Treg cells CXCR4,CXCL12 decreased in tumors PD-L1 reduction", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL12 / SDF-1; PD-L1 / CD274; FOXP3; Regulatory T cells / Tregs; Immune checkpoint pathway; CXCR4", "Immune_System_function_unaffected": "CXCR7, PD-1 expression", "Controlled_Terms_Unaffected": "PD-1 / PDCD1; CXCR7", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1819", "Drug": "Sunitinib plus a-GITR induced", "Drug_category": "others/combination", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "26239999", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal - Metastatic Renal Cell Cancer", "Animal_Strain_used": "B6", "Cell_line_used_to_induce_tumor_in_mice": "RENCA cells", "Dose": ", a-GITR (100 µg, i.p.), or Sunitinib (20 mg/kg weight, oral gavage)", "Technique": "Flow cytometry, real-time quantitative\n PCR (q-PCR)", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "lymphocytic infiltration, localization of leukocytes in or around tumor foci , infiltration of CD8 T\n cells, NK cells, DCs and macrophages within the livers IFN-g expression in CD8 T cells, IL-12 and TNF alpha. CXCR3 and its ligands CXCL9/MIG, CXCL10/IP-10 and CXCL11/I-TAC CD69 and NKG2D on CD8 T cells, Ki67 protein\n in both NK cells and CD 8 T cells , CD40, CD80,\n CD86 and MHC-II on macrophages and DCs", "Controlled_Terms_Function_enhanced_Number_increased": "IL-12; TNF-α / TNF; CXCL9 / MIG; CXCL10 / IP-10; CXCL11 / I-TAC; CD8; CD69; CD80; CD86; CD40; MHC class II; Macrophages; Dendritic cells; NK cells; T cells; CD8+ T cells; NKG2D ligand / receptor pathway; CXCR3; Cell proliferation / Ki-67; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "liver-infiltrating CD4 T cells, CD41FoxP3 Tregs, CD11b1Gr-11\n MDSC infiltration CCL2/MCP1, CXCL12/SDF-1a, S100A8/9, CCL17 and CCL22, TGF-b, IL-10 PD1, CTLA-4,, GATA-3 and FoxP3 as well as the MDSC-associated gene products arginase-1 and IDO-1", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; CCL2 / MCP-1; CXCL12 / SDF-1; CD4; PD-1 / PDCD1; CTLA-4; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; T cells; CD4+ T cells; IDO1; Arginase-1 / ARG1; Immune-cell infiltration", "Immune_System_function_unaffected": "IL-17 ROR-gt", "Controlled_Terms_Unaffected": "IL-17 / IL-17A", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1820", "Drug": "Sorafenib + TLR3 agonist: lysine-stabilized polyinosinic-polycytidylic-acid (poly-ICLC)", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "26287667", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Hepa 1-6 cells", "Dose": "20 μl of poly-ICLC (40 μg/dose) + 8.5–11.5 μg Sorafenib per gram of body weight per day", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "NK cells and T cells Apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; T cells; Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": "PD-1 expressing CD 8 cells", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1822", "Drug": "LBH589 (panobinostat) +PD-1 blocking antibody", "Drug_category": "others/combination", "Drugbank_ID": "DB06603", "Target/s_or_mechanism_of_action": "Panobinostat is a potent inhibitor of histone deacetylase, which is responsible for the regulation of gene transcription, cellular differentiation, cell-cycle progression, and apoptosis.", "KEGG_Drug_ID": "D10019", "Drug_Pubchem": "6918837", "STR_LINK_(SMILES)": "CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C2=CC=CC=C2N1", "Single/Combination": "Combination", "PMID": "26297712", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "B16F10", "Dose": "LBH589 (15mg/kg) (Monday, Wednesday and Friday), PD-1 blocking antibody (3mg/kg) (Tuesday and Thursday)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "improved survival", "Controlled_Terms_Function_enhanced_Number_increased": "Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1829", "Drug": "Murine anti–PD-1 antibody and mTOR inhibitor (rapamycin; )/Sirolimus", "Drug_category": "others/combination", "Drugbank_ID": "DB00877", "Target/s_or_mechanism_of_action": "Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15.", "KEGG_Drug_ID": "D00753", "Drug_Pubchem": "5284616", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "26637667", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Tumors", "Animal_Strain_used": "C57BL/6 KRAS LA2", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": null, "Technique": "Immunohistochemical Staining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD3+T cells A marker of apoptosis, cleaved caspase-3,", "Controlled_Terms_Function_enhanced_Number_increased": "CD3; T cells; Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": "FoxP3 Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1831", "Drug": "BRAF inhibitor (BRAF-I) Vemurafenib and IFN-a +HLA-A2-\n NY-ESO-1 peptide157-165-complex- specific T-cells", "Drug_category": "others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Drug_Pubchem": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "26851802", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "SCID", "Cell_line_used_to_induce_tumor_in_mice": "BRAFV600E M21 melanoma cells", "Dose": "1x106 cells/\n mouse", "Technique": "Flow Cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1832", "Drug": "BRAF inhibitor (BRAF-I) Vemurafenib and IFN-a +HLA-A2-\n NY-ESO-1 peptide157-165-complex- specific T-cells", "Drug_category": "others/combination", "Drugbank_ID": "DB08881", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Drug_Pubchem": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "26851802", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "NSG", "Cell_line_used_to_induce_tumor_in_mice": "BRAFV600E SK-MEL-37 melanoma cells", "Dose": "1x106 cells/\n mouse", "Technique": "Flow Cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1835", "Drug": "BRAFi PLX4720+Anti PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "26943572", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer", "Animal_Strain_used": "B6129SF1/J", "Cell_line_used_to_induce_tumor_in_mice": "105 genetically engineered murine ATC; TBP 3743\n BRAFV600E/WT P53-/- cells", "Dose": "PLX4720-impregnated chow (417 mg/kg) and anti PD-L1 200ug/mouse/I.P dose every other day (4 total doses)", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1836", "Drug": "Anti-PD-1 and romidepsin", "Drug_category": "others/combination", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug_ID": "D06637", "Drug_Pubchem": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Combination", "PMID": "26964571", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "129S4/SvJaeJ", "Cell_line_used_to_induce_tumor_in_mice": "LKR cells", "Dose": "Romidepsin - i.p. (2 mg/kg) on days 14, 16 and 18 after tumor inoculation. Anti-PD-1 - i i.p. (300 μg/mouse per injection) on days 15, 17 and 19 after tumor inoculation", "Technique": "RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD4 and CD8 T IFNγ Cxcl10 and Cxcl9", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL9 / MIG; CXCL10 / IP-10; CD4; CD8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1838", "Drug": "Trametinib + ALT-803", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "26980764", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Tumors", "Animal_Strain_used": "Ly5.1 (CD45.1+)", "Cell_line_used_to_induce_tumor_in_mice": "ID8-OVA cells", "Dose": "trametinib (1.0 mg/kg) from day 9–13. On day 10, Cell Trace labelled OT-I T cells (CD45.2+) were injected i.p. and mice were treated i.p. with ALT-803 (0.2 mg/kg) or PBS", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "overcome trametinib-induced CD8+ T cell suppression in the tumor microenvironment.", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1840", "Drug": "Cediranib and MEDI3617", "Drug_category": "others/combination", "Drugbank_ID": "DB04849", "Target/s_or_mechanism_of_action": "Cediranib inhibits vacular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK).", "KEGG_Drug_ID": "D08881", "Drug_Pubchem": "9933475", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1", "Single/Combination": "Combination", "PMID": "27044097", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "Animal_Strain_used": "nude or C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Gl261 cells", "Dose": "cediranib (6 mg/kg) + MEDI3617 (10 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "M1/M2 ratio", "Controlled_Terms_Function_enhanced_Number_increased": "M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1841", "Drug": "MEDI3617", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "27044097", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "Animal_Strain_used": "nude or C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Gl261 cells", "Dose": "MEDI3617 (10 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "increased TAMs compared with cediranib-treated tumors", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor-associated macrophages / TAMs", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1850", "Drug": "CD40 monoclonal antibody (mAb) therapy + sunitinib", "Drug_category": "others/combination", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "27385210", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Murine B16.F10 melanoma", "Dose": "30 μg agonistic rat-anti-mouse CD40 antibody +sunitinib- dose of 50 mg/kg", "Technique": "Flow cytometry,Immunofluorescence Staining", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "CD86 on cDCs (B220−CD11b+/−CD11c+), intratumoral CD8+ T-cells ICAM-1 and VCAM-1", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD86; CD11b / ITGAM; CD11c / ITGAX; T cells; VCAM-1; ICAM-1 / CD54", "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1852", "Drug": "Cetuximab + IL-21", "Drug_category": "others/combination", "Drugbank_ID": "DB00002", "Target/s_or_mechanism_of_action": "Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.", "KEGG_Drug_ID": "D03455", "Drug_Pubchem": "46507042", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "27435400", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Adenocarcinoma", "Animal_Strain_used": "01B74 nude athymic nude", "Cell_line_used_to_induce_tumor_in_mice": "Panc02EGFR tumor cells", "Dose": "5 μg IL-21, 0.5 mg/kg cetuximab", "Technique": "NK cells depletion studies", "Controlled_Technique": "Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": "NK cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1853", "Drug": "Imatinib + PD-1/PD-L1 blockade", "Drug_category": "others/combination", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Drug_Pubchem": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Combination", "PMID": "27470968", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "Animal_Strain_used": "KitV558Δ/+", "Cell_line_used_to_induce_tumor_in_mice": "spontaneous", "Dose": null, "Technique": "Flow cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "intratumoral cytokine-producing CD8+ T cells.", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "PD-1 and PD-L1 expression on tumor cells phosphorylated KIT, phosphorylated STAT1, IDO and TGFβ and its upstream mediator phosphorylated SMAD2", "Controlled_Terms_Function_inhibited_Number_decreased": "TGF-β; PD-L1 / CD274; PD-1 / PDCD1; Immune checkpoint pathway; STAT1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1857", "Drug": "Dabrafenib plus trametinib", "Drug_category": "others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Drug_Pubchem": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "27622011", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - SM1 Murine Melanoma", "Animal_Strain_used": "BRAFV600E mutant transgenic", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "30 mg/kg of dabrafenib or/and 0.6mg/kg of trametinib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+CD8+cells, CD3+CD4+cells, Ly6ClowLy6GhighCD11b+ (PMN-MDSC), Ly6ChighLy6GlowCD11b+ (MO-MDSC), F4/80+CD11b+ (TAMS), CD4+\n CD25+ FOXp3+ (Tregs) PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD3; CD25 / IL2RA; CD11b / ITGAM; PD-L1 / CD274; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / granulocytic MDSCs; Tumor-associated macrophages / TAMs; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1858", "Drug": "Dabrafenib+ trametinib +anti-\n PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Drug_Pubchem": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "27622011", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - SM1 Murine Melanoma", "Animal_Strain_used": "BRAFV600E mutant transgenic", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "30 mg/kg of dabrafenib or/and 0.6mg/kg of trametinib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+CD8+cells, CD3+CD4+cells, Ly6ClowLy6GhighCD11b+ (PMN-MDSC), Ly6ChighLy6GlowCD11b+ (MO-MDSC), F4/80+CD11b+ (TAMS), CD4+\n CD25+ FOXp3+ (Tregs) PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD3; CD25 / IL2RA; CD11b / ITGAM; PD-L1 / CD274; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / granulocytic MDSCs; Tumor-associated macrophages / TAMs; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1859", "Drug": "Dabrafenib+anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB08912", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene.", "KEGG_Drug_ID": "D10064", "Drug_Pubchem": "44462760", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1", "Single/Combination": "Combination", "PMID": "27622011", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1", "Dose": "30 mg/kg of dabrafenib + 4 doses of 200 ug of PD-1", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD3+CD8+ cells in the tumors,CD3+CD4+ cells in the tumors,", "Controlled_Terms_Unaffected": "CD4; CD8; CD3", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1860", "Drug": "Dabrafenib+trametinib", "Drug_category": "others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Drug_Pubchem": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "27622011", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1", "Dose": "30 mg/kg of dabrafenib+0.6mg/kg of trametinib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+CD8+ cells in the tumors,CD3+CD4+ cells in the tumors, MDSCs (CD11b+) in the tumors and spleens, mature TAMs\n (F4/80+CD11b+) in tumors, CD4+CD25+FOXp3+ Tregs in tumors PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD3; CD25 / IL2RA; CD11b / ITGAM; PD-L1 / CD274; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Tumor-associated macrophages / TAMs; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1861", "Drug": "Dabrafenib+Trametinib+anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB08912, DB08911", "Target/s_or_mechanism_of_action": "Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. \n trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10064, D10175", "Drug_Pubchem": "44462760, 11707110", "STR_LINK_(SMILES)": "CC(C(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O(=O)C2=C(F)C=CC=C2F)=CC=C1,\n CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "27622011", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1", "Dose": "30 mg/kg of dabrafenib+0.6mg/kg of trametinib+4 doses of 200 ug of PD-1", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD3+CD8+ cells in the tumors,CD3+CD4+ cells in the tumors, MDSCs (CD11b+) in the tumors and spleens, mature TAMs\n (F4/80CCD11bC) in tumors, CD4+CD25+FOXp3+ Tregs in tumors PD-L1", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD3; CD25 / IL2RA; CD11b / ITGAM; PD-L1 / CD274; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Tumor-associated macrophages / TAMs; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1865", "Drug": "Sunitinib +LCP-Trp2 vaccine- targeted polymeric micelle nano-delivery system (SUNb-PM)", "Drug_category": "others/combination", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "27863995", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "B16F10 melanoma cell lines", "Dose": "VAC was injected on day 14 at a dose of 0.3 mg/kg; SUNOS and SUNb-PM were p.o. or i.v. administered on days 14, 16, and 18 at a dose of 30 mg/kg or 10 mg/kg, respectively.", "Technique": "Flow cytometry, Western blot analysis,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic T-cell infiltration Th1 cytokine expression", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Th1 / type 1 T-cell response; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs and Tregs Stat3 and AKT", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; STAT3 signaling; AKT signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1866", "Drug": "Celecoxib and sunitinib", "Drug_category": "others/combination", "Drugbank_ID": "DB00482, DB01268", "Target/s_or_mechanism_of_action": "celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme. \n sunitinib Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D00567,D06402", "Drug_Pubchem": "2662, 5329102", "STR_LINK_(SMILES)": "CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,\n CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "27926489", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "Renca cells", "Dose": "sunitinib 40 mg/kg/d", "Technique": "Flow Cytometry, Western Blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "CD4+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs, Tregs STAT-3", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1869", "Drug": "Trametinib + PLX4720", "Drug_category": "others/combination", "Drugbank_ID": "DB08911, DB06999", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity. \n PLX4720 Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110, 24180719", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,\n CCCS(=O(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "28123875", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "D4M.3A mouse melanoma cells", "Dose": "BRAFi [B] PLX4720 was provided in chow; MEKi [M] trametinib was dosed by daily oral gavage at 15 µg (on average 0.75 mg/kg)", "Technique": "Flow Cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD3+ T cell infiltration, CD4+ and CD8+ T cell subsets ,Tregs and cancer-associated B cells,intratumoral IFNγ positive CD8+ T cells intratumoral IFNγ positive CD8+ T cells The infiltrating CD8+ T cells expressed high levels of PD-1 in about 50% of the cells , a marker shown to be associated with tumor-antigen-specific T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD3; PD-1 / PDCD1; Regulatory T cells / Tregs; B cells; T cells; CD8+ T cells; Antigen-specific recognition; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "macrophages with a M2-like phenotype PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Macrophages; Immune checkpoint pathway; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1870", "Drug": "Trametinib + PLX4720 + anti-PD-1 combination", "Drug_category": "others/combination", "Drugbank_ID": "DB08911, DB06999", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity. \n PLX4720 Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110, 24180719", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,\n CCCS(=O(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "28123875", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "D4M.3A mouse melanoma cells", "Dose": "BRAFi [B] PLX4720 was provided in chow; MEKi [M] trametinib was dosed by daily oral gavage at 15 µg (on average 0.75 mg/kg); PI3Ki [P] BKM120 daily oral gavage at 400 µg (on average 20 mg/kg) + anti-PD-1 or isotype mAb (twice weekly 100 µg intraperitoneal", "Technique": "Flow Cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "infiltrating CD3+ T cells, IFNγ+ CD8+ T cell proportion, the granzyme B+ CD8+ T cell", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; CD3; T cells; CD8+ T cells; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1871", "Drug": "Trametinib + PLX4720 + BKM120", "Drug_category": "others/combination", "Drugbank_ID": "DB08911, DB06999, DB11666", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity. \n PLX4720 Target: Serine/threonine-protein kinase B-raf,\n Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.", "KEGG_Drug_ID": "D10175, \n D10584", "Drug_Pubchem": "11707110, 24180719, 16654980", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,\n CCCS(=O(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F, \n NC1=CC(=C(C=N1)C1=NC(=NC(=C1)N1CCOCC1)N1CCOCC1)C(F)(F)F", "Single/Combination": "Combination", "PMID": "28123875", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "D4M.3A mouse melanoma cells", "Dose": "BRAFi [B] PLX4720 was provided in chow; MEKi [M] trametinib was dosed by daily oral gavage at 15 µg (on average 0.75 mg/kg); PI3Ki [P] BKM120 daily oral gavage at 400 µg (on average 20 mg/kg)", "Technique": "Flow Cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "increased CD3+ T cell, Tregs and cancer-associated B cells, intratumoral IFNγ positive CD8+ T cells intratumoral IFNγ positive CD8+ T cells The infiltrating CD8+ T cells expressed high levels of PD-1 in about 50% of the cells , a marker shown to be associated with tumor-antigen-specific T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; CD3; PD-1 / PDCD1; Regulatory T cells / Tregs; B cells; T cells; CD8+ T cells; Antigen-specific recognition; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "macrophages with a M2-like phenotype PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Macrophages; Immune checkpoint pathway; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1872", "Drug": "Trametinib + PLX4720 + BKM120 + anti-PD-1 combination", "Drug_category": "others/combination", "Drugbank_ID": "DB08911, DB06999, DB11666", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity. \n PLX4720 Target: Serine/threonine-protein kinase B-raf,\n Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.", "KEGG_Drug_ID": "D10175, \n D10584", "Drug_Pubchem": "11707110, 24180719, 16654980", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,\n CCCS(=O(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F, \n NC1=CC(=C(C=N1)C1=NC(=NC(=C1)N1CCOCC1)N1CCOCC1)C(F)(F)F", "Single/Combination": "Combination", "PMID": "28123875", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "D4M.3A mouse melanoma cells", "Dose": "BRAFi [B] PLX4720 was provided in chow; MEKi [M] trametinib was dosed by daily oral gavage at 15 µg (on average 0.75 mg/kg); PI3Ki [P] BKM120 daily oral gavage at 400 µg (on average 20 mg/kg) + anti-PD-1 or isotype mAb (twice weekly 100 µg intraperitoneal", "Technique": "Flow Cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "infiltrating CD3+ T cells, IFNγ+ CD8+ T cell proportion, the granzyme B+ CD8+ T cell", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; CD3; T cells; CD8+ T cells; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1873", "Drug": "Vorinostat +IKK inhibitor -Bay 117085", "Drug_category": "others/combination", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D06320", "Drug_Pubchem": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "28167529", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "athymic nude", "Cell_line_used_to_induce_tumor_in_mice": "SKOV3 cells", "Dose": "IKK inhibitor -Bay 117085 (5 mg/kg) and vorinostat (50 mg/kg)", "Technique": "ELISA, Western Blotting,Densitometry", "Controlled_Technique": "Western blot/immunoblot analysis; Enzyme-linked immunosorbent assay (ELISA); Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "proangiogenic chemokine IL-8 (CXCL-8)", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-8 / CXCL8", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1877", "Drug": "Sorafenib +HER-2-targeted cellular vaccine (3T3neuGM)", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "28282575", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Breast Tumor", "Animal_Strain_used": "FVB/N", "Cell_line_used_to_induce_tumor_in_mice": "NT2.5 tumor cells", "Dose": "(30 mg/kg)", "Technique": "ELISPOT assay", "Controlled_Technique": "ELISpot/FluoroSpot assay", "Immune_System-Function_enhanced/numbers_increased": "CD4+ and CD8+ T cells,41BB receptor expression on Thy1.2+ HER-2-specific CD8+ T cell IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "regulatory T cells and MDSC", "Controlled_Terms_Unaffected": "Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1881", "Drug": "JQ1, an inhibitor of the BET family of bromodomain proteins", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma.", "KEGG_Drug_ID": null, "Drug_Pubchem": "46907787", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C", "Single/Combination": "Single Drug", "PMID": "28408401", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Animal_Strain_used": "Genetically engineered harboring Kras+/LSL-G12DTrp53L/L (KP)", "Cell_line_used_to_induce_tumor_in_mice": "For lung tumor induction, mice received 1 × 106 CFU Cre-encoding adenovirus intranasally at 5–6 weeks of age", "Dose": "25 mg/kg daily", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD4+Foxp3+ Tregs Foxp3, CTLA-4, and PD-1-on CD4+Foxp3+ Tregs phospho-STAT5,", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; PD-1 / PDCD1; CTLA-4; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1883", "Drug": "Entinostat and azacytidine", "Drug_category": "others/combination", "Drugbank_ID": "DB11841, DB00928", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.\n As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug_ID": "D09338,\n D03021", "Drug_Pubchem": "4261, 9444", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, \n NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "28498806", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "SCID", "Cell_line_used_to_induce_tumor_in_mice": "ovarian PDX tumors", "Dose": "azacytidine 2mg/kg, entinostat 5mg/kg", "Technique": "Quantitative PCR", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CIITA,CD74 expression, HLA-DPA1", "Controlled_Terms_Function_enhanced_Number_increased": "CIITA", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1884", "Drug": "Entinostat and azacytidine", "Drug_category": "others/combination", "Drugbank_ID": "DB11841, DB00928", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.\n As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.", "KEGG_Drug_ID": "D09338,\n D03021", "Drug_Pubchem": "4261, 9444", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, \n NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "Single/Combination": "Combination", "PMID": "28498806", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "MISIIR-Tag", "Cell_line_used_to_induce_tumor_in_mice": "spontaneously develop ovarian tumors", "Dose": "azacytidine 2 mg/kg, entinostat 5 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC II and CD74 proteins in ovarian tumors", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1886", "Drug": "Vorinostat (V) + mithramycin A (MA)", "Drug_category": "others/combination", "Drugbank_ID": "vorinostat (V): DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). Mithramycin (also known as Plicamycin) is an antineoplastic antibiotic produced by Streptomyces plicatus. Mithramycin A is a DNA/RNA polymerase inhibitor, DNA-binding transcriptional inhibitor, antibiotic, and observed to facilitate tumor necrosis factor (TNF)-α and Fas ligand-induced apoptosis.", "KEGG_Drug_ID": "vorinostat (V): D06320", "Drug_Pubchem": "vorinostat (V): 5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,\n C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]", "Single/Combination": "Combination", "PMID": "28536458", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin Cancer - Merkel Cell Carcinoma-Skin Cancer", "Animal_Strain_used": "NOD.CB17/Prkdc scid", "Cell_line_used_to_induce_tumor_in_mice": "WaGa tumors", "Dose": "60mg/kg vorinostat in combination with 0.2 mg/kg", "Technique": "Immunohistochemistry,RT-qPCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "HLA class-I surface expression APM components LMP2, LMP7 and TAP2", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I; TAP2; Antigen processing and presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1888", "Drug": "UNC2025 plus XRT", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "28605477", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "TRP-MSCV-luc cells", "Dose": "external beam radiotherapy (XRT) (5 Gy q.o.d. fractions on days 7, 9, and 11) + UNC2025 (65 mg/kg via oral gavage daily starting day 7", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "GAMs with M2 phenotype", "Controlled_Terms_Function_inhibited_Number_decreased": "M2 phenotype-associated glioma-associated macrophages (GAMs)", "Immune_System_function_unaffected": "F4-80+ cells", "Controlled_Terms_Unaffected": "F4-80+ cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1889", "Drug": "XRT", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28605477", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "TRP-MSCV-luc cells", "Dose": "external beam radiotherapy (XRT) (5 Gy q.o.d. fractions on days 7, 9, and 11)", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "F4-80+ cells", "Controlled_Terms_Unaffected": "F4-80+ cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1891", "Drug": "Entinostat + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "28698201", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "Animal_Strain_used": "BALB/c or C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "luciferin tagged RENCA cells", "Dose": "entinostat (5mg/kg), anti-PD-1 (10mg/kg)", "Technique": "Flow Cytometry, Proteome Profiler Analysis (Ary028)", "Controlled_Technique": "Flow cytometry; Protein array/profiler assay", "Immune_System-Function_enhanced/numbers_increased": "tumor infiltrating CD8+ T cells IL-1ra and innate anti-tumor response (IL-4 & IL-12p40), T cell attractants & anti-endothelial markers (CXCL9, CXCL10 ), tumor proliferation inhibitory cytokines (IL-4 & IL-13 ), T cell chemoattractant (E-selectin ), and anti-tumor marker (IL-12p40 )", "Controlled_Terms_Function_enhanced_Number_increased": "IL-4; IL-12; IL-13; CXCL9 / MIG; CXCL10 / IP-10; CD8; T cells; CD8+ T cells; Cell proliferation / Ki-67; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "CD4+FoxP3+ cells, TAMs MDSC activation cytokines-G-CSF, GM-CS, IL-1β & IL-10 (despite increase in number of MDSC,s)", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; IL-10; G-CSF; CD4; FOXP3; Myeloid-derived suppressor cells / MDSCs; Tumor-associated macrophages / TAMs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1894", "Drug": "Regorafenib and NU", "Drug_category": "others/combination", "Drugbank_ID": "DB08896", "Target/s_or_mechanism_of_action": "Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. \n NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor", "KEGG_Drug_ID": "D10138", "Drug_Pubchem": "11167602, 11327430", "STR_LINK_(SMILES)": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1, \n C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56", "Single/Combination": "Combination", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "B16-F1", "Dose": "NU7026 (6 mg/kg) + Reg (8 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "intratumoral CD45+ leukocytes and CD8+ T cells MHC-I", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD45; MHC class I; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD155, semaphorin 4D, CEACAM1, and galectin-9", "Controlled_Terms_Function_inhibited_Number_decreased": "CD155 / PVR", "Immune_System_function_unaffected": "intratumoral dendritic cells, macrophages, myeloid-derived suppressor cells, or natural killer cells", "Controlled_Terms_Unaffected": "Myeloid-derived suppressor cells / MDSCs; Macrophages; Dendritic cells; NK cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1897", "Drug": "Anti-CTLA-4 + MEK inhibitor selumetinib", "Drug_category": "others/combination", "Drugbank_ID": "DB11689", "Target/s_or_mechanism_of_action": "The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.", "KEGG_Drug_ID": "D09666", "Drug_Pubchem": "10127622", "STR_LINK_(SMILES)": "CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO", "Single/Combination": "Combination", "PMID": "28807001", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "25 mg/kg, twice daily", "Technique": "Flow Cytometry Analysis", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor-infiltrating CD8+ T-cell, intratumoral MHC-II+ Ly6C+ intermediary differentiating monocytes", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; MHC class II; Monocytes; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "tumor-infiltrating Tregs, tumor-infiltrating gMDSC/neutrophil , MHCIIlo/− TAMs and pDCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; PMN-MDSCs / granulocytic MDSCs; Tumor-associated macrophages / TAMs; Neutrophils / granulocytes; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1899", "Drug": "Pemetrexed + sildenafil", "Drug_category": "others/combination", "Drugbank_ID": "DB00642, DB00203", "Target/s_or_mechanism_of_action": "Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. \n sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP", "KEGG_Drug_ID": "D07472, \n D08514", "Drug_Pubchem": "446556, \n 5212", "STR_LINK_(SMILES)": "NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,\n CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1", "Single/Combination": "Combination", "PMID": "28812434", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Animal_Strain_used": "C57/BL6", "Cell_line_used_to_induce_tumor_in_mice": "0.5x106 Lewis Lung Carcinoma cancer cell", "Dose": "pemetrexed (Day 1, 25\n mg/kg) C sildenafil (Days 1–3, 5.0 mg/kg)], sodium valproate\n (50 mg/kg)", "Technique": "Immuno-Histochemical Analyses", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "M1 macrophages, NK cells, total T cell levels and activated T cell levels, MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; NK cells; T cells; M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1900", "Drug": "Pemetrexed + sildenafil + anti CTLA 4", "Drug_category": "others/combination", "Drugbank_ID": "DB00642, DB00203", "Target/s_or_mechanism_of_action": "Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. \n sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP", "KEGG_Drug_ID": "D07472, \n D08514", "Drug_Pubchem": "446556, \n 5212", "STR_LINK_(SMILES)": "NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,\n CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1", "Single/Combination": "Combination", "PMID": "28812434", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Animal_Strain_used": "C57/BL6", "Cell_line_used_to_induce_tumor_in_mice": "0.5x106 Lewis Lung Carcinoma cancer cell", "Dose": "\"pemetrexed (Day 1, 25\n mg/kg) C sildenafil (Days 1–3, 5.0 mg/kg)], sodium valproate\n (50 mg/kg)\" + anti-CTLA4 IgG (100 mg)", "Technique": "Immuno-Histochemical Analyses", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1901", "Drug": "Pemetrexed + sildenafil + Anti PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB00642, DB00203", "Target/s_or_mechanism_of_action": "Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. \n sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP", "KEGG_Drug_ID": "D07472, \n D08514", "Drug_Pubchem": "446556, \n 5212", "STR_LINK_(SMILES)": "NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,\n CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1", "Single/Combination": "Combination", "PMID": "28812434", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Animal_Strain_used": "C57/BL6", "Cell_line_used_to_induce_tumor_in_mice": "0.5x106 Lewis Lung Carcinoma cancer cell", "Dose": "\"pemetrexed (Day 1, 25\n mg/kg) C sildenafil (Days 1–3, 5.0 mg/kg)], sodium valproate\n (50 mg/kg)\" + anti-PD-1\n IgG (100 mg)", "Technique": "Immuno-Histochemical Analyses", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "M1 macrophages, NK cells, total T cell levels and activated T cell levels, MHCA", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; NK cells; T cells; M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1903", "Drug": "NK cells + entinostat", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "28919994", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "Animal_Strain_used": "nu/nu", "Cell_line_used_to_induce_tumor_in_mice": "LM7 cells/ genetically modified LM7 OS cell line that expresses firefly luciferase to identify onset of micrometastasis in the lung more precisely", "Dose": "Mice received 5 mg/kg of entinostat or 200 μL of DMSO (control) by oral gavage three times a week for 5 weeks. A total of 50 × 106 NK cells were injected via the tail vein twice a week for 5 weeks", "Technique": "Quantitative RT-PCR,bioluminescent imaging (BLI),immunohistochemical staining", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC); Bioluminescence/luciferase assay", "Immune_System-Function_enhanced/numbers_increased": "MICA and MICB", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D ligand / receptor pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "overall survival of mice treated with NK cells + entinostat was not improved", "Controlled_Terms_Unaffected": "NK cells; Survival outcome", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1906", "Drug": "Trametinib and α-OX-40 antibody", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "28928458", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "AT3ova", "Dose": "trametinib (1 mg/kg/daily)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8 T-cell frequency, proliferation was also enhanced in CD8+ T cells, IFNγ production from CD4+ FOXP3− T cells and enhanced proliferation of these T cells, macrophages (CD11b+ F4/80+) IFNγ production by CD8+ T cells T-cell markers such as Tbet+ and CCR7+, associated with a TH1-like memory response", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD11b / ITGAM; FOXP3; Macrophages; T cells; Th1 / type 1 T-cell response; CD8+ T cells; Cell proliferation / Ki-67", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs (CD11b+ Ly6C+)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1907", "Drug": "Trametinib with α-4-1BB", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "28928458", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "AT3ova", "Dose": "trametinib (1 mg/kg/daily)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8 T-cell frequency, proliferation was also enhanced in CD8+ T cells, IFNγ production from CD4+ FOXP3− T cells and enhanced proliferation of these T cells, macrophages (CD11b+ F4/80+) IFNγ production by CD8+ T cells T-cell markers such as Tbet+ and CCR7+, associated with a TH1-like memory response", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD11b / ITGAM; FOXP3; Macrophages; T cells; Th1 / type 1 T-cell response; CD8+ T cells; Cell proliferation / Ki-67", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs (CD11b+ Ly6C+)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1908", "Drug": "7A7", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "D122", "Dose": "7A7 (56 μg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "a strong induction of H-2Kb and H-2Db expression, MHC-I expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2000", "Drug": "Anti -PD-1 +peptide R", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31661001", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - B16 Melanoma", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "B16-hCXCR4 (5 × 105)", "Dose": "murine anti-PD-1 [RMP1–14] (5 mg/kg, twice week for 2 weeks), Pep R (2 mg/kg, 5 days per week for 2 weeks)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Granzyme B (GRZB) positive immune cells, ratio CD8+ T cells/Tregs", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Regulatory T cells / Tregs; T cells; CD8+ T cells; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "FoxP3 positive Treg cells,pDC (CD 45+ cells) CXCR4 decreased in tumors", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs; CXCR4", "Immune_System_function_unaffected": "PD-1 expression", "Controlled_Terms_Unaffected": "PD-1 / PDCD1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1910", "Drug": "Pazopanib + anti-PD-1 IgG", "Drug_category": "others/combination", "Drugbank_ID": "DB06589", "Target/s_or_mechanism_of_action": "Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit.", "KEGG_Drug_ID": "D05380", "Drug_Pubchem": "10113978", "STR_LINK_(SMILES)": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "Single/Combination": "Combination", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57B6", "Cell_line_used_to_induce_tumor_in_mice": "mouse B16 melanoma cells", "Dose": "pazopanib 25 mg/kg (Days 1, 2, 3)+ anti-PD-1 IgG (100 μg)", "Technique": "Immuno-Histostaining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "F4/80+\n macrophages (M1 macrophages), NK cells, neutrophils and activated\n T cells", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; Neutrophils / granulocytes; NK cells; T cells; M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1911", "Drug": "Pazopanib + AR42", "Drug_category": "others/combination", "Drugbank_ID": "DB06589,DB12707", "Target/s_or_mechanism_of_action": "Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit.", "KEGG_Drug_ID": "D05380", "Drug_Pubchem": "10113978, 6918848", "STR_LINK_(SMILES)": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,\n CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57B6", "Cell_line_used_to_induce_tumor_in_mice": "mouse B16 melanoma cells", "Dose": "pazopanib 25 mg/kg (Days 1, 2, 3)+AR42 15 mg/kg (Days 1 and 3)", "Technique": "Immuno-Histostaining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "F4/80+\n macrophages (M1 macrophages), NK cells, neutrophils and activated\n T cells", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; Neutrophils / granulocytes; NK cells; T cells; M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1912", "Drug": "Pazopanib + AR42 + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB06589,DB12707", "Target/s_or_mechanism_of_action": "Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit.", "KEGG_Drug_ID": "D05380", "Drug_Pubchem": "10113978, 6918848", "STR_LINK_(SMILES)": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,\n CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57B6", "Cell_line_used_to_induce_tumor_in_mice": "mouse B16 melanoma cells", "Dose": "pazopanib 25 mg/kg (Days 1, 2, 3)+ AR42 15 mg/kg (Days 1 and 3)+ anti-PD-1 IgG (100 μg)", "Technique": "Immuno-Histostaining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "F4/80+\n macrophages (M1 macrophages), NK cells, neutrophils and activated\n T cells IL-6, IL-12, CCL2, CCL3,\n CCL5, CXCL9 and CXCL2, TGF\n beta", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; IL-12; CCL2 / MCP-1; CCL3 / MIP-1α; CCL5 / RANTES; CXCL9 / MIG; Macrophages; Neutrophils / granulocytes; NK cells; T cells; M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": "IL1a\n levels", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1913", "Drug": "Pazopanib + sodium valproate + anti-PD-1 IgG", "Drug_category": "others/combination", "Drugbank_ID": "DB06589, DB00313", "Target/s_or_mechanism_of_action": "Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit.\n Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug_ID": "D05380, D00399", "Drug_Pubchem": "10113978, 3121", "STR_LINK_(SMILES)": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,\n CCCC(CCC)C(O)=O", "Single/Combination": "Combination", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57B6", "Cell_line_used_to_induce_tumor_in_mice": "mouse B16 melanoma cells", "Dose": "pazopanib 25 mg/kg (Days 1, 2, 3)+ sodium valproate 50 mg/kg (Days 1, 2, 3) + anti-PD-1 IgG (100 μg)", "Technique": "Immuno-Histostaining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "F4/80+\n macrophages (M1 macrophages), NK cells, neutrophils and activated\n T cells IL-6, IL-12, CCL2, CCL3,\n CCL5, CXCL9 and CXCL2", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; IL-12; CCL2 / MCP-1; CCL3 / MIP-1α; CCL5 / RANTES; CXCL9 / MIG; Macrophages; Neutrophils / granulocytes; NK cells; T cells; M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1914", "Drug": "Pazopanib+ sodium valproate", "Drug_category": "others/combination", "Drugbank_ID": "DB06589, DB00313", "Target/s_or_mechanism_of_action": "Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit.\n Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug_ID": "D05380, D00399", "Drug_Pubchem": "10113978, 3121", "STR_LINK_(SMILES)": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,\n CCCC(CCC)C(O)=O", "Single/Combination": "Combination", "PMID": "29137331", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57B6", "Cell_line_used_to_induce_tumor_in_mice": "mouse B16 melanoma cells", "Dose": "pazopanib 25 mg/kg (Days 1, 2, 3)+ sodium valproate 50 mg/kg (Days 1, 2, 3)", "Technique": "Immuno-Histostaining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "F4/80+\n macrophages (M1 macrophages), NK cells, neutrophils and activated\n T cells", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; Neutrophils / granulocytes; NK cells; T cells; M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1915", "Drug": "Decitabine (DAC) in combination with allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor cells (HSPC-NK cells)", "Drug_category": "others/combination", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "29138222", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "Animal_Strain_used": "NOD/SCID/IL2Rgnull (NSG)", "Cell_line_used_to_induce_tumor_in_mice": "THP-1", "Dose": "DAC (1.25 mg/m2)", "Technique": "Flow cytometry, RT PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "NK cell–mediated killing. perforin, and TRAIL NKp44 expression,upregulation of NKG2D- and DNAM-1-activating ligands on AML cells", "Controlled_Terms_Function_enhanced_Number_increased": "NK cells; Perforin / PRF1; NKG2D ligand / receptor pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1918", "Drug": "Vorinostat + anti-PD-1+ anti-CTLA-4", "Drug_category": "others/combination", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D06320", "Drug_Pubchem": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "29371976", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1 cells", "Dose": "vorinostat (50 mg/Kg i.p.), anti-PD-1 (10 mg/Kg i.p.) combined with anti-CTLA-4 (10mg/Kg i.p.)", "Technique": "RNA in situ hybridization analysis on formalin fixed paraffin embedded (FFPE) tissues, TUNEL assay", "Controlled_Technique": "Apoptosis/cell viability assay; RNA in situ hybridization (RISH)", "Immune_System-Function_enhanced/numbers_increased": "CD4+ T cells, CD8+ T cells PD-L1 expression in tumor cells reduced the tumor burden, survival increase, apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; PD-L1 / CD274; T cells; CD8+ T cells; CD4+ T cells; Apoptosis / caspase activation; Immune checkpoint pathway; Survival outcome; Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1919", "Drug": "PD-1 Ab +sorafenib and DC-TEX", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "29413757", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "hepa1-6 cell", "Dose": "sorafenib (50 mg/kg/day) and PD-1 Ab (200 μg)", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "AFP", "Controlled_Terms_Function_inhibited_Number_decreased": "AFP", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1921", "Drug": "Sorafenib + dendritic cells with exosomes derived from tumor cells (DC-TEX)", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "29413757", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "hepa1-6 cell", "Dose": "50 mg/kg +DCs were pulsed with exosomes (4×106, injected intravenously)", "Technique": "Flow Cytometry, Immunohistochemistry And ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+T cells IFN-γ and IL-2", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4+CD25+FoxP3+ Tregs IL-10 and TGF-β", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; TGF-β; CD4; CD25 / IL2RA; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1922", "Drug": "Imatinib + anti CD 40", "Drug_category": "others/combination", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Drug_Pubchem": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Combination", "PMID": "29467128", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "Animal_Strain_used": "KitV558Δ/+", "Cell_line_used_to_induce_tumor_in_mice": "spontaneous", "Dose": "one dose of an agonistic CD40 antibody (clone FGK4.5, 100 μg intraperitoneal [i.p.]) or rat IgG2a (clone 2A3, 100 μg i.p.) on day 0, which indicates first day of treatment. Imatinib (600 mg/L in drinking water; Novartis) was started on day 3 and continued until the end of the experiment,", "Technique": "Flow cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "Macrophages and CD8+ T Cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Macrophages; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4+ T cells and B cells", "Controlled_Terms_Unaffected": "CD4; B cells; T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1930", "Drug": "Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a) + anti PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "29703841", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "(BALB/c)", "Cell_line_used_to_induce_tumor_in_mice": "5 million CT26.WT-hHER2 cells", "Dose": "DS-8201a (10 mg/kg once a week, twice, i.v.)+ anti-PD1 (5 mg/kg, twice a week, 2 cycles, i.v.)", "Technique": "Survival Was Analyzed By The Kaplan–Meier Method", "Controlled_Technique": "Survival analysis (Kaplan–Meier)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1932", "Drug": "JQ1+ACY-1215", "Drug_category": "others/combination", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor.\n JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma.", "KEGG_Drug_ID": "D10661", "Drug_Pubchem": "53340666, 46907787", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1, O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C", "Single/Combination": "Combination", "PMID": "29760044", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung - Small Cell Lung Cancer", "Animal_Strain_used": "SCLC xenograft models", "Cell_line_used_to_induce_tumor_in_mice": "NCl-H60", "Dose": "JQ1(25 mg/kg daily)+ACY-1215( (50 mg/kg daily)", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells, HLA-DR expression on tumor cells MHC II on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1933", "Drug": "JQ1+ACY-1215", "Drug_category": "others/combination", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor.\n JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma.", "KEGG_Drug_ID": "D10661", "Drug_Pubchem": "53340666, 46907787", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1, O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C", "Single/Combination": "Combination", "PMID": "29760044", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung - Small Cell Lung Cancer", "Animal_Strain_used": "SCLC xenograft models", "Cell_line_used_to_induce_tumor_in_mice": "GLC-16", "Dose": "JQ1(25 mg/kg daily)+ACY-1215( (50 mg/kg daily)", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "NK cells, HLA-DR expression on tumor cells MHC II on tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1935", "Drug": "Decitabine (DAC, a DNA demethylation drug) and γδ T cells", "Drug_category": "others/combination", "Drugbank_ID": "DB01262", "Target/s_or_mechanism_of_action": "Reactivation of silenced genes and differentiation at low doses, and cytotoxicity at high doses", "KEGG_Drug_ID": "D03665", "Drug_Pubchem": "451668", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "Single/Combination": "Combination", "PMID": "29910819", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "Animal_Strain_used": "BALB/c-nu", "Cell_line_used_to_induce_tumor_in_mice": "HOS cells", "Dose": "DAC -1 µg/g of body weight, γδ T cells (5 × 107 in 100 µL PBS)", "Technique": "Western Blotting", "Controlled_Technique": "Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "MICB and ULBP1 proteins in OS tumor tissues", "Controlled_Terms_Function_enhanced_Number_increased": "NKG2D ligand / receptor pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1940", "Drug": "Romidepsin + IBET151", "Drug_category": "others/combination", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug_ID": "D06637", "Drug_Pubchem": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Combination", "PMID": "30249811", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Ad5.Gag vaccination", "Dose": "Romidepsin (1 mg/kg single dose at the time of vaccination) + IBET151 (30 mg/kg single dose at the time of vaccination)", "Technique": "Flow Cytometry, Luminex", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "Gag- (epitope AL11) specific CD8+\n T cells, CD8+ T cells that produced IFN-g IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "total number of circulating CD8+ T cells or the percentage of regulatory Foxp3+ CD4 T cells", "Controlled_Terms_Unaffected": "CD4; CD8; FOXP3; T cells; CD8+ T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1941", "Drug": "Romidepsin + IBET151", "Drug_category": "others/combination", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell to release a zinc-binding thiol. The thiol binds to a zinc atom in the binding pocket of Zn-dependent histone deacetylase to block its activity. Thus it is an HDAC inhibitor.", "KEGG_Drug_ID": "D06637", "Drug_Pubchem": "57515973", "STR_LINK_(SMILES)": "C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C", "Single/Combination": "Combination", "PMID": "30249811", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "mice were primed with Ad26.OVA (107 vp) followed by the\n s.c. injection of 500,000 B16-OVA cells 28 d later.", "Dose": "Ad5.SIINFEKL + Romidepsin (1 mg/kg single dose at the time of vaccination) + IBET151 (30 mg/kg single dose at the time of vaccination)", "Technique": "Flow Cytometry, Luminex", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "OVA-specific SIINFEKL+CD8+\n T cells IL-6", "Controlled_Terms_Function_enhanced_Number_increased": "IL-6; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1943", "Drug": "Entinostat in combination with anti–PD-1 or anti–CTLA-4", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "30341213", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "female neu-N", "Cell_line_used_to_induce_tumor_in_mice": "NT2.5 cells", "Dose": "anti–PD-1, 100 μg/mouse via intraperitoneal injection (i.p.)or anti–CTLA-4, 100 μg/mouse,ENT dosing solution (5 mg/kg)", "Technique": "Flow Cytometry,Immunosuppression Assays,Colorimetric Arginase Activity Assay", "Controlled_Technique": "Flow cytometry; Colorimetric/biochemical activity assay; Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": "shifts the TME from an M-MDSC to a G-MDSC dominated milieu,infiltration of CD8+ T effector cells(active) improved survival", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / granulocytic MDSCs; Immune-cell infiltration; Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression on G-MDSC Arg-1 by MDSCs-a marker of immunosupressive activity of MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / granulocytic MDSCs; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1996", "Drug": "Anti-CD3 + Anti-PD-1+ Trametinib 10 nm", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "31648326", "Cancer_Type": "Leukemia", "Cancer_Type_Description": "Leukemia - Acute Myeloid Leukemia (AML)", "Animal_Strain_used": "AML mouse model", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "Anti-CD3 5 ug/mL + Anti-PD-1 10 ug/mL+ Trametinib 10 nm", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 and PD-L2 expression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; PD-L2 / PDCD1LG2; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1944", "Drug": "Entinostat in combination with anti–PD-1 or anti–CTLA-4", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "30341213", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Adenocarcinoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "(Panc02)", "Dose": "anti–PD-1, 100 μg/mouse via intraperitoneal injection (i.p.)or anti–CTLA-4, 100 μg/mouse,ENT dosing solution (5 mg/kg)", "Technique": "Flow Cytometry,Immunosuppression Assays", "Controlled_Technique": "Flow cytometry; Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": "shifts the TME from an M-MDSC to a G-MDSC dominated milieu,infiltration of CD8+ T effector cells(active) improved survival", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / granulocytic MDSCs; Immune-cell infiltration; Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression on G-MDSC Arg-1 by MDSCs-a marker of immunosupressive activity of MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / granulocytic MDSCs; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1953", "Drug": "MEK inhibitor trametinib + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "30546955", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Head And Neck Squamous Cell Carcinoma (HNSCC)", "Animal_Strain_used": "C3H", "Cell_line_used_to_induce_tumor_in_mice": "SCCVII cells", "Dose": "trametinib (1 mg/kg) by oral gavage once daily and/or an anti-PD-L1 mAb (10 mg/kg) by intraperitoneal (i.p.) injection twice weekly.", "Technique": "Flow cytometry,qRT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD3+CD8+ tumor infiltrating lymphocytes (TILs) CXCL9 and CXCL10 T cell activation marker CD25", "Controlled_Terms_Function_enhanced_Number_increased": "CXCL9 / MIG; CXCL10 / IP-10; CD8; CD3; CD25 / IL2RA; T cells; Tumor-infiltrating lymphocytes / TILs; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "neutrophils (CD11b+Ly6G+) Erk1/2 activation in tumor tissues", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Neutrophils / granulocytes", "Immune_System_function_unaffected": "TAMs (CD11b+F4/80+)", "Controlled_Terms_Unaffected": "CD11b / ITGAM; Tumor-associated macrophages / TAMs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1960", "Drug": "Sunitinib and MD5-1 combination", "Drug_category": "others/combination", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "30713805", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Mammary Carcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1 mammary carcinoma cells", "Dose": "35 mg/kg", "Technique": "Flow cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells and dendritic cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Dendritic cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1961", "Drug": "Sunitinib and MD5-1 combination", "Drug_category": "others/combination", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Combination", "PMID": "30713805", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "(CT26) carcinoma", "Dose": "35 mg/kg", "Technique": "Flow cytometry, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells and dendritic cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Dendritic cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1965", "Drug": "Trametinib+anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Drug_Pubchem": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "30771521", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "PKL (Lung tumors were induced by Ad-Cre in the transgenic mouse model)", "Cell_line_used_to_induce_tumor_in_mice": "3 × 105 PKL5–2 cells into the right flank of mice", "Dose": "trametinib for three days prior to initiation of combination or single treatment follwed by MEKi (0.25, 0.5, and 1 mg/kg)+ anti-PD-1 (200ug) for three weeks", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "percentage of CD4+ and CD8+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8", "Immune_System-Function_inhibited/numbers_decreased": "PMN-MDSCs, CD45+/CD11b+/Ly6Ghigh/Ly6Clow", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / granulocytic MDSCs", "Immune_System_function_unaffected": "monocytic-MDSCs CD45+/CD11b+/Ly6G-/Ly6Chigh", "Controlled_Terms_Unaffected": "CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1966", "Drug": "Trametinib+anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase.", "KEGG_Drug_ID": "D09996", "Drug_Pubchem": "42611257", "STR_LINK_(SMILES)": "CCCS(=O(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "30771521", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "PKL (Lung tumors were induced by Ad-Cre in the transgenic mouse model)", "Cell_line_used_to_induce_tumor_in_mice": "3 × 105 PKL5–2 cells into the right flank of mice", "Dose": "trametinib for three days prior to initiation of combination or single treatment follwed by MEKi (0.25, 0.5, and 1 mg/kg) + anti-PD-L1(200ug twice a week) for three weeks", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "percentage of CD4+ and CD8+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8", "Immune_System-Function_inhibited/numbers_decreased": "PMN-MDSCs, CD45+/CD11b+/Ly6Ghigh/Ly6Clow", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / granulocytic MDSCs", "Immune_System_function_unaffected": "monocytic-MDSCs CD45+/CD11b+/Ly6G-/Ly6Chigh", "Controlled_Terms_Unaffected": "CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1968", "Drug": "CXCR4 inhibitor AMD 3100 /\n Plerixafor\"+ αPD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB06809", "Target/s_or_mechanism_of_action": "Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered.", "KEGG_Drug_ID": "D08971", "Drug_Pubchem": "65015", "STR_LINK_(SMILES)": "C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Combination", "PMID": "30802149", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "luciferase-expressing syngeneic ID8-luc cells", "Dose": "AMD3100 (3 mg/kg of mouse body weight) 10 times every other day from d 20 post–tumor implantation + αPD-1 (200 μg per mouse) every other day starting from d 23 for 9 doses.", "Technique": "ELISA, Flow cytometery", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ and CD4+ T cells intratumoral filteration, FN-γ expressing on CD8+ and CD4+ T cells, CD8+ IL-2+ cells , CD44+CD27+CD4+ and CD44+CD27+CD8+ memory T cells , forkhead box P3 (FoxP3)+CD25−CD4+ T cells in the tumor, IL-2+CD40L+FoxP3+CD25− cells, M1 macrophagess F4/80+CD11b+ cells (CD163-MHCII+) IL-2", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; CD4; CD8; CD25 / IL2RA; CD40L / CD154; CD11b / ITGAM; CD163; MHC class II; FOXP3; T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4+FoxP3+CD25+ Treg cells in tumor, CD11b+ GR-1+ , M2 macrophages F4/80+CD11b+ cells (CD163+MHC II−) , PD-L1+CD38+ cells CXCL12", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL12 / SDF-1; CD4; CD25 / IL2RA; CD11b / ITGAM; CD163; PD-L1 / CD274; MHC class II; FOXP3; Regulatory T cells / Tregs; Macrophages; Immune checkpoint pathway; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1969", "Drug": "ΑPD-1", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "30802149", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "luciferase-expressing syngeneic ID8-luc cells", "Dose": "αPD-1 (200 μg per mouse) every other day starting from d 23 for 9 doses.", "Technique": "ELISA, Flow cytometery", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ and CD4+ T cells intratumoral filteration, FN-γ expressing on CD8+ and CD4+ T cells, CD4+ and CD8+ memory T cells , M1 macrophagess F4/80+CD11b+ cells (CD163-MHCII+) IL-2", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; CD4; CD8; CD11b / ITGAM; CD163; MHC class II; T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "M2 macrophages F4/80+CD11b+ cells (CD163+MHC II−) CXCL12", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL12 / SDF-1; CD11b / ITGAM; CD163; MHC class II; Macrophages; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1998", "Drug": "Anti -PD-1 +peptide R", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31661001", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38 (1 × 106)", "Dose": "murine anti-PD-1 [RMP1–14] (5 mg/kg, twice week for 2 weeks), Pep R (2 mg/kg, 5 days per week for 2 weeks)", "Technique": "Immunostaining, Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC); Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "Granzyme B (GRZB) positive immune cells", "Controlled_Terms_Function_enhanced_Number_increased": "Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "FoxP3 positive Treg cells CXCR4,CXCL12 decreased in tumors PD-L1 reduction", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL12 / SDF-1; PD-L1 / CD274; FOXP3; Regulatory T cells / Tregs; Immune checkpoint pathway; CXCR4", "Immune_System_function_unaffected": "CXCR7, PD-1 expression", "Controlled_Terms_Unaffected": "PD-1 / PDCD1; CXCR7", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1971", "Drug": "Nexturastat A + anti-PD-1 immune checkpoint blockade", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "71462653", "STR_LINK_(SMILES)": "CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2", "Single/Combination": "Combination", "PMID": "30992475", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Murine Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "SM1 murine melanoma tumor cells", "Dose": "3 mg/kg anti-PD-1, 15 mg/kg NextA", "Technique": "Kaplan-Meier survival plot, Flow cytometry,qRT-PCR, immunoblot", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Survival analysis (Kaplan–Meier)", "Immune_System-Function_enhanced/numbers_increased": "ratio M1/M2 of TAMs, CD8+ lymphocytes in tumor,effector memory T cell, infiltration of NK and NKT cells IFNγ and IL-2 MHC class I expression, MHC class II reduction in tumor, robust increase in overall survival", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; CD8; MHC class II; MHC class I; Tumor-associated macrophages / TAMs; NKT cells; T cells; Immune-cell infiltration; Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": "M2 macrophages, pDC , MDSC population IL-10 and TGFβ PD-L1 in tumor cells", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; TGF-β; PD-L1 / CD274; Myeloid-derived suppressor cells / MDSCs; Macrophages; Immune checkpoint pathway; M2 macrophage phenotype", "Immune_System_function_unaffected": "B7-H3 and B7-H4, galectin-9, ICOS-L, CD80, CD86, CD70, and HVEM", "Controlled_Terms_Unaffected": "CD80; CD86", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1973", "Drug": "JQ1 (BET inhibitor) in combination with ricolinostat", "Drug_category": "others/combination", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug_ID": "D10661", "Drug_Pubchem": "46907787, 53340666", "STR_LINK_(SMILES)": "O=C(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C,\n ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "31015208", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple Myeloma (MM)", "Animal_Strain_used": "SCID", "Cell_line_used_to_induce_tumor_in_mice": "RPMI-8226 tumors", "Dose": "50 mg/kg JQ1, 50 mg/kg ricolinostat intraperitoneally once per day for 5 days per week for 3 weeks", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "significant reduction in disease burden,apoptosis (active caspase-3)", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": "MM cell proliferation (PCNA),expression of c-MYC and BCL-2", "Controlled_Terms_Function_inhibited_Number_decreased": "Cell proliferation / Ki-67", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1974", "Drug": "CTGF/E7 DNA vaccine and everolimus", "Drug_category": "others/combination", "Drugbank_ID": "DB01590", "Target/s_or_mechanism_of_action": "Everolimus is a mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies", "KEGG_Drug_ID": "D02714", "Drug_Pubchem": "46505248", "STR_LINK_(SMILES)": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "Single/Combination": "Combination", "PMID": "31052575", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "TC-1 tumor cells", "Dose": "everolimus: 1 mg/kg , On day 11, the tumor-bearing mice were treated with 2 µg CTGF/E7 DNA vaccine twice per week for two weeks", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD86+MHC IIhi DCs in tumor-infiltrating lymphocytes (TILs), E7-specific CD8+ T cells, E7-specific IFN-γ-secreting CD8+ T cells IFN-γ CD86+MHC IIhi DCs better disease control and longer survivals", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; CD86; Dendritic cells; T cells; CD8+ T cells; Tumor-infiltrating lymphocytes / TILs; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1975", "Drug": "MCAR T cells", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31078430", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Hepa1-6-chGPC3 cells", "Dose": "GPC3 mCAR T cells administered on days 9 and 13 after subcutaneous injection of Hepa1-6-chGPC3 tumor cells", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Increased mCAR T cell infiltration and a higher percentage of CAR+ IFN-γ+ T cells in tumor tissues", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1977", "Drug": "Sorafenib + huCAR T cells", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "31078430", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "NOD/Scid IL2RγCnull (NSG)", "Cell_line_used_to_induce_tumor_in_mice": "GPC3+ PLC/PRF/5 cells", "Dose": "one dose of 2 × 106 huCAR T cells+ 7.5 mg/kg sorafenib for 2 consecutive weeks", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "huCAR T cell accumulation in tumor tissues", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1978", "Drug": "Sorafenib + mCAR T cells", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "31078430", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Hepa1-6-chGPC3 cells", "Dose": "GPC3 mCAR T cells administered on days 9 and 13 after subcutaneous injection of Hepa1-6-chGPC3 tumor cells + 7.5 mg/kg per day sorafenib from days 8 to 18", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Increased mCAR T cell infiltration and a higher percentage of CAR+ IFN-γ+ T cells in tumor tissues", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1979", "Drug": "Sorafenib + mCAR T cells", "Drug_category": "others/combination", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Combination", "PMID": "31078430", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Hepa1-6-chGPC3 cells", "Dose": "GPC3 mCAR T cells administered on days 9 and 13 after subcutaneous injection of Hepa1-6-chGPC3 tumor cells + 30 mg/kg per day sorafenib from days 8 to 18", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Increased mCAR T cell infiltration and a higher percentage of CAR+ IFN-γ+ T cells in tumor tissues", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1980", "Drug": "Fluorouracil +Docosahexaenoic acid (DHA)", "Drug_category": "others/combination", "Drugbank_ID": "DB00544,DB03756", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA, DHA inhibits endotoxin-stimulated production of IL-6 and IL-8 in human endothelial cells. Derivatives of DHA are anti-inflammatory lipid mediators.", "KEGG_Drug_ID": "D00584,\n C06429", "Drug_Pubchem": "3385,\n 445580", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O, \n CC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CCC(O)=O", "Single/Combination": "Combination", "PMID": "31217433", "Cancer_Type": "Thymoma", "Cancer_Type_Description": "Thymoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "EL4 cells", "Dose": "(50 mg/kg)", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL-1β release by MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-1 family; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1981", "Drug": "Fluorouracil +Docosahexaenoic acid (DHA)", "Drug_category": "others/combination", "Drugbank_ID": "DB00544,DB03756", "Target/s_or_mechanism_of_action": "Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA, DHA inhibits endotoxin-stimulated production of IL-6 and IL-8 in human endothelial cells. Derivatives of DHA are anti-inflammatory lipid mediators.", "KEGG_Drug_ID": "D00584,\n C06429", "Drug_Pubchem": "3385,\n 445580", "STR_LINK_(SMILES)": "FC1=CNC(=O)NC1=O, \n CC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CCC(O)=O", "Single/Combination": "Combination", "PMID": "31217433", "Cancer_Type": "Thymoma", "Cancer_Type_Description": "Thymoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "EL4 cells", "Dose": "(50 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "JNK in MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs; MAPK signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1982", "Drug": "OKI-179 plus anti-PD1", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "novel oral Class I histone deacetylase (HDAC) inhibitor", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31235619", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphomas", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "A20 lymphomas", "Dose": "anti-PD1 (10mg/kg/dose) , OKI-179 (60mg/kg/dose)", "Technique": "Kaplan-Meier Curve Of Recipient Mice", "Controlled_Technique": "Survival analysis (Kaplan–Meier)", "Immune_System-Function_enhanced/numbers_increased": "inhibited tumor growth, suurvival", "Controlled_Terms_Function_enhanced_Number_increased": "Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2003", "Drug": "Peptide R", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31661001", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - B16 Melanoma", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "B16-hCXCR4 (5 × 105)", "Dose": "Pep R (2 mg/kg, 5 days per week for 2 weeks)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Granzyme B (GRZB) positive immune cells, ratio CD8+ T cells/Tregs", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Regulatory T cells / Tregs; T cells; CD8+ T cells; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "FoxP3 positive Treg cells,neutrophils infiltration, pDC (CD 45+ cells) CXCR4 decreased in tumors", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs; Neutrophils / granulocytes; CXCR4; Immune-cell infiltration", "Immune_System_function_unaffected": "PD-1 expression", "Controlled_Terms_Unaffected": "PD-1 / PDCD1", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2004", "Drug": "Peptide R54", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31661001", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "Athymic Nude-Foxn1nu", "Cell_line_used_to_induce_tumor_in_mice": "PES43 (2.5 × 106) melanoma cells", "Dose": "Peptide R54 (GL BiochemShangay LTD) (2 mg/kg ip, 5 days week/3 weeks)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Granzyme B (GRZB) positive immune cells", "Controlled_Terms_Function_enhanced_Number_increased": "Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "CXCR4 PD-L1 CXCR4 expression, p-ERK and KI67, pERK1/2, pP38 MAPK, pAKT and p4EBP", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway; MAPK signaling; CXCR4; Cell proliferation / Ki-67", "Immune_System_function_unaffected": "DTC-PES43 cells CXCL12 and cognate receptor CXCR7 expression", "Controlled_Terms_Unaffected": "CXCL12 / SDF-1; CXCR7", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2005", "Drug": "Peptide R54+nivolumab", "Drug_category": "others/combination", "Drugbank_ID": "DB09035", "Target/s_or_mechanism_of_action": "The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response", "KEGG_Drug_ID": "D10316", "Drug_Pubchem": "348000000", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "31661001", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "Athymic Nude-Foxn1nu", "Cell_line_used_to_induce_tumor_in_mice": "PES43 (2.5 × 106) melanoma cells", "Dose": "anti-human PD-1/(CD279) IgG4 (S228P) (nivolumab) monoclonal antibody (5 mg/kg ip, twice week/3 weeks)+ Peptide R54 (GL BiochemShangay LTD) (2 mg/kg ip, 5 days week/3 weeks)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "DTC-PES43 cells CXCR4 PD-L1 CXCR4 expression, p-ERK and KI67", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway; MAPK signaling; CXCR4; Cell proliferation / Ki-67", "Immune_System_function_unaffected": "CXCL12 and cognate receptor CXCR7 expression", "Controlled_Terms_Unaffected": "CXCL12 / SDF-1; CXCR7", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2008", "Drug": "PLX4720+TLR7A", "Drug_category": "others/combination", "Drugbank_ID": "DB06999", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F", "Single/Combination": "Combination", "PMID": "31702822", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "BRAFV600E/PTEN D4M-3A (RRID:CVCL_0P27)25 murine\n melanoma cell line", "Dose": "3 × 105 D4M cells injected subcutaneously (s.c.)+ BRAFi containg Chow(417 mg PLX4720/kg) +2 mg/kg of\n the TLR7A at Day 19 (middle of sensitive phase)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD69+\n NK and T cells, PD-1+ T cells, IFN-γ production by NK and T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD69; PD-1 / PDCD1; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "TNF-α NKG2D", "Controlled_Terms_Unaffected": "TNF-α / TNF; NKG2D ligand / receptor pathway", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2011", "Drug": "Domatinostat (4SC-202) + agonistic 4-1BB antibody", "Drug_category": "others/combination", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Combination", "PMID": "31703604", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "C57BL/6 J", "Cell_line_used_to_induce_tumor_in_mice": "C38 tumor fragments", "Dose": "20 mg/kg domatinostat twice daily ; agonistic anti-4-1BB antibody was administered at 10 mg/kg", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "reduce tumor volumes", "Controlled_Terms_Function_enhanced_Number_increased": "reduce tumor volumes", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2012", "Drug": "Domatinostat (4SC-202) + PD-L1 blockade", "Drug_category": "others/combination", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Combination", "PMID": "31703604", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cell", "Dose": "20 mg/kg domatinostat twice daily, 10 mg/kg anti-PD-L1 antibody twice a week", "Technique": "Kaplan-Meier Event-Free Survival Plots", "Controlled_Technique": "Survival analysis (Kaplan–Meier)", "Immune_System-Function_enhanced/numbers_increased": "prolonged event-free survival of the animals", "Controlled_Terms_Function_enhanced_Number_increased": "Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2013", "Drug": "Domatinostat (4SC-202) + PD-L1 blockade", "Drug_category": "others/combination", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Combination", "PMID": "31703604", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "C57BL/6 J", "Cell_line_used_to_induce_tumor_in_mice": "C38 tumor fragments", "Dose": "60 mg/kg domatinostat once daily or 20 mg/kg domatinostat twice daily ); anti-PD-1", "Technique": "Kaplan-Meier Event-Free Survival Plots", "Controlled_Technique": "Survival analysis (Kaplan–Meier)", "Immune_System-Function_enhanced/numbers_increased": "prolonged the median event-free survival", "Controlled_Terms_Function_enhanced_Number_increased": "Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2014", "Drug": "Domatinostat (4SC-202) + PD-L1 blockade +LAG3 blockade", "Drug_category": "others/combination", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Combination", "PMID": "31703604", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "C57BL/6 J", "Cell_line_used_to_induce_tumor_in_mice": "C38 tumor fragments", "Dose": "60 mg/kg domatinostat once daily or 20 mg/kg domatinostat twice daily ); anti-PD-1 and anti-LAG3 antibodies were administered at 10 mg/kg", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "reduce tumor volumes", "Controlled_Terms_Function_enhanced_Number_increased": "reduce tumor volumes", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2017", "Drug": "Entinostat (MS275) +PD1 blockade", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "TS/A tumor cells", "Dose": "20 mg/kg ENT,200 μg\n anti-PD1", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T-cell function, intratumoral T-cell clonal expansion", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2019", "Drug": "Vorinostat (SAHA) plus tumor lysates", "Drug_category": "others/combination", "Drugbank_ID": "DB02546", "Target/s_or_mechanism_of_action": "Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM)", "KEGG_Drug_ID": "D06320", "Drug_Pubchem": "5311", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "Single/Combination": "Combination", "PMID": "31737100", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "GL261 cells", "Dose": "SAHA (100 mg/kg)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "longer period of survival", "Controlled_Terms_Function_enhanced_Number_increased": "Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2021", "Drug": "BRAFi PLX4720 + MEKi PD0325901", "Drug_category": "others/combination", "Drugbank_ID": "DB06999, DB07101", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf.\n PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719, 9826528", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F,\n [H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "31796433", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "D4M3.A cells", "Dose": "combination BRAFi + MEKi chow (200 ppm PLX4720 plus 7 ppm PD0325901)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ and CD4+ cells in tumors, activated (CD44+) and proliferating (Ki67+) T cells in tumors MHC-II on tumor-infiltrating DCs", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; MHC class II; Dendritic cells; T cells; Cell proliferation / Ki-67; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSCs) were decreased intra-tumorally, IDO-1, FasL, LGasS9, and OX40L on CD45.2-negative and CD45.2-positive cells within tumors TNFα from intra-tumoral and splenic CD4+ and CD8+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "TNF-α / TNF; CD4; CD8; CD45; Myeloid-derived suppressor cells / MDSCs; Tumor-associated macrophages / TAMs; Macrophages; T cells; CD8+ T cells; IDO1", "Immune_System_function_unaffected": "IFNγ, IL-2 from intra-tumoral and splenic CD4+ and CD8+ T cells", "Controlled_Terms_Unaffected": "IFN-γ; IL-2; CD4; CD8; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2056", "Drug": "Domatinostat + agonistic anti-4-1BB", "Drug_category": "others/combination", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Domatinostat modulates tumor immune microenvironment; agonistic 4-1BB stimulation enhances T-cell costimulation", "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Combination", "PMID": "31703604", "Cancer_Type": "Adenocarcinoma", "Cancer_Type_Description": null, "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "C38 murine colon carcinoma", "Dose": "Domatinostat 20 mg/kg twice daily + anti-4-1BB 10 mg/kg every 3 days", "Technique": "Tumor-volume measurement; response analysis", "Controlled_Technique": "Tumor growth/survival analysis", "Immune_System-Function_enhanced/numbers_increased": "Antitumor T-cell response increased; 14/20 animals responded", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "NR", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "NR", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Inhibitory/exhaustion-associated immune regulation was counteracted through 4-1BB costimulation", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2022", "Drug": "BRAFi PLX4720 + MEKi PD0325901", "Drug_category": "others/combination", "Drugbank_ID": "DB06999, DB07101", "Target/s_or_mechanism_of_action": "Target: Serine/threonine-protein kinase B-raf.\n PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK.", "KEGG_Drug_ID": null, "Drug_Pubchem": "24180719, 9826528", "STR_LINK_(SMILES)": "CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=C2C=C(Cl)C=N3)=C1F,\n [H][C@@](O)(CO)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1", "Single/Combination": "Combination", "PMID": "31796433", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "YUMM1.7 cells", "Dose": "combination BRAFi + MEKi chow (200 ppm PLX4720 plus 7 ppm PD0325901)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ and CD4+ cells in tumors, activated (CD44+) and proliferating (Ki67+) T cells in tumors MHC-II on tumor-infiltrating DCs", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; MHC class II; Dendritic cells; T cells; Cell proliferation / Ki-67; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSCs) were decreased intra-tumorally, IDO-1, FasL, LGasS9, and OX40L on CD45.2-negative and CD45.2-positive cells within tumors TNFα from intra-tumoral and splenic CD4+ and CD8+ T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "TNF-α / TNF; CD4; CD8; CD45; Myeloid-derived suppressor cells / MDSCs; Tumor-associated macrophages / TAMs; Macrophages; T cells; CD8+ T cells; IDO1", "Immune_System_function_unaffected": "IFNγ, IL-2 from intra-tumoral and splenic CD4+ and CD8+ T cells", "Controlled_Terms_Unaffected": "IFN-γ; IL-2; CD4; CD8; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2023", "Drug": "Chidamide (CS055/HBI-8000/Tucidinostat) and Rituximab", "Drug_category": "others/combination", "Drugbank_ID": "DB06334, DB00073", "Target/s_or_mechanism_of_action": "Histone deacetylase inhibitor", "KEGG_Drug_ID": "D10993, \n D02994", "Drug_Pubchem": "12136798, 46505820", "STR_LINK_(SMILES)": "NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\\C=C\\C2=CN=CC=C2)C=C1", "Single/Combination": "Combination", "PMID": "31907371", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Diffuse Large B Cell Lymphoma (DLBCL)", "Animal_Strain_used": "BALB/c nude", "Cell_line_used_to_induce_tumor_in_mice": "DLBCL OCI-Ly7", "Dose": "The dose of Rituximab for in vivo use is 200 µg/mice, equivalent to 10 µg/ml. The dose of Chidamide for mice is 3.9 mg/kg, equivalent to 10 µM", "Technique": "Immunohistochemistry,Kaplan Meier overall survival (OS) curves", "Controlled_Technique": "Immunohistochemistry (IHC); Survival analysis (Kaplan–Meier)", "Immune_System-Function_enhanced/numbers_increased": "CD20 prlonged survival and improved response", "Controlled_Terms_Function_enhanced_Number_increased": "CD20 / MS4A1; Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2036", "Drug": "VPA (valpromide) + anti- PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug_ID": "D00399", "Drug_Pubchem": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Combination", "PMID": "32158627", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "EL4", "Dose": "VPA and anti-PD-1 (200 μg/\n mouse on day 4, 7 and 8)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2037", "Drug": "VPA (valpromide) + anti- PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB00313", "Target/s_or_mechanism_of_action": "Valproic acid exhibits its pharmacologic effects in a couple of ways, such as by acting on GABA (γ aminobutyric acid) levels in the CNS, blocking voltage-gated ion channels, and inhibiting histone deacetylase", "KEGG_Drug_ID": "D00399", "Drug_Pubchem": "3121", "STR_LINK_(SMILES)": "CCCC(CCC)C(O)=O", "Single/Combination": "Combination", "PMID": "32158627", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "B16-F10", "Dose": "VPA (500 mg/kg) and anti-PD-1 (200 μg/\n mouse on days 7, 10 and 13)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2040", "Drug": "MEKi GDC-0623/CD40 Ab", "Drug_category": "others/combination", "Drugbank_ID": "DB11982", "Target/s_or_mechanism_of_action": "Not Available", "KEGG_Drug_ID": null, "Drug_Pubchem": "42642654", "STR_LINK_(SMILES)": "OCCONC(=O)C1=C(NC2=C(F)C=C(I)C=C2)N2C=NC=C2C=C1", "Single/Combination": "Combination", "PMID": "32358491", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Murine Colon Carcinoma", "Animal_Strain_used": "C57BL/6-Ly5.1", "Cell_line_used_to_induce_tumor_in_mice": "MC-38", "Dose": "Mice were treated daily with 30 mg kg−1 GDC-0623 or vehicle for ~2 weeks (gray rectangle). Anti-CD40 or control Ab were administered on treatment days 3, 5, 7 as well as 1 day prior to biomarker analyses", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD206+ M2-like macrophages,Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD206 / MRC1; Regulatory T cells / Tregs; Macrophages; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2043", "Drug": "MEKi GDC-0623/CD40 Ab", "Drug_category": "others/combination", "Drugbank_ID": "DB11982", "Target/s_or_mechanism_of_action": "Not Available", "KEGG_Drug_ID": null, "Drug_Pubchem": "42642654", "STR_LINK_(SMILES)": "OCCONC(=O)C1=C(NC2=C(F)C=C(I)C=C2)N2C=NC=C2C=C1", "Single/Combination": "Combination", "PMID": "32358491", "Cancer_Type": "Pancreas Cancer", "Cancer_Type_Description": "Pancreatic Tumor", "Animal_Strain_used": "C57BL/6-Ly5.1", "Cell_line_used_to_induce_tumor_in_mice": "PDA30364", "Dose": "Mice were treated daily with 30 mg kg−1 GDC-0623 or vehicle for ~2 weeks (gray rectangle). Anti-CD40 or control Ab were administered on treatment days 3, 5, 7 as well as 1 day prior to biomarker analyses", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD206+ M2-like macrophages,Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD206 / MRC1; Regulatory T cells / Tregs; Macrophages; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2044", "Drug": "MRX-2843", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "32642716", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "Animal_Strain_used": "Syngeneic orthotopic glioblastoma mouse model (BALB/c)", "Cell_line_used_to_induce_tumor_in_mice": "GL261 cells", "Dose": "MRX-2843 administration started on day 7 (oral gavage daily, 50 mg/kg) after intracranial injection of GL261 cells", "Technique": "Multiplex Fluorescence IHC, Flow cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC); Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "CD80high/CD86high positive pro-inflammatory macrophages", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages", "Immune_System-Function_inhibited/numbers_decreased": "macrophages and microglia (CD206+ CD11c+) in the tumor microenvironment in vivo, CD163high/CD206high positive anti-inflammatory macrophages CD206 expression was decreased within the tumor site compared to control", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11c / ITGAX; CD206 / MRC1; Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2046", "Drug": "Anti PD-1 + abemaciclib", "Drug_category": "others/combination", "Drugbank_ID": "DB12001", "Target/s_or_mechanism_of_action": "Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells", "KEGG_Drug_ID": "D10688", "Drug_Pubchem": "46220502", "STR_LINK_(SMILES)": "CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1", "Single/Combination": "Combination", "PMID": "32929370", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "ID8 (ID8-luc) cells", "Dose": "abemaciclib (50 mg/kg) daily +anti-PD-1 mAb (200 μg) every 3 days for a total period of 21 days after three weeks after cell implantation", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "increased infiltration of CD8+ T\n cells expressing CD69, CD107a or IFN-γ, CD4+ T cells\n expressing CD69, CD107a or IFN-γ, and CD19+ B cells,", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD69; CD19; B cells; T cells; CD4+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2048", "Drug": "B7-H3 × CD3 BiAb with MEK inhibitor trametinib", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "32984002", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small-Cell Lung Cancer (NSCLC) And Bladder Cancer (BC)", "Animal_Strain_used": "NOD-SCID", "Cell_line_used_to_induce_tumor_in_mice": "T24", "Dose": "2 million cells + trametinib (0.6 mg/kg)", "Technique": "FFow cytometry and CCK-8 assay, H$E staining", "Controlled_Technique": "Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "CD3+ T cells CD31 and caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "CD3; CD31 / PECAM-1; T cells; Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2049", "Drug": "B7-H3 × CD3 BiAb with MEK inhibitor trametinib", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of_ MEK1_ and MEK2 kinase activity.", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1", "Single/Combination": "Combination", "PMID": "32984002", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small-Cell Lung Cancer (NSCLC) And Bladder Cancer (BC)", "Animal_Strain_used": "NOD-SCID", "Cell_line_used_to_induce_tumor_in_mice": "H460", "Dose": "2 million cells+ trametinib (0.6 mg/kg), 8 × 106 T cells+100U IL-2, 2 mg/kg BiAb", "Technique": "Flow cytometry and CCK-8 assay", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "CD3+ T cells CD31 and caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "CD3; CD31 / PECAM-1; T cells; Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2052", "Drug": "ACY1215 and anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB12376", "Target/s_or_mechanism_of_action": "Ricolinostat (ACY-1215) is an orally available selective HDAC6 inhibitor", "KEGG_Drug_ID": "D10661", "Drug_Pubchem": "53340666", "STR_LINK_(SMILES)": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "Single/Combination": "Combination", "PMID": null, "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "ARID1Aflox/flox/PIK3CAH1047R OCCC mouse model", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "ACY1215 (50 mg/kg, daily)) +anti-PD-L1 (10mg/kg, twice a week)", "Technique": "Flow Cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFNγ+ CD8 cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4 T cells", "Controlled_Terms_Unaffected": "CD4; T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2057", "Drug": "Domatinostat + anti-PD-1 + anti-LAG3", "Drug_category": "others/combination", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Domatinostat increases antigen presentation/CTL activity; anti-PD-1 and anti-LAG3 inhibit checkpoint-mediated T-cell suppression", "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Combination", "PMID": "31703604", "Cancer_Type": "Adenocarcinoma", "Cancer_Type_Description": null, "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "C38 murine colon carcinoma", "Dose": "Domatinostat 20 mg/kg twice daily or 60 mg/kg once daily + anti-PD-1 10 mg/kg + anti-LAG3 10 mg/kg", "Technique": "Tumor-volume measurement; response analysis; event-free survival", "Controlled_Technique": "Tumor growth/survival analysis", "Immune_System-Function_enhanced/numbers_increased": "Antitumor T-cell response increased; response rate increased; reported response in 80% of animals in the triple-combination experiment", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "PD-1 and LAG3-mediated inhibitory signaling blocked", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1; LAG-3", "Immune_System_function_unaffected": "NR", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Negative immune-checkpoint regulation through PD-1/LAG3 reduced", "Controlled_Terms_Negative_Regulation": "PD-1 / PDCD1; LAG-3"}, {"ID": "CANIMM/2058", "Drug": "Domatinostat + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB17521", "Target/s_or_mechanism_of_action": "Domatinostat increases antigen presentation and CTL activity; anti-PD-1 blocks PD-1-mediated T-cell inhibition", "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N", "Single/Combination": "Combination", "PMID": "31703604", "Cancer_Type": "Adenocarcinoma", "Cancer_Type_Description": null, "Animal_Strain_used": "BALB/c and C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "CT26 and C38 murine colon carcinoma", "Dose": "Domatinostat 20 mg/kg twice daily + anti-PD-1 10 mg/kg twice weekly", "Technique": "Tumor-volume measurement; event-free survival; flow cytometry", "Controlled_Technique": "Tumor growth/survival analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CTL activity/function increased; antitumor response increased; tumor control increased", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": "PD-1-mediated inhibitory signaling blocked", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1", "Immune_System_function_unaffected": "NR", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Negative immune-checkpoint regulation through PD-1 reduced", "Controlled_Terms_Negative_Regulation": "PD-1 / PDCD1"}, {"ID": "CANIMM/2063", "Drug": "Trastuzumab deruxtecan (T-DXd)", "Drug_category": "others/combination", "Drugbank_ID": "DB14962", "Target/s_or_mechanism_of_action": "Fcγ-receptor activation; antibody-dependent cellular phagocytosis (ADCP); ICD", "KEGG_Drug_ID": "D11529", "Drug_Pubchem": "384585505", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "40175391", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2-positive", "Animal_Strain_used": "Au565 cells", "Cell_line_used_to_induce_tumor_in_mice": "1 µg/mL for 4-hour ADCP assays; separate co-culture conditions", "Dose": "Phagocytosis flow cytometry; ELISA; flow cytometry", "Technique": "Macrophage HLA-A2, HLA-DR, CD80, CD40 and CCR7; antigen-presentation and chemokine genes; inflammatory cytokines", "Controlled_Technique": "Cytokine/chemokine analysis", "Immune_System-Function_enhanced/numbers_increased": "NR", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Macrophages were not susceptible to T-DXd or payload cytotoxicity in vitro", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": "CD47 upregulation may limit phagocytosis", "Controlled_Terms_Unaffected": "CD4", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2076", "Drug": "IL-12 + trabectedin + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Murine TNBC", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "IL-12 and trabectedin as above; anti-PD-L1 dose to verify in full protocol", "Technique": "Mouse tumor model; tumor growth and immune profiling", "Controlled_Technique": "Tumor growth/survival analysis; Immune-cell profiling/phenotyping", "Immune_System-Function_enhanced/numbers_increased": "Enhanced tumor control; increased IFN-γ and effector CD8+ T-cell proportion; decreased Tregs and total MDSCs", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; T cells; Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2077", "Drug": "IL-12 + trabectedin", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Murine TNBC", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "IL-12 0.5 μg IP, 3×/week + trabectedin 0.15 mg/kg IV, 1×/week", "Technique": "Tumor growth, plasma cytokines, mass cytometry, spatial profiling", "Controlled_Technique": "Tumor growth/survival analysis; Cytokine/chemokine analysis; Immune-cell profiling/phenotyping", "Immune_System-Function_enhanced/numbers_increased": "Reduced tumor burden, MDSCs and M2-like macrophages; increased IFN-γ and intratumoral CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; Myeloid-derived suppressor cells / MDSCs; Macrophages; T cells; Tumor growth / burden outcome", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2078", "Drug": "IL-12 + trabectedin", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "DNA minor-groove binding; DNA damage", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39777457", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Murine TNBC", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "EMT6", "Dose": "IL-12 0.5 μg IP, 3×/week + trabectedin 0.15 mg/kg IV, 1×/week", "Technique": "Mouse tumor model; tumor growth", "Controlled_Technique": "Tumor growth/survival analysis", "Immune_System-Function_enhanced/numbers_increased": "Significantly reduced tumor volume compared with controls and single-agent treatments", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2079", "Drug": "Olaparib + AZD1775 + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB09074 + DB11740 + N/A", "Target/s_or_mechanism_of_action": "DNA-damage/STING activation + blockade of PD-1 inhibitory signaling", "KEGG_Drug_ID": "D09713 + D11361 + N/A", "Drug_Pubchem": "23725625 + 24856436 + N/A", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wild-type TNBC with moderate pre-existing TILs", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "AT3OVA", "Dose": "Olaparib 40 mg/kg + AZD1775 30 mg/kg orally 5 days/week + anti-PD-1 200 µg/mouse i.p. on days 1, 5, 8, 12", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ and CD4⁺ effector T cells; CD4⁺/FOXP3⁻ T cells ; CD4⁺ cells expressing IFNγ ; tumor MHC-I", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; FOXP3; T cells; MHC class I; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "PD-1-mediated T-cell inhibition blocked", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-1/PD-L1 negative regulation inhibited", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-1 / PDCD1"}, {"ID": "CANIMM/2080", "Drug": "Olaparib + AZD1775", "Drug_category": "others/combination", "Drugbank_ID": "DB09074 + DB11740", "Target/s_or_mechanism_of_action": "PARP/WEE1 inhibition → DNA damage + cGAS-STING signaling", "KEGG_Drug_ID": "D09713 + D11361", "Drug_Pubchem": "23725625 + 24856436", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wild-type TNBC", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "AT3OVA", "Dose": "40 mg/kg olaparib + 30 mg/kg AZD1775, oral, 5 days/week", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-I (H2Kb/H2Db) , MHC-II , CD80, CD86,  CD4⁺ T cells ; CD8:Treg ratio ; mature MHC-II⁺ DCs ; CD8⁺ and CD4⁺ IFNγ/granzyme B production ; CD4⁺ Ki67⁺PD1+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD80; CD86; PD-1 / PDCD1; Regulatory T cells / Tregs; T cells; Granzyme B / GZMB; MHC class I; MHC class II; Cell proliferation / Ki-67; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2081", "Drug": "Olaparib + AZD1775 + ADU-S100", "Drug_category": "others/combination", "Drugbank_ID": "DB09074 + DB11740 + N/A", "Target/s_or_mechanism_of_action": "DNA damage/replication stress + direct STING activation", "KEGG_Drug_ID": "D09713 + D11361 + N/A", "Drug_Pubchem": "23725625 + 24856436 + N/A", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wild-type TNBC", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "AT3", "Dose": "Reduced-dose of olaparib and AZD1775 (40 mg) + ADU-S100 40 µg/tumor i.t. days 1, 3, 5", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "MHC-I, MHC-II , tumor-infiltrating CD8⁺ T cells, CD8⁺ IFNγ , CD11c⁺CD11b⁻ DCs , CD103⁺ DCs , CD80/CD86⁺ DCs,", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; CD11b / ITGAM; CD11c / ITGAX; CD80; CD86; T cells; MHC class I; MHC class II; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "Tumor-cell CD80, CD86 and PD-L1 were not significantly changed", "Controlled_Terms_Unaffected": "CD8; CD80; CD86; PD-L1 / CD274", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "No significant PD-L1 induction,  therefore negative PD-L1 regulation was not increased", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2114", "Drug": "Vinblastine (VBL)", "Drug_category": "others/combination", "Drugbank_ID": "DB00570", "Target/s_or_mechanism_of_action": "Binds tubulin/microtubules and inhibits microtubule polymerization.", "KEGG_Drug_ID": "D08675", "Drug_Pubchem": "241903", "STR_LINK_(SMILES)": "CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1", "Single/Combination": "Combination", "PMID": "37652576", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "VBL 1.25 mg/kg + anti-PD-1 100 µg/mouse", "Technique": "CD8⁺ T-cell antitumor response, macrophage reprogramming", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "M2-like phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2082", "Drug": "Olaparib + AZD1775", "Drug_category": "others/combination", "Drugbank_ID": "DB09074 + DB11740", "Target/s_or_mechanism_of_action": "Combined PARP/WEE1 inhibition → replication catastrophe, DNA damage and cGAS-STING activation", "KEGG_Drug_ID": "D09713 + D11361", "Drug_Pubchem": "23725625 + 24856436", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wild-type TNBC", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "AT3", "Dose": "50 mg/kg olaparib + 50 mg/kg AZD1775, oral, 5 days/week", "Technique": "flow cytometry, immune profiling", "Controlled_Technique": "Flow cytometry; Immune-cell profiling/phenotyping", "Immune_System-Function_enhanced/numbers_increased": "Tumor MHC-I ; CD11c⁺CD11b⁻ DCs ; MHC-II⁺ DCs ; CD80/CD83⁺ DC maturation ; CD8⁺/CD4⁺ T cells showed increased numbers (not always significant); CD8:Treg ratio", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD11b / ITGAM; CD11c / ITGAX; CD80; CD83; Regulatory T cells / Tregs; Dendritic cells; T cells; MHC class I; MHC class II; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "CD80/CD86 on tumor cells ↓", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; CD80; CD86", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 significantly increased indicates activation of PD-1/PD-L1 immune suppression", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-1 / PDCD1"}, {"ID": "CANIMM/2083", "Drug": "Olaparib + AZD1775", "Drug_category": "others/combination", "Drugbank_ID": "DB09074 + DB11740", "Target/s_or_mechanism_of_action": "Combined PARP/WEE1 inhibition → replication catastrophe, DNA damage and cGAS-STING activation", "KEGG_Drug_ID": "D09713 + D11361", "Drug_Pubchem": "23725625 + 24856436", "STR_LINK_(SMILES)": "CN1CCN(CC1)C2=NC3=C(N2C4=CC=CC=C4C5=CC=CC=C5)C=CC(=C3)C(=O)N and CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=O)N(C4=CC=C3)CC=C)N(C5=CC=CC(=C5)C(C)(C)O)", "Single/Combination": "Combination", "PMID": "37582853", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "BRCA1/2-wild-type TNBC", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1ch9", "Dose": "50 mg/kg olaparib + 50 mg/kg AZD1775, oral, 5 days/week", "Technique": "flow cytometry, immune profiling", "Controlled_Technique": "Flow cytometry; Immune-cell profiling/phenotyping", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2084", "Drug": "Entinostat + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibitors", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Combination", "PMID": "31720815", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast cancer", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "TS/A", "Dose": "20 mg/kg/day", "Technique": "flow cytometry, gene-expression analysis", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T-cell , CD4+ Tcell", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2085", "Drug": "B102 + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "B102 activates cGAS-STING/type-I IFN pathway; anti-PD-L1 blocks PD-L1 checkpoint signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "38182579", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Triple-negative breast cancer", "Animal_Strain_used": "Female BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "15 mg/kg B102 + anti-PD-L1; syngeneic orthotopic model", "Technique": "Anti-tumor immune response ↑; tumor growth inhibition ↑", "Controlled_Technique": "Tumor growth/survival analysis", "Immune_System-Function_enhanced/numbers_increased": "IFNβ, CCL5, CXCL10, activation of the cGAS–STING signaling pathway", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-β; CCL5 / RANTES; CXCL10 / IP-10; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 inhibitory signaling ↓", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2086", "Drug": "B302 + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "B302 activates cGAS-STING/type-I IFN pathway; anti-PD-L1 blocks PD-L1 checkpoint signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "38182579", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Triple-negative breast cancer", "Animal_Strain_used": "Female BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "50 mg/kg B302 + anti-PD-L1; syngeneic orthotopic model", "Technique": "Anti-tumor immune response ↑; tumor growth inhibition ↑", "Controlled_Technique": "Tumor growth/survival analysis", "Immune_System-Function_enhanced/numbers_increased": "IFNβ, CCL5, CXCL10, activation of the cGAS–STING signaling pathway", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-β; CCL5 / RANTES; CXCL10 / IP-10; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 inhibitory signaling ↓", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2087", "Drug": "Trametinib+anti‐CD73 antibody", "Drug_category": "others/combination", "Drugbank_ID": "DB08911", "Target/s_or_mechanism_of_action": "Selective MEK1/MEK2 inhibition → inhibition of RAS–RAF–MEK–ERK signaling; paradoxically causes sustained p38 activation", "KEGG_Drug_ID": "D10175", "Drug_Pubchem": "11707110", "STR_LINK_(SMILES)": "CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5", "Single/Combination": "Combination", "PMID": "34165921", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "4T1 mouse mammary carcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "daily MEKi (1 mg·kg−1), anti‐CD73 antibody (TY/23, days 5, 9, 13, and 17)", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "enrichment of CD45+CD3− in tumors", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD3; CD45", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2088", "Drug": "Entinostat+Ad-Twist vaccine+N-803 (1 μg, s.c.)", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibition, particularly HDAC1/HDAC3; immunomodulatory effects include reduction of Tregs and MDSCs and reduction of VISTA expression on multiple immune-cell populations.", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Combination", "PMID": "31645354", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": null, "Animal_Strain_used": "BALB/c mice, CEA-transgenic mice", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "12 mg/kg/day in CEA-Tg/NSG mice, 3 mg/kg/day for Balb/c mice", "Technique": "Flow cytometry, ELISPOT, cytokine analysis, tumor-growth/survival analysis, immune-cell depletion, NanoString gene-expression analysis, chemokine analysis, immunological rechallenge, in-vitro PBMC experiments", "Controlled_Technique": "Flow cytometry; ELISpot/FluoroSpot assay; Cytokine/chemokine analysis; Survival analysis (Kaplan–Meier); In-vivo/in-vitro immunological assay; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "Elevated the proinflammatory cytokines IFNγ (3-fold) and TNFα (2-fold),increase in splenic CD4+ T cells, CD8⁺ T-cell tumor infiltration increased; activated CD8⁺ T cells increased, increased expression of CD25 and Ki67 on CD8⁺ T cells, increase in granzyme B", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; TNF-α / TNF; CD4; CD8; CD25 / IL2RA; T cells; Granzyme B / GZMB; Cell proliferation / Ki-67; Immune-cell infiltration; Cytokines", "Immune_System-Function_inhibited/numbers_decreased": "Elevated the proinflammatory cytokines IFNγ (3-fold) and TNFα (2-fold),increase in splenic CD4+ T cells, CD8⁺ T-cell tumor infiltration increased; activated CD8⁺ T cells increased, increased expression of CD25 and Ki67 on CD8⁺ T cells, increase in granzyme B", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; TNF-α / TNF; CD4; CD8; CD25 / IL2RA; T cells; Granzyme B / GZMB; Cell proliferation / Ki-67; Immune-cell infiltration; Cytokines", "Immune_System_function_unaffected": "Frequency of activated (CD44hi) or total CD4+ T cells remained unchanged", "Controlled_Terms_Unaffected": "CD4; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "elevated programmed death-ligand 1 (PD-L1)", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2089", "Drug": "Macrocarpal I", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Binds TUBB2B and PARP1; disrupts microtubule polymerization and DNA repair; promotes immunogenic tumor-cell death", "KEGG_Drug_ID": null, "Drug_Pubchem": "10028546", "STR_LINK_(SMILES)": "CC(C)C[C@@H]([C@@H]1CC[C@@]([C@H]2[C@]1(CC[C@H](C2)C(C)(C)O)C)(C)O)C3=C(C(=C(C(=C3O)C=O)O)C=O)O", "Single/Combination": "Single", "PMID": "39987121", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Mouse colon adenocarcinoma syngeneic tumor model", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38K", "Dose": "60 mg/kg intraperitoneally once daily for 7 days; n=8 mice/group", "Technique": "Mouse tumor model; tumor growth measurement; tumor-infiltrating immune-cell isolation; flow cytometry", "Controlled_Technique": "Tumor growth/survival analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "remarkable enhancement of ICD activation, increased the infiltration of total T cells, CD4+ and CD8+ T cells, Granzyme B+ CD8+ T cells, dendritic cells, CD8+/Treg ratio", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; Regulatory T cells / Tregs; Dendritic cells; T cells; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "Decreased tumor-infiltrating FOXP3+ CD4+ regulatory T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; FOXP3; Regulatory T cells / Tregs; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2092", "Drug": "Macrocarpal I + anti-PD-1 antibody", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Macrocarpal I targets TUBB2B and PARP1 and promotes immunogenic cell death; anti-PD-1 blocks PD-1-mediated immune inhibition", "KEGG_Drug_ID": null, "Drug_Pubchem": "10028546", "STR_LINK_(SMILES)": "CC(C)C[C@@H]([C@@H]1CC[C@@]([C@H]2[C@]1(CC[C@H](C2)C(C)(C)O)C)(C)O)C3=C(C(=C(C(=C3O)C=O)O)C=O)O", "Single/Combination": "Combination", "PMID": "39987121", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Mouse colon adenocarcinoma syngeneic tumor model MC38K", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38K", "Dose": "Macrocarpal I: 60 mg/kg intraperitoneally daily for 7 days; anti-PD-1: 200 µg/injection intraperitoneally every 2 days", "Technique": "Combination treatment; tumor growth monitoring; tumor-infiltrating immune-cell flow cytometry", "Controlled_Technique": "Tumor growth/survival analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "marked enhancement of the ICD effect , ncrease in the infiltration of total T cells, CD4+ T cells CD8+ T cells and Granzyme B+ CD8+ T cells, substantial increase in intratumoral DCs cell population , CD8+/Treg ratio", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; Regulatory T cells / Tregs; T cells; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "decrease in Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2093", "Drug": "HBI-8000 + anti-PD-1 mAb", "Drug_category": "others/combination", "Drugbank_ID": "DB06334", "Target/s_or_mechanism_of_action": "Epigenetic immune modulation + PD-1 checkpoint blockade", "KEGG_Drug_ID": "D10993", "Drug_Pubchem": "12136798", "STR_LINK_(SMILES)": "C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N", "Single/Combination": "Combination", "PMID": "34461854", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Murine colon carcinoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "HBI-8000 50 mg/kg daily + anti-PD-1 10 mg/kg twice weekly", "Technique": "Syngeneic tumor model + NanoString profiling", "Controlled_Technique": "Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "dendritic cells, macrophages, NK/cytotoxic cells, CD45 cells, antigen presentation, MHC expression, immune-effector signatures,  increased expression of the immune checkpoints PD-1, PD-L1, CTLA-4, and CD86 (CD28L), CD276/B7-H3 and CD244, lymphocyte activation gene-3 (LAG-3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), ecto-5′-nucleotidase (NT5E/CD73), signal regulatory protein α (SIRPα), nuclear factor of activated T cells 4 (NFATC4), and poliovirus receptor (CD155), increased T-effector and interferon-γ gene scores, which, along with increases in granzyme B (GZMB) and perforin-1 (PRF1)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD45; CD86; CD155 / PVR; PD-L1 / CD274; PD-1 / PDCD1; CTLA-4; LAG-3; TIGIT; Macrophages; Dendritic cells; NK cells; T cells; Granzyme B / GZMB; Perforin / PRF1; CD276 / B7-H3; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "PD-1 signaling inhibited", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-1-mediated negative regulation inhibited", "Controlled_Terms_Negative_Regulation": "PD-1 / PDCD1"}, {"ID": "CANIMM/2094", "Drug": "Entinostat+Ad-CEA+N-803 (1 μg, s.c.)", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibition, particularly HDAC1/HDAC3; immunomodulatory effects include reduction of Tregs and MDSCs and reduction of VISTA expression on multiple immune-cell populations.", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Combination", "PMID": "31645354", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": null, "Animal_Strain_used": "BALB/c mice, CEA-transgenic mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38-CEA", "Dose": "12 mg/kg/day in CEA-Tg/NSG mice, 3 mg/kg/day for Balb/c mice", "Technique": "Flow cytometry, ELISPOT, cytokine analysis, tumor-growth/survival analysis, immune-cell depletion, NanoString gene-expression analysis, chemokine analysis, immunological rechallenge, in-vitro PBMC experiments", "Controlled_Technique": "Flow cytometry; ELISpot/FluoroSpot assay; Cytokine/chemokine analysis; Survival analysis (Kaplan–Meier); In-vivo/in-vitro immunological assay; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "Elevated the proinflammatory cytokines IFNγ (3-fold) and TNFα (2-fold),increase in splenic CD4+ T cells, CD8⁺ T-cell tumor infiltration increased; activated CD8⁺ T cells increased, increased expression of CD25 and Ki67 on CD8⁺ T cells, increase in granzyme B", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; TNF-α / TNF; CD4; CD8; CD25 / IL2RA; T cells; Granzyme B / GZMB; Cell proliferation / Ki-67; Immune-cell infiltration; Cytokines", "Immune_System-Function_inhibited/numbers_decreased": "Elevated the proinflammatory cytokines IFNγ (3-fold) and TNFα (2-fold),increase in splenic CD4+ T cells, CD8⁺ T-cell tumor infiltration increased; activated CD8⁺ T cells increased, increased expression of CD25 and Ki67 on CD8⁺ T cells, increase in granzyme B", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; TNF-α / TNF; CD4; CD8; CD25 / IL2RA; T cells; Granzyme B / GZMB; Cell proliferation / Ki-67; Immune-cell infiltration; Cytokines", "Immune_System_function_unaffected": "No change in level of IL-10, Tumor infiltration of G-MDSCs and M-MDSCs", "Controlled_Terms_Unaffected": "IL-10; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; PMN-MDSCs / G-MDSCs; Immune-cell infiltration", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "elevated programmed death-ligand 1 (PD-L1)", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2095", "Drug": "CKI27 + anti-GITR (DTA-1) + anti-CTLA-4 (9D9)", "Drug_category": "others/combination", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "KI27 inhibits MEK1/2–ERK signaling; DTA-1 agonizes GITR/TNFRSF18 and provides T-cell costimulation; 9D9 blocks CTLA-4-mediated inhibitory signaling and promotes T-cell activation/Treg depletion", "KEGG_Drug_ID": null, "Drug_Pubchem": "72726305", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Combination", "PMID": "38885362", "Cancer_Type": "Colon Cancer; Lung Cancer", "Cancer_Type_Description": "Lung cancer / colon cancer", "Animal_Strain_used": "C57BL/6 mice- KRAS-mutant Lewis lung carcinoma (LLC)", "Cell_line_used_to_induce_tumor_in_mice": "LLC", "Dose": "LLC: 5 mg/kg orally, 4 days on/3 days off (4-on/3-off); Anti-GITR -1 mg/mouse, i.p., single dose on day 1, Anti-CTLA-4-100 µg/mouse, i.p., twice weekly beginning day 1", "Technique": "low cytometry TIL profiling", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ T-cell, CD4⁺ effector T-cell, CD8⁺/CD4⁺ effector-memory and memory phenotypes,  cytotoxic T-cell function, CD8:Treg ratio, cytotoxic/effector genes including Gzma, Gzmm, Tbx21 and Eomes", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; Regulatory T cells / Tregs; T cells", "Immune_System-Function_inhibited/numbers_decreased": "Intratumoral Tregs, MDSCs, CTLA-4/CD25 expression on Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD25 / IL2RA; CTLA-4; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2096", "Drug": "CKI27 + anti-GITR (DTA-1) + anti-CTLA-4 (9D9)", "Drug_category": "others/combination", "Drugbank_ID": "DB14779", "Target/s_or_mechanism_of_action": "KI27 inhibits MEK1/2–ERK signaling; DTA-1 agonizes GITR/TNFRSF18 and provides T-cell costimulation; 9D9 blocks CTLA-4-mediated inhibitory signaling and promotes T-cell activation/Treg depletion", "KEGG_Drug_ID": null, "Drug_Pubchem": "72726305", "STR_LINK_(SMILES)": "CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N", "Single/Combination": "Combination", "PMID": "38885362", "Cancer_Type": "Colon Cancer; Lung Cancer", "Cancer_Type_Description": "Lung cancer / colon cancer", "Animal_Strain_used": "BALB/cJ mice-KRAS-mutant CT26 colon carcinoma", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "CT26: 2 mg/kg orally, 4-on/3-off; Anti-GITR -1 mg/mouse, i.p., single dose on day 1, Anti-CTLA-4-100 µg/mouse, i.p., twice weekly", "Technique": "low cytometry TIL profiling", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ T-cell, CD4⁺ effector T-cell, CD8⁺/CD4⁺ effector-memory and memory phenotypes,  cytotoxic T-cell function, CD8:Treg ratio, cytotoxic/effector genes including Gzma, Gzmm, Tbx21 and Eomes", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; Regulatory T cells / Tregs; T cells", "Immune_System-Function_inhibited/numbers_decreased": "Intratumoral Tregs, MDSCs, CTLA-4/CD25 expression on Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD25 / IL2RA; CTLA-4; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2097", "Drug": "JQ1", "Drug_category": "others/combination", "Drugbank_ID": "DB17021", "Target/s_or_mechanism_of_action": "BRD4 inhibition", "KEGG_Drug_ID": null, "Drug_Pubchem": "46907787", "STR_LINK_(SMILES)": "CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C", "Single/Combination": "Single", "PMID": "35517410", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "Animal_Strain_used": "C57BL/6 mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "50 mg/kg i.p. daily", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "infiltrating Foxp3+ Treg cells", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2103", "Drug": "Doxorubicin (DOX) + indocyanine green (ICG) + anti-PD-L1 antibody (αPD-L1)", "Drug_category": "others/combination", "Drugbank_ID": "DB00997+DB09374", "Target/s_or_mechanism_of_action": "DOX causes DNA damage; ICG generates ROS upon ultrasound exposure, promoting mitochondrial DNA oxidation and cGAS–STING activation; αPD-L1 blocks PD-L1-mediated immune suppression.", "KEGG_Drug_ID": "D03899+D01342", "Drug_Pubchem": "31703+11967809", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2= and CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS([O-])(=O)=O)C3=CC=C4=CC=CC=C4C=C3C2(C)C)N(CCCCS(O)(=O)=O)C2=CC=C3C=CC=CC3=C12", "Single/Combination": "Combination", "PMID": "37391428", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "DOX 0.5 mg/kg + ICG 4 mg/kg intravenously; treatment on days 10 and 13, ultrasound on days 11 and 14", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ T-cell infiltration; antitumor T-cell immunity", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1-mediated immune suppression", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1-mediated immunosuppression was blocked", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2104", "Drug": "Luminespib + Emricasan + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition+Inhibits caspases, including caspase-associated apoptotic signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": "135539077 + 12000240", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C and C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Combination", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "B16", "Dose": "Luminespib 75 mg/kg every 2 days; emricasan 10 mg/kg daily; anti-PD-L1 100 µg/mouse every 4 days", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Antitumor immune response and sensitivity to PD-L1 blockade", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274", "Immune_System-Function_inhibited/numbers_decreased": "Caspase activity inhibited by emricasan; PD-L1-mediated immune suppression blocked by anti-PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1-mediated adaptive immune resistance is the therapeutic target; B16 model was used to assess whether the combination could overcome resistance", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2105", "Drug": "Venetoclax + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug_ID": "49846579", "Drug_Pubchem": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Combination", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "Venetoclax 100 mg/kg orally daily + anti-PD-L1 10 mg/kg intravenously twice weekly", "Technique": "Flow cytometry, ELISA, qRT-PCR", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD3+ and CD8+ T cells; IFN-γ, IL-2 and TNF-α increased; mRNA expression of Ccl5, Cxcl10, and Ifnβ( STING signaling pathway)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; TNF-α / TNF; CCL5 / RANTES; CXCL10 / IP-10; CD8; CD3; T cells; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression increased", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2106", "Drug": "Venetoclax + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug_ID": "49846579", "Drug_Pubchem": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Combination", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "Venetoclax 100 mg/kg orally daily + anti-PD-L1 10 mg/kg intravenously twice weekly", "Technique": "Flow cytometry, ELISA, qRT-PCR", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD3+ and CD8+ T cells; IFN-γ, IL-2 and TNF-α increased; mRNA expression of Ccl5, Cxcl10, and Ifnβ( STING signaling pathway)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; TNF-α / TNF; CCL5 / RANTES; CXCL10 / IP-10; CD8; CD3; T cells; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression increased", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2107", "Drug": "Venetoclax + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB11581", "Target/s_or_mechanism_of_action": "D10679", "KEGG_Drug_ID": "49846579", "Drug_Pubchem": "40300857", "STR_LINK_(SMILES)": "CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C", "Single/Combination": "Combination", "PMID": "40300857", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "EMT6", "Dose": "Venetoclax 100 mg/kg orally daily + anti-PD-L1 10 mg/kg intravenously twice weekly", "Technique": "Flow cytometry, ELISA, qRT-PCR", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA); Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "CD3+ and CD8+ T cells; IFN-γ, IL-2 and TNF-α increased; mRNA expression of Ccl5, Cxcl10, and Ifnβ( STING signaling pathway)", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; TNF-α / TNF; CCL5 / RANTES; CXCL10 / IP-10; CD8; CD3; T cells; cGAS–STING signaling", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression increased", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2108", "Drug": "Doxorubicin (DOX)+ indocyanine green +Ultrasound", "Drug_category": "others/combination", "Drugbank_ID": "DB00997+DB09374", "Target/s_or_mechanism_of_action": "DOX inhibits topoisomerase II and intercalates DNA. ICG acts as a sonosensitizer under ultrasound exposure, promoting reactive oxygen species (ROS) generation and mitochondrial DNA oxidation/release, activating the cGAS–STING–TBK1–IRF3 pathway and type I interferon responses", "KEGG_Drug_ID": "D03899+D01342", "Drug_Pubchem": "31703+11967809", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2= and CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS([O-])(=O)=O)C3=CC=C4=CC=CC=C4C=C3C2(C)C)N(CCCCS(O)(=O)=O)C2=CC=C3C=CC=CC3=C12", "Single/Combination": "Combination", "PMID": "37391428", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal/colon cancer", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "DOX 0.5 mg/kg + ICG 4 mg/kg intravenously; treatment on days 10 and 13, ultrasound on days 11 and 14", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Dendritic-cell activation (CD80 + DC,CD86 + DC, SIINFEKL/H-2Kb); antigen presentation, type I interferon signaling, intratumoral CD8⁺ T-cell infiltration, and antitumor immune responses", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; CD80; CD86; Dendritic cells; T cells; MHC class I; Immune-cell infiltration; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2109", "Drug": "JQ1", "Drug_category": "others/combination", "Drugbank_ID": "DB17021", "Target/s_or_mechanism_of_action": "BRD4 inhibition", "KEGG_Drug_ID": null, "Drug_Pubchem": "46907787", "STR_LINK_(SMILES)": "CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C", "Single/Combination": "Combination", "PMID": "35517410", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "Animal_Strain_used": "C57BL/6 mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "50 mg/kg i.p. daily", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "infiltrating Foxp3+ Treg cells", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2110", "Drug": "Luminespib + Emricasan + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition+Inhibits caspases, including caspase-associated apoptotic signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": "135539077 + 12000240", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C and C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Combination", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "Luminespib 75 mg/kg every 2 days; emricasan 10 mg/kg daily; anti-PD-L1 100 µg/mouse every 4 days", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Type I interferon signaling; CD45⁺ immune-cell infiltration; CD8⁺ T-cell infiltration and activation; granzyme B expression; antitumor immune response", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD45; T cells; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1-mediated immune checkpoint suppression blocked by anti-PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression induced by the luminespib–emricasan combination, contributing to adaptive immune resistance; anti-PD-L1 blocks this pathway", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2111", "Drug": "FK228 (Romidepsin)", "Drug_category": "others/combination", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "HDAC inhibitor; reported to directly inhibit HDAC1, HDAC2, HDAC4 and HDAC6. In this study, FK228 induces ER-stress-associated necroptosis in tumor cells, producing immunogenic cell death and remodeling the tumor immune microenvironment.", "KEGG_Drug_ID": "D06637", "Drug_Pubchem": "5352062", "STR_LINK_(SMILES)": "C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C", "Single/Combination": "Combination", "PMID": "40940553", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "colorectal cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "anti-PD-L1 and FK228", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Greatest infiltration of anticancer immune cells, such as proinflammatory Mφ, dendritic cell (DC), neutrophil, and CD8+ T cells, as well the modest accumulation of anticancer natural killer (NK)\ncells. Highest frequency of GZMB-positive CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Macrophages; Dendritic cells; NK cells; T cells; Neutrophils / granulocytes; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "remarkable decrease in anti-inflammatory Mφs", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2112", "Drug": "FK228 (Romidepsin)", "Drug_category": "others/combination", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "HDAC inhibitor; reported to directly inhibit HDAC1, HDAC2, HDAC4 and HDAC6. In this study, FK228 induces ER-stress-associated necroptosis in tumor cells, producing immunogenic cell death and remodeling the tumor immune microenvironment.", "KEGG_Drug_ID": "D06637", "Drug_Pubchem": "5352062", "STR_LINK_(SMILES)": "C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C", "Single/Combination": "Combination", "PMID": "40940553", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "colorectal cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1", "Dose": "anti-PD-L1 and FK228", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Greatest infiltration of anticancer immune cells, such as proinflammatory Mφ, dendritic cell (DC), neutrophil, and CD8+ T cells, as well the modest accumulation of anticancer natural killer (NK)\ncells. Highest frequency of GZMB-positive CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Macrophages; Dendritic cells; NK cells; T cells; Neutrophils / granulocytes; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "remarkable decrease in anti-inflammatory Mφs", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2113", "Drug": "Irinotecan (IRIN)+Radiotherapy", "Drug_category": "others/combination", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "DNA damage; cGAS–STING pathway activation", "KEGG_Drug_ID": "D08086", "Drug_Pubchem": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7", "Single/Combination": "Combination", "PMID": "37779919", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "IRIN silicasome 40 mg/kg IV every 3 days for 4 administrations; radiation 2 Gy × 4 fractions", "Technique": "Western blot, flow cytometry, immunofluorescence", "Controlled_Technique": "Western blot/immunoblot analysis; Flow cytometry; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "Increased tumor-infiltrating CD4⁺ T cells, CD8⁺ T cells and CD11c⁺ dendritic cells; increased IFN-γ expression", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; CD11c / ITGAX; Dendritic cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2115", "Drug": "Luminespib + Emricasan", "Drug_category": "others/combination", "Drugbank_ID": "DB05408", "Target/s_or_mechanism_of_action": "Hsp90 inhibition+Inhibits caspases, including caspase-associated apoptotic signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": "135539077 + 12000240", "STR_LINK_(SMILES)": "CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C and C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C", "Single/Combination": "Combination", "PMID": "38056894", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Murine colorectal cancer", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "Luminespib 75 mg/kg every 2 days; emricasan 10 mg/kg daily", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "ype I IFN/IFN-β production; CD8⁺ T-cell-dependent antitumor immunity", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression can increase following combination treatment, contributing to adaptive immune resistance", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2119", "Drug": "FK228 (Romidepsin)", "Drug_category": "others/combination", "Drugbank_ID": "DB06176", "Target/s_or_mechanism_of_action": "HDAC inhibitor; reported to directly inhibit HDAC1, HDAC2, HDAC4 and HDAC6. In this study, FK228 induces ER-stress-associated necroptosis in tumor cells, producing immunogenic cell death and remodeling the tumor immune microenvironment.", "KEGG_Drug_ID": "D06637", "Drug_Pubchem": "5352062", "STR_LINK_(SMILES)": "C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C", "Single/Combination": "Combination", "PMID": "40940553", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": null, "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "FK228 (0.5 mg/kg) via the tail vein every 2 days (5 times\nin total) and FK228 treated dead MC38 cells", "Technique": "In-vivo vaccination assay, immunohistochemistry/immunofluorescence, flow cytometry, single-cell RNA sequencing (scRNA-seq), pySCENIC transcription-factor analysis.", "Controlled_Technique": "In-vivo/in-vitro immunological assay; Immunohistochemistry (IHC); Immunofluorescence assay; Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ T-cell infiltration increased,CD8⁺ T-cell activation increased, GZMB- and IFN-γ-expressing CD8⁺ T cells increased, NK-cell infiltration increased, macrophages shifted toward a pro-inflammatory phenotype, neutrophils increased in the combination-treatment tumor microenvironment.", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; Macrophages; NK cells; T cells; Neutrophils / granulocytes; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression increased on cancer cells and macrophages; PD-1 expression increased on total T cells and CD8⁺ T cells following FK228 treatment. Tregs also increased", "Controlled_Terms_Negative_Regulation": "CD8; PD-L1 / CD274; PD-1 / PDCD1; Regulatory T cells / Tregs; Macrophages; T cells"}, {"ID": "CANIMM/2120", "Drug": "Melarsoprol (MEL)", "Drug_category": "others/combination", "Drugbank_ID": "DB12864", "Target/s_or_mechanism_of_action": "DNA damage; activates cGAS–STING–TBK1–IRF3 signaling, promoting IFN-β production", "KEGG_Drug_ID": "D00832", "Drug_Pubchem": "10311", "STR_LINK_(SMILES)": "C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO", "Single/Combination": "Single", "PMID": "40528981", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "mouse HCC cell line", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Hepa1–6", "Dose": "1 and 2.5 mg/kg in vivo", "Technique": "Western blot, RT-qPCR, ELISA, cGAS–STING signaling", "Controlled_Technique": "Western blot/immunoblot analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "TNF-α production through NF-κB signaling increases; potentially pro-tumorigenic", "Controlled_Terms_Function_enhanced_Number_increased": "TNF-α / TNF", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2121", "Drug": "Melarsoprol (MEL)+Lenalidomide (LEN)", "Drug_category": "others/combination", "Drugbank_ID": "DB12864+DB00480", "Target/s_or_mechanism_of_action": "DNA damage; activates cGAS–STING–TBK1–IRF3 signaling, promoting IFN-β production", "KEGG_Drug_ID": "D00832+\t\nD04687", "Drug_Pubchem": "10311+216326", "STR_LINK_(SMILES)": "C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO and C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N", "Single/Combination": "Combination", "PMID": "40528981", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "mouse HCC cell line", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Hepa1–6", "Dose": "2 mg/kg MEL + 2.5 mg/kg LEN; intravenous", "Technique": "flow cytometry; RT-qPCR; ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Activated dendritic cells, CD8⁺ cytotoxic T cells, CD4⁺ helper T cells, CD4⁺ and CD8⁺ memory T cells; IFN-β, IL-12, IFN-γ, CXCL9 and CXCL10 increased", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; IL-12; CXCL9; CXCL10 / IP-10; CD4; CD8; Dendritic cells; T cells", "Immune_System_function_unaffected": "Tregs, IL-10, TGF-β and TNF-α decreased", "Controlled_Terms_Unaffected": "IL-10; TNF-α / TNF; TGF-β; Regulatory T cells / Tregs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2122", "Drug": "Lycorine hydrochloride", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits viability; induces cell-cycle arrest and reduces cyclin D1, cyclin D3 and CDK2 expression", "KEGG_Drug_ID": null, "Drug_Pubchem": "164943", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "28416753", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renca murine renal carcinoma cell line; Renca-Luc used in mouse tumor model", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "RENCA", "Dose": "lycorine 5 mg/kg/day for 7 days", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ CD44+ CD62L− effector T cells increased in combination-treated mice; 42.89 ± 0.49%", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4+ Foxp3+ regulatory T cells decreased in combination-treated mice; 13.88 ± 0.75%", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; FOXP3; Regulatory T cells / Tregs; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2124", "Drug": "Lycorine hydrochloride Anti-mouse CTLA-4 monoclonal antibody (clone 9H10)", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits viability; induces cell-cycle arrest and reduces cyclin D1, cyclin D3 and CDK2 expression", "KEGG_Drug_ID": null, "Drug_Pubchem": "164943", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "28416753", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renca murine renal carcinoma cell line; Renca-Luc used in mouse tumor model", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "RENCA", "Dose": "lycorine 5 mg/kg/day for 7 days; anti-CTLA-4 100 μg/mouse on treatment days 0 and 7", "Technique": "flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ CD44+ CD62L− effector T cells increased in combination-treated mice; 52.95 ± 3.40%", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4+ Foxp3+ regulatory T cells decreased in combination-treated mice; 3.70 ± 0.23%", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; FOXP3; Regulatory T cells / Tregs; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CTLA-4 blockade reduces inhibitory checkpoint signaling; combination treatment decreases immunosuppressive Tregs", "Controlled_Terms_Negative_Regulation": "CTLA-4; Regulatory T cells / Tregs"}, {"ID": "CANIMM/2125", "Drug": "OBP-801 + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "DB12279", "Target/s_or_mechanism_of_action": "Potent class-I HDAC inhibitor", "KEGG_Drug_ID": null, "Drug_Pubchem": "11178958", "STR_LINK_(SMILES)": "CC(C)[C@H]1NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C)C(=O)N2)OC(=O)C[C@@H]1O", "Single/Combination": "Combination", "PMID": "39682244", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Clear cell renal cell carcinoma", "Animal_Strain_used": "BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "RENCA", "Dose": "OBP-801 10 mg/kg IV + anti-PD-1 10 mg/kg IP; days 1,4,7 for immune-analysis experiment", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "LMP2, MHC-I presentation, CD45⁺CD3e⁺ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD3; CD45; T cells; MHC class I; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "PD-1 inhibitory signaling blocked", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1", "Immune_System_function_unaffected": "CD8a⁺CD8b⁺ T cells", "Controlled_Terms_Unaffected": "CD8; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-1/PD-L1 negative immune regulation inhibited", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; PD-1 / PDCD1"}, {"ID": "CANIMM/2127", "Drug": "NHS-IL12", "Drug_category": "others/combination", "Drugbank_ID": "DB17585", "Target/s_or_mechanism_of_action": "NHS76 antibody targets exposed DNA/histones in necrotic tumor regions; IL-12 activates NK/T cells and induces IFN-γ", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "35764364", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "MHC-I-deficient, IFN-γ-responsive lung tumor", "Animal_Strain_used": "Female C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "TC-1/a9", "Dose": "2 µg s.c., alternate days ×3", "Technique": "Flow cytometry; immunofluorescence; cytokine/chemokine analysis; RNA-seq", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Cytokine/chemokine analysis; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T-cell frequency, NK-cell proliferation, increased IFN-γ/IL-12-associated responses", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-12; CD8; NK cells; T cells; Cell proliferation / Ki-67", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "Treg tumor infiltration in TC-1/a9; CD8+ TIL absolute number in TC-1/a9", "Controlled_Terms_Unaffected": "CD8; Regulatory T cells / Tregs; Immune-cell infiltration", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2128", "Drug": "NHS-IL12", "Drug_category": "others/combination", "Drugbank_ID": "DB17585", "Target/s_or_mechanism_of_action": "Tumor-localized IL-12 → activation of NK/T cells, IFN-γ production, antigen presentation", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "35764364", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "MHC-I/APM-deficient, IFN-γ-response-defective lung tumor", "Animal_Strain_used": "Female C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "CMT.64", "Dose": "2 µg s.c., alternate days ×3", "Technique": "Flow cytometry; immunofluorescence; cytokine/chemokine analysis", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Cytokine/chemokine analysis", "Immune_System-Function_enhanced/numbers_increased": "H-2Kb expression, CD8+ TIL frequency, M1-like macrophages, cDC1; increased IFN-γ/TNFα; increased chemokines including CCL5/CXCL10/CXCL13", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; TNF-α / TNF; CCL5 / RANTES; CXCL10 / IP-10; CXCL13; CD8; Macrophages; MHC class I; Immune-cell infiltration; Chemokines", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2028", "Drug": "Oxaliplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug_ID": "D01790", "Drug_Pubchem": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "2.5 mg/kg", "Technique": "Immunoblotting,Immunohistochemistry", "Controlled_Technique": "Western blot/immunoblot analysis; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "tumor programmed cell death 1 ligand 1 (PD-L1) level", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2134", "Drug": "Doxorubicin + Celecoxib", "Drug_category": "others/combination", "Drugbank_ID": "DB00997 + DB00482", "Target/s_or_mechanism_of_action": "DNA damage and ICD induction combined with COX-2/IDO1 pathway suppression", "KEGG_Drug_ID": "D03899+D00567", "Drug_Pubchem": "31703 + 2662", "STR_LINK_(SMILES)": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O and CC1=CC(=NN1C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=C(C=C3)C(F)(F)F", "Single/Combination": "Combination", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "LLC tumor-bearing mice", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "LLC", "Dose": "25 mg/kg; 50 mg/kg", "Technique": "Flow cytometery", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "increased mature DCs reported in the DOX + celecoxib treatment comparison", "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD8+ T-cell depletion reduces the antitumor effect", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "COX-2/IDO1-associated immunosuppression is a proposed mechanism", "Controlled_Terms_Negative_Regulation": "IDO1; COX-2"}, {"ID": "CANIMM/2135", "Drug": "Gemcitabine + Celecoxib + Anti-PD-1 (GCP)", "Drug_category": "others/combination", "Drugbank_ID": "DB00441 + DB00482 + NR", "Target/s_or_mechanism_of_action": "GEM-induced ICD plus celecoxib-mediated IDO1 suppression and anti-PD-1 checkpoint blockade", "KEGG_Drug_ID": "D02368+D00567", "Drug_Pubchem": "60750 + 2662", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F and CC1=CC(=NN1C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=C(C=C3)C(F)(F)F", "Single/Combination": "Combination", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "LLC tumor-bearing C57BL/6J mice", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "LLC", "Dose": "GEM 25 mg/kg IV; celecoxib 50 mg/kg oral gavage; aPD-1 100 µg/mouse IV", "Technique": "Tumor growth and survival monitoring; flow cytometry; immunohistochemistry; ELISA", "Controlled_Technique": "Tumor growth/survival analysis; Flow cytometry; Immunohistochemistry (IHC); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "Enhanced antitumor efficacy; increased tumor CD8 staining; reduced MDSCs; improved tumor control and survival", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Myeloid-derived suppressor cells / MDSCs; Tumor growth / burden outcome; Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": "Reduced IDO1 and COX-2 expression; reduced MDSC numbers", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs; IDO1; COX-2", "Immune_System_function_unaffected": "No significant difference in IL-2; no significant difference in CD4+ T cells or CD8+IFN-γ+ cells among groups", "Controlled_Terms_Unaffected": "IFN-γ; IL-2; CD4; CD8; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Reduced IDO1-associated immunosuppression and PD-1 checkpoint-mediated inhibition", "Controlled_Terms_Negative_Regulation": "PD-1 / PDCD1; IDO1"}, {"ID": "CANIMM/2136", "Drug": "Entinostat + anti-PD-1 + anti-CTLA-4", "Drug_category": "others/combination", "Drugbank_ID": "DB11842", "Target/s_or_mechanism_of_action": "HDAC1/HDAC3 inhibition; systemic immune modulation", "KEGG_Drug_ID": "D09339", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C4", "Single/Combination": "Combination", "PMID": "42515717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Syngeneic murine NSCLC", "Animal_Strain_used": "C57BL/6 mice", "Cell_line_used_to_induce_tumor_in_mice": "KPN1.1", "Dose": "Entinostat 7.5 mg/kg p.o., 5×/week, 8 doses + anti-PD-1 200 µg i.p. twice weekly ×3 + anti-CTLA-4 200 µg i.p. twice weekly ×3", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4⁺ and CD8⁺ T cells, effector CD8⁺ T cells, antigen-specific CD8⁺ response, IFN-γ production by gp33-specific CD8⁺ cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4⁺ IFN-γ response not significantly altered by gp33/gp66 stimulation", "Controlled_Terms_Unaffected": "IFN-γ; CD4", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2137", "Drug": "Entinostat + NHS-IL12", "Drug_category": "others/combination", "Drugbank_ID": "DB11841 + DB17585", "Target/s_or_mechanism_of_action": "Synergistic enhancement of MHC-I/APM, cytotoxic lymphocyte activation, IFN-γ/JAK-STAT signaling and antigen presentation", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Combination", "PMID": "35764364", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "MHC-I-deficient CMT.64 lung tumor", "Animal_Strain_used": "Female C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "CMT.64", "Dose": "Entinostat 6 mg/kg/day p.o.; NHS-IL12 2 µg s.c., alternate days ×3", "Technique": "Flow cytometry; immunofluorescence; cytokine/chemokine assays", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Cytokine/chemokine analysis", "Immune_System-Function_enhanced/numbers_increased": "CD8+ TILs, cytolytic GzmB, increased CD8+ proliferation, increased NK proliferation, increased M1-like TAMs, increased DC activation, increased cDC1, increased IFN-γ/TNFα/IL-12p70/CXCL9, increased CD8+/Treg ratio", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; TNF-α / TNF; CXCL9; CD8; Regulatory T cells / Tregs; Macrophages; Dendritic cells; NK cells; Granzyme B / GZMB; Cell proliferation / Ki-67", "Immune_System-Function_inhibited/numbers_decreased": "Dampened Treg TILs, M2-like macrophage phenotype", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Macrophages", "Immune_System_function_unaffected": "Activated splenic DC frequency remained unchanged", "Controlled_Terms_Unaffected": "Dendritic cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2138", "Drug": "Entinostat + anti-PD-1 + anti-CTLA-4", "Drug_category": "others/combination", "Drugbank_ID": "DB11843", "Target/s_or_mechanism_of_action": "HDAC1/HDAC3 inhibition; systemic immune modulation", "KEGG_Drug_ID": "D09340", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C5", "Single/Combination": "Combination", "PMID": "42515717", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Orthotopic syngeneic murine NSCLC", "Animal_Strain_used": "C57BL/6 mice", "Cell_line_used_to_induce_tumor_in_mice": "KPN1.1", "Dose": "Entinostat 7.5 mg/kg p.o., 5×/week for 2 weeks + dual ICI", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Effector T-cell phenotype particularly CD8⁺ effector T cells, antigen-specific CD8⁺ immune response", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells", "Immune_System-Function_inhibited/numbers_decreased": "—", "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "—", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "—", "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2139", "Drug": "Citarinostat + Oxaliplatin", "Drug_category": "others/combination", "Drugbank_ID": "DB15449 + DB00526", "Target/s_or_mechanism_of_action": "HDAC6 inhibition/immunomodulation + platinum-mediated DNA damage", "KEGG_Drug_ID": "D10918 + D01790", "Drug_Pubchem": "53340426 + 9887054", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "35223194", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC / lung adenocarcinoma", "Animal_Strain_used": "Kras+/LSL-G12D; Trp53L/L (KP) mice", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "ACY241 3×/week + oxaliplatin 10 mg/kg 1×/week for 6 weeks", "Technique": "Flow cytometery, transcriptomics", "Controlled_Technique": "Flow cytometry; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CD8:Treg ratio, CD8+ T-cell expressing IL-2, TNF-α, IFN-γ, CD4+ T-cell", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; TNF-α / TNF; CD4; CD8; Regulatory T cells / Tregs; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2140", "Drug": "Vinblastine (VBL)", "Drug_category": "others/combination", "Drugbank_ID": "DB00570", "Target/s_or_mechanism_of_action": "Binds tubulin/microtubules and inhibits microtubule polymerization.", "KEGG_Drug_ID": "D08675", "Drug_Pubchem": "241903", "STR_LINK_(SMILES)": "CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1", "Single/Combination": "Combination", "PMID": "37652576", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Pulmonary/lung cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "LLC (Lewis lung carcinoma)", "Dose": "VBL 1.25 mg/kg + anti-PD-1 100 µg/mouse", "Technique": "macrophage reprogramming and T-cell activity", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "M2-like phenotype", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2141", "Drug": "Gemcitabine + Celecoxib", "Drug_category": "others/combination", "Drugbank_ID": "DB00441 + DB00482", "Target/s_or_mechanism_of_action": "Enhances ICD and antitumor immunity; celecoxib suppresses COX-2/PGE2-associated PI3K/AKT/IDO1 signaling", "KEGG_Drug_ID": "D02368+D00567", "Drug_Pubchem": "60750 + 2662", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F and CC1=CC(=NN1C2=CC=C(C=C2)S(=O)(=O)N)C3=CC=C(C=C3)C(F)(F)F", "Single/Combination": "Combination", "PMID": "38988937", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "LLC tumor-bearing C57BL/6J mice", "Animal_Strain_used": "C57BL/6J mice", "Cell_line_used_to_induce_tumor_in_mice": "LLC", "Dose": "GEM 25 mg/kg IV; celecoxib 50 mg/kg oral gavage; frequency per study protocol", "Technique": "Tumor-volume monitoring; flow cytometry; immunohistochemistry", "Controlled_Technique": "Tumor growth/survival analysis; Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "Increased CD8+ T-cell proportion and mature DC proportion reported for GC-related treatment comparisons", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Dendritic cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "Reduced COX-2/IDO1-associated immunosuppressive signaling", "Controlled_Terms_Function_inhibited_Number_decreased": "IDO1; COX-2", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Reduced IDO1-associated immunosuppression", "Controlled_Terms_Negative_Regulation": "IDO1"}, {"ID": "CANIMM/2143", "Drug": "Entinostat + NHS-IL12", "Drug_category": "others/combination", "Drugbank_ID": "DB11841 + DB17585", "Target/s_or_mechanism_of_action": "HDAC inhibition increases tumor immune recognition/MHC-I/APM while tumor-targeted IL-12 activates cytotoxic lymphocytes and IFN-γ pathways", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Combination", "PMID": "35764364", "Cancer_Type": "Lung Cancer; Hpv16-Expressing Tumors", "Cancer_Type_Description": "MHC-I-deficient, HPV16 E6/E7+ lung tumor", "Animal_Strain_used": "Female C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "TC-1/a9", "Dose": "Entinostat 6 mg/kg/day p.o.; NHS-IL12 2 µg s.c., alternate days ×3", "Technique": "Flow cytometry; immunofluorescence; RNA-seq; GSEA; cytokine/chemokine assays", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay; Gene expression/sequencing analysis; Cytokine/chemokine analysis", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T-cell infiltration, activation and proliferation, GzmB, NK-cell proliferation, M1-like macrophages, activated APC/DCs, increased MHC-I/APM, increased IFN-γ, IL-12, CXCL9/CXCL13", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-12; CXCL9; CXCL13; CD8; Macrophages; Dendritic cells; NK cells; T cells; Granzyme B / GZMB; MHC class I; Cell proliferation / Ki-67; Immune-cell infiltration; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "M2-like macrophages, Treg activity/infiltration in tumor-dependent manner", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Macrophages; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1876", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "28282575", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Breast Tumor", "Animal_Strain_used": "FVB/N", "Cell_line_used_to_induce_tumor_in_mice": "NT2.5 tumor cells", "Dose": "(30 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ and CD8+ T lymphocytes, induction of T cell memory.", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2144", "Drug": "Belantamab mafodotin (GSK2857916)", "Drug_category": "others/combination", "Drugbank_ID": "DB15719", "Target/s_or_mechanism_of_action": "Binds BCMA (TNFRSF17) on multiple myeloma cells; delivers MMAF, inducing apoptosis. Promotes immunogenic cell death (ICD), DAMP release, and dendritic-cell maturation.", "KEGG_Drug_ID": "D11595", "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "34253590", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma", "Animal_Strain_used": "Female C57BL/6 mice", "Cell_line_used_to_induce_tumor_in_mice": "EL4-hBCMA", "Dose": "15 mg/kg", "Technique": "Flow cytometry; immunohistochemistry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "activation markers including CD25, CD69, and inducible T-cell costimulator (ICOS), CD8+PD-1+ cells and CD8+ granzyme B (GrzB)+ cytotoxic cells ;CD4+ T-cells, regulatory T cells (Treg: CD4+CD25+FoxP3+) in tumor, NK cell (CD49+) and DC infiltration (CD11c+), and expression of the costimulatory molecule CD86", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD11c / ITGAX; CD25 / IL2RA; CD69; CD86; PD-1 / PDCD1; FOXP3; Regulatory T cells / Tregs; Dendritic cells; NK cells; T cells; Granzyme B / GZMB; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "CD8+ T-cell depletion reduced or abrogated antitumor efficacy", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; T cells", "Immune_System_function_unaffected": "No specific immune function conclusively established as unaffected", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "No direct evidence of enhanced regulatory T-cell activity or other negative immune-regulatory functions reported", "Controlled_Terms_Negative_Regulation": "Regulatory T cells / Tregs; T cells"}, {"ID": "CANIMM/2147", "Drug": "Glaucocalyxin A", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Inhibits STAT3 phosphorylation; reduces STAT3-associated survival signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": "10471963", "STR_LINK_(SMILES)": "C[C@@]12CCC(=O)C([C@H]1C[C@H]([C@]34[C@H]2CC[C@H]([C@H]3O)C(=C)C4=O)O)(C)C", "Single/Combination": "Single", "PMID": "34923957", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Multiple myeloma", "Animal_Strain_used": "Nude mice", "Cell_line_used_to_induce_tumor_in_mice": "RPMI-8226", "Dose": "30 mg/kg body weight", "Technique": "Western blotting, and immunohistochemistry (IHC)", "Controlled_Technique": "Western blot/immunoblot analysis; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "Cleaved PARP and cleaved caspase-3 increased", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": "phosphorylated STAT3 (p-STAT3) decreased,  Ki-67 and PCNA expression significantly decreased", "Controlled_Terms_Function_inhibited_Number_decreased": "STAT3 signaling; Cell proliferation / Ki-67", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2148", "Drug": "Pomalidomide+ CAR T cells", "Drug_category": "others/combination", "Drugbank_ID": "DB08910", "Target/s_or_mechanism_of_action": "Enhances BCMA CAR-T-cell activity, effector cytokine production and tumor infiltration; supports T-cell-mediated antitumor responses through immunomodulation", "KEGG_Drug_ID": "D04690", "Drug_Pubchem": "9826528", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N", "Single/Combination": "Combination", "PMID": "41410870", "Cancer_Type": "Myeloma", "Cancer_Type_Description": "Human U266 multiple myeloma xenograft model", "Animal_Strain_used": "Female NOD-SCID mice", "Cell_line_used_to_induce_tumor_in_mice": "U266", "Dose": "U266 cells: 1 × 10^7 cells/mouse; pomalidomide: 2.5 mg/kg intraperitoneally, 5 times/week for 21 days; BCMA CAR-T cells: 1 × 10^7 cells/mouse intravenously", "Technique": "ELISA; flow cytometry, qPCR", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "Increased intratumoral CD3+ T-cell infiltration; increased IL-2, IFN-γ and increased tumor-tissue expression of IL-2, IFNG and CXCL9–CXCL11", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-2; CXCL9; CXCL11 / I-TAC; CD3; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "TNF-α, IL-10 and IL-6 were not further increased by pomalidomide in the CAR-T combination", "Controlled_Terms_Unaffected": "IL-6; IL-10; TNF-α / TNF", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2149", "Drug": "Dendritic cell vaccine + pomalidomide + dexamethasone", "Drug_category": "others/combination", "Drugbank_ID": "DB08910+DB01234", "Target/s_or_mechanism_of_action": "Pomalidomide binds CRBN and promotes IKZF1/IKZF3 degradation; dexamethasone activates the glucocorticoid receptor and has anti-inflammatory and antimyeloma effects", "KEGG_Drug_ID": "D08976+D00292", "Drug_Pubchem": "134780+5743", "STR_LINK_(SMILES)": "C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N and C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C", "Single/Combination": "Combination", "PMID": "30123221", "Cancer_Type": "Plasmacytoma", "Cancer_Type_Description": "Murine MOPC-315 plasmacytoma model", "Animal_Strain_used": "Female BALB/c mice", "Cell_line_used_to_induce_tumor_in_mice": "MOPC-315", "Dose": "Pomalidomide: 0.06 mg/kg/day orally; dexamethasone: 0.6 mg/kg intravenously on scheduled days; DC vaccine: 1×1061×106 cells/mouse per dose", "Technique": "flow cytometry; IFN-γ ELISPOT; ELISA", "Controlled_Technique": "Flow cytometry; ELISpot/FluoroSpot assay; Cytokine/chemokine analysis; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD4⁺ effector T cells, CD8⁺ effector T cells, Effector memory T cells, Natural killer (NK) cells, M1 macrophages, IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; Macrophages; NK cells; T cells", "Immune_System-Function_inhibited/numbers_decreased": "Myeloid-derived suppressor cells (MDSCs; CD11b⁺Gr-1⁺), Regulatory T cells (Tregs; CD4⁺CD25⁺FoxP3⁺), M2 macrophages (CD11b⁺F4/80⁺CD206⁺)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD11b / ITGAM; CD25 / IL2RA; CD206 / MRC1; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Macrophages; T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2151", "Drug": "CN133 + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "NR", "Target/s_or_mechanism_of_action": "Potent class-I HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3", "KEGG_Drug_ID": "NR", "Drug_Pubchem": "NR", "STR_LINK_(SMILES)": "CN(Cc1ccc(/C=C/C(=O)NO)cc1)CC12CC3CC(CC(C3)C1)C2", "Single/Combination": "Combination", "PMID": "37880708", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Subcutaneous prostate-cancer allograft; combination therapy tested for enhancement of anti-PD-1 response", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "RM1 prostate cancer cells", "Dose": "CN133 1 mg/kg IP twice/week + anti-PD-1 10 mg/kg IP twice/week", "Technique": "flow cytometry; immunofluorescence", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ TIL infiltration, CD4⁺ and CD8⁺ T cells, CD8⁺ T-cell granzyme B, perforin", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells; Granzyme B / GZMB; Perforin / PRF1; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "PMN-MDSCs(CD11b⁺Ly6G⁺),PMN-MDSC (Arg-1, iNOS)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / G-MDSCs; Arginase-1 / ARG1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2152", "Drug": "CN133 + anti-PD-1", "Drug_category": "others/combination", "Drugbank_ID": "NR", "Target/s_or_mechanism_of_action": "Potent class-I HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3", "KEGG_Drug_ID": "NR", "Drug_Pubchem": "NR", "STR_LINK_(SMILES)": "CN(Cc1ccc(/C=C/C(=O)NO)cc1)CC12CC3CC(CC(C3)C1)C2", "Single/Combination": "Combination", "PMID": "37880708", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Subcutaneous MyC-CaP prostate-cancer model", "Animal_Strain_used": "FVB", "Cell_line_used_to_induce_tumor_in_mice": "MyC-CaP", "Dose": "CN133 1 mg/kg IP twice/week + anti-PD-1 10 mg/kg IP twice/week", "Technique": "flow cytometry; immunofluorescence", "Controlled_Technique": "Flow cytometry; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ TIL infiltration, CD4⁺ and CD8⁺ T cells, CD8⁺ T-cell granzyme B, perforin", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; T cells; Granzyme B / GZMB; Perforin / PRF1; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "PMN-MDSCs(CD11b⁺Ly6G⁺),PMN-MDSC (Arg-1, iNOS)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs; PMN-MDSCs / G-MDSCs; Arginase-1 / ARG1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2153", "Drug": "Trabectedin + oHSV 107107", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Binds DNA minor groove; interferes with transcription and DNA repair", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39492947", "Cancer_Type": "Rhabdomyosarcoma", "Cancer_Type_Description": "Human rhabdomyosarcoma PDX", "Animal_Strain_used": "CB17 SCID", "Cell_line_used_to_induce_tumor_in_mice": "PDX-0027", "Dose": "0.15 mg/kg IV on days 0 and 7; HSV1716 intratumorally on days 0 and 2", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Increased granzyme expression in tumor-infiltrating T cells and NK cells; oHSV-associated increase in tumor-infiltrating GP70+ CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; NK cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "decrease in immunosuppressive cells, including CD206hi tumor-associated macrophages (TAM), T regulatory cells, and CTLA4+ CD4 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD206 / MRC1; CTLA-4; Regulatory T cells / Tregs; Macrophages; Tumor-associated macrophages / TAMs; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2154", "Drug": "NHS-IL12", "Drug_category": "others/combination", "Drugbank_ID": "DB17585", "Target/s_or_mechanism_of_action": "Tumor-targeted IL-12; activation of innate/adaptive immunity and IFN-γ pathways", "KEGG_Drug_ID": "NR", "Drug_Pubchem": "NR", "STR_LINK_(SMILES)": "NR", "Single/Combination": "Single", "PMID": "35764364", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "MHC-I-deficient, IFN-γ-resistant RVP3 sarcoma", "Animal_Strain_used": "Female C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "RVP3", "Dose": "2 µg s.c., alternate days ×3", "Technique": "Flow cytometry; cytokine/chemokine analysis", "Controlled_Technique": "Flow cytometry; Cytokine/chemokine analysis", "Immune_System-Function_enhanced/numbers_increased": "Increased M1-like TAMs; decreased M2-like TAMs; increased M1:M2 ratio", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages", "Immune_System-Function_inhibited/numbers_decreased": "M2-like TAMs decreased", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": "NK TIL number remained unchanged", "Controlled_Terms_Unaffected": "NK cells; Immune-cell infiltration", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2166", "Drug": "Palbociclib", "Drug_category": "others/combination", "Drugbank_ID": "DB09073", "Target/s_or_mechanism_of_action": "Inhibits CDK4/6, reducing RB1 phosphorylation and cell-cycle progression", "KEGG_Drug_ID": "D10372", "Drug_Pubchem": "5330286", "STR_LINK_(SMILES)": null, "Single/Combination": "Single", "PMID": "32661093", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "BRAF V600E-mutant, PTEN-loss melanoma", "Animal_Strain_used": "C57BL/6; NSG", "Cell_line_used_to_induce_tumor_in_mice": "D4M3.A", "Dose": "429 ppm in chow", "Technique": "Flow cytometry; Western blot", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "Increased tumor immunogenicity and CD8⁺ T-cell infiltration , CD137L (4-1BBL) expression is implicated in the immune response to treatment", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD137 / 4-1BB; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "No significant changes reported in CD4⁺ T cells, FOXP3⁺ regulatory T cells or NK cells in the reported comparison", "Controlled_Terms_Unaffected": "CD4; FOXP3; Regulatory T cells / Tregs; NK cells; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2157", "Drug": "Trabectedin + rRp450 oHSV", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Binds DNA minor groove; interferes with transcription and DNA repair", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39492947", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Human Ewing sarcoma xenograft", "Animal_Strain_used": "Athymic nude", "Cell_line_used_to_induce_tumor_in_mice": "A673", "Dose": "0.15 mg/kg IV on days 0 and 7; oHSV 107107 PFU intratumorally on days 0 and 2", "Technique": "RNA-seq, flow cytometry", "Controlled_Technique": "Gene expression/sequencing analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "Increased granzyme expression in tumor-infiltrating T cells and NK cells; oHSV-associated increase in tumor-infiltrating GP70+ CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; NK cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "decrease in immunosuppressive cells, including CD206hi tumor-associated macrophages (TAM), T regulatory cells, and CTLA4+ CD4 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD206 / MRC1; CTLA-4; Regulatory T cells / Tregs; Macrophages; Tumor-associated macrophages / TAMs; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2158", "Drug": "Trabectedin + rRp450 oHSV", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Binds DNA minor groove; interferes with transcription and DNA repair", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39492947", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Human Ewing sarcoma PDX", "Animal_Strain_used": "Athymic nude", "Cell_line_used_to_induce_tumor_in_mice": "CHLA258 (PDX)", "Dose": "0.15 mg/kg IV on days 0 and 7; oHSV 107107 PFU intratumorally on days 0 and 2", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Increased granzyme expression in tumor-infiltrating T cells and NK cells; oHSV-associated increase in tumor-infiltrating GP70+ CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; NK cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "decrease in immunosuppressive cells, including CD206hi tumor-associated macrophages (TAM), T regulatory cells, and CTLA4+ CD4 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD206 / MRC1; CTLA-4; Regulatory T cells / Tregs; Macrophages; Tumor-associated macrophages / TAMs; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2159", "Drug": "Trabectedin + oHSV 107107", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Binds DNA minor groove; interferes with transcription and DNA repair", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39492947", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Human Ewing sarcoma PDX", "Animal_Strain_used": "Athymic nude", "Cell_line_used_to_induce_tumor_in_mice": "EW5 (PDX)", "Dose": "0.15 mg/kg IV on days 0 and 7; oHSV 107107 PFU intratumorally on days 0 and 2", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Increased granzyme expression in tumor-infiltrating T cells and NK cells; oHSV-associated increase in tumor-infiltrating GP70+ CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; NK cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "decrease in immunosuppressive cells, including CD206hi tumor-associated macrophages (TAM), T regulatory cells, and CTLA4+ CD4 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD206 / MRC1; CTLA-4; Regulatory T cells / Tregs; Macrophages; Tumor-associated macrophages / TAMs; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2160", "Drug": "Trabectedin + oHSV 107107", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Binds DNA minor groove; interferes with transcription and DNA repair", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39492947", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Human Ewing sarcoma xenograft in NK-deficient mice", "Animal_Strain_used": "NSG-SGM3", "Cell_line_used_to_induce_tumor_in_mice": "A673", "Dose": "0.15 mg/kg IV on days 0 and 7; HSV1716 intratumorally on days 0 and 2", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Increased granzyme expression in tumor-infiltrating T cells and NK cells; oHSV-associated increase in tumor-infiltrating GP70+ CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; NK cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "decrease in immunosuppressive cells, including CD206hi tumor-associated macrophages (TAM), T regulatory cells, and CTLA4+ CD4 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD206 / MRC1; CTLA-4; Regulatory T cells / Tregs; Macrophages; Tumor-associated macrophages / TAMs; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2161", "Drug": "Trabectedin + oHSV 107107", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Binds DNA minor groove; interferes with transcription and DNA repair", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39492947", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Syngeneic murine osteosarcoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "K7M2", "Dose": "0.15 mg/kg IV on day 0 for immune profiling; HSV1716 108108 PFU/mL intratumorally on days 0, 2 and 4", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Increased granzyme expression in tumor-infiltrating T cells and NK cells; oHSV-associated increase in tumor-infiltrating GP70+ CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; NK cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "decrease in immunosuppressive cells, including CD206hi tumor-associated macrophages (TAM), T regulatory cells, and CTLA4+ CD4 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD206 / MRC1; CTLA-4; Regulatory T cells / Tregs; Macrophages; Tumor-associated macrophages / TAMs; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2162", "Drug": "Trabectedin + rRp450 oHSV", "Drug_category": "others/combination", "Drugbank_ID": "DB05109", "Target/s_or_mechanism_of_action": "Binds DNA minor groove; interferes with transcription and DNA repair", "KEGG_Drug_ID": "D06199", "Drug_Pubchem": "108150", "STR_LINK_(SMILES)": "CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O", "Single/Combination": "Combination", "PMID": "39492947", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Syngeneic murine osteosarcoma", "Animal_Strain_used": "B6-albino; C57BL/6 background", "Cell_line_used_to_induce_tumor_in_mice": "F420", "Dose": "0.15 mg/kg IV in initial regimen; dose alterations were investigated due to toxicity; oHSV intratumorally", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "Increased granzyme expression in tumor-infiltrating T cells and NK cells; oHSV-associated increase in tumor-infiltrating GP70+ CD8 T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; NK cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "decrease in immunosuppressive cells, including CD206hi tumor-associated macrophages (TAM), T regulatory cells, and CTLA4+ CD4 T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD206 / MRC1; CTLA-4; Regulatory T cells / Tregs; Macrophages; Tumor-associated macrophages / TAMs; T cells; CD4+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2163", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "others/combination", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Combination", "PMID": "12907617", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Fibrosarcoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "C3", "Dose": "ATRA pellets (21-day release, 5 mg)", "Technique": "ELISPOT assay", "Controlled_Technique": "ELISpot/FluoroSpot assay; Cytokine/chemokine analysis", "Immune_System-Function_enhanced/numbers_increased": "antigenspecific IFN-γ -producing T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2164", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "others/combination", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Combination", "PMID": "12907617", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "MethA sarcoma", "Dose": "ATRA pellets (21-day release, 5 mg)", "Technique": "ELISPOT assay, Flow cytometry", "Controlled_Technique": "ELISpot/FluoroSpot assay; Cytokine/chemokine analysis; Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "antigenspecific T cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+CD11b+ ImCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2165", "Drug": "Entinostat + NHS-IL12", "Drug_category": "others/combination", "Drugbank_ID": "DB11841 + DB17585", "Target/s_or_mechanism_of_action": "Combined epigenetic and cytokine immunostimulation; activation of CD8+ T/NK cells, APCs and M1-like macrophages", "KEGG_Drug_ID": "D09338 + NR", "Drug_Pubchem": "4261 + NR", "STR_LINK_(SMILES)": "Entinostat SMILES + NHS-IL12 NR", "Single/Combination": "Combination", "PMID": "35764364", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "MHC-I-deficient, IFN-γ-resistant RVP3 sarcoma", "Animal_Strain_used": "Female C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "RVP3", "Dose": "Entinostat 6 mg/kg/day p.o.; NHS-IL12 2 µg s.c., alternate days ×3", "Technique": "Flow cytometry; cytokine/chemokine analysis; immunophenotyping", "Controlled_Technique": "Flow cytometry; Cytokine/chemokine analysis; Immune-cell profiling/phenotyping", "Immune_System-Function_enhanced/numbers_increased": "cytolytic/proliferative CD8+ TILs, NK cells,  M1-like TAMs, increased B-cell activity, increased DC MHC-II/PD-L1,  CXCL9/CXCL13/CCL20/CXCL5", "Controlled_Terms_Function_enhanced_Number_increased": "CCL2 / MCP-1; CXCL9; CXCL13; CD8; PD-L1 / CD274; Macrophages; Dendritic cells; NK cells; B cells; MHC class II; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "Decreased M2-like TAMs; M1:M2 ratio increased", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": "NK TIL absolute number unchanged", "Controlled_Terms_Unaffected": "NK cells; Immune-cell infiltration", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1887", "Drug": "UNC2025", "Drug_category": "Tyrosine Kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28605477", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "Animal_Strain_used": "C57Bl/6", "Cell_line_used_to_induce_tumor_in_mice": "TRP-MSCV-luc cells", "Dose": "UNC2025 (65 mg/kg via oral gavage daily starting day 7", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "F4-80+ cells", "Controlled_Terms_Unaffected": "F4-80+ cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2170", "Drug": "AZD0156 + RT + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "AZD0156", "Target/s_or_mechanism_of_action": "ATM inhibition and RT promote interferon signaling; anti-PD-L1 blocks PD-1/PD-L1 immune-checkpoint signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "37730275", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Murine melanoma model", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "B78-D14 (B78)", "Dose": "AZD0156: 10 mg/kg orally; RT: 12 Gy; anti-PD-L1: 200 µg intraperitoneally on days 0, 4, 8 and 12", "Technique": "flow cytometry; qPCR; ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "Improved antitumor response and survival; enhanced antitumor immune activity", "Controlled_Terms_Function_enhanced_Number_increased": "Survival outcome", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1-mediated immune inhibition targeted pharmacologically", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274", "Immune_System_function_unaffected": "NR", "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression induced by IFN-β provides a rationale for checkpoint blockade", "Controlled_Terms_Negative_Regulation": "IFN-γ; PD-L1 / CD274"}, {"ID": "CANIMM/2171", "Drug": "AZD0156 + RT", "Drug_category": "others/combination", "Drugbank_ID": "AZD0156", "Target/s_or_mechanism_of_action": "ATM inhibition increases radiation-associated cytosolic DNA and STING-dependent IFN-β signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "37730275", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Murine melanoma model", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "B78-D14 (B78)", "Dose": "AZD0156: 10 mg/kg orally daily for 5 days; RT: 12 Gy", "Technique": "flow cytometry; qPCR; ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "increased the proportion of CD45+tumor-infiltrating cells composed of CD4+, CD8+, and natural killer (NK)1.1+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD45; NK cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Increased PD-L1 expression", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2172", "Drug": "NextA + anti-SIRPα", "Drug_category": "others/combination", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "NextA promotes M1 macrophage polarization; anti-SIRPα blocks SIRPα-mediated immunosuppressive signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "38414061", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Murine melanoma", "Animal_Strain_used": "C57BL/6 mice", "Cell_line_used_to_induce_tumor_in_mice": "SM1 melanoma cells", "Dose": "20 mg/kg every other day", "Technique": "In vivo melanoma model; immune-cell analysis", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "M1 Macrophages, CD4⁺ T cells, CD4⁺ and CD8⁺ effector-memory T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; Macrophages; T cells", "Immune_System-Function_inhibited/numbers_decreased": "M2 macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": "Total CD45⁺ immune cells, CD8⁺ T cells, T-regs, CD4⁺/CD8⁺ central-memory T cells", "Controlled_Terms_Unaffected": "CD4; CD8; CD45; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "M2 macrophage-mediated immunosuppression decreased", "Controlled_Terms_Negative_Regulation": "Macrophages"}, {"ID": "CANIMM/2173", "Drug": "PD0325901 + Palbociclib", "Drug_category": "others/combination", "Drugbank_ID": "DB09073", "Target/s_or_mechanism_of_action": "Combined MEK and CDK4/6 inhibition; reduces ERK1/2 and RB1 phosphorylation and enhances tumor antigen presentation", "KEGG_Drug_ID": "D10372", "Drug_Pubchem": "5330286", "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "32661093", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "BRAF V600E-mutant, PTEN-loss melanoma", "Animal_Strain_used": "C57BL/6; NSG", "Cell_line_used_to_induce_tumor_in_mice": "D4M3.A", "Dose": "7 ppm PD0325901 + 429 ppm palbociclib in chow", "Technique": "Flow cytometry; Western blot, CD8⁺ T-cell depletion; CD137L-receptor blockade", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis", "Immune_System-Function_enhanced/numbers_increased": "Increased MHC-I/MHC-II expression and intratumoral CD8⁺ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; MHC class I; MHC class II; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "CD8⁺ T-cell depletion or CD137L-receptor blockade reduced the duration of tumor control", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; CD137 / 4-1BB; T cells; Tumor growth / burden outcome", "Immune_System_function_unaffected": "No significant changes reported in CD4⁺ T cells, FOXP3⁺ regulatory T cells or NK cells in the reported profiling experiment", "Controlled_Terms_Unaffected": "CD4; FOXP3; Regulatory T cells / Tregs; NK cells; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2175", "Drug": "AZD0156 + RT", "Drug_category": "others/combination", "Drugbank_ID": "AZD0156", "Target/s_or_mechanism_of_action": "ATM inhibition increases radiation-associated cytosolic DNA and STING-dependent IFN-β signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "37730275", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Murine HNSCC model", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MOC2", "Dose": "AZD0156: 10 mg/kg orally daily for 5 days; RT: 8 Gy", "Technique": "flow cytometry; qPCR; ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "Increased CD8+ T-cell infiltration and activation; increased IFN-β and MHC-I expression, upregulated CD69 and the cytotoxic enzyme GZMB in CD8+T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-β; CD8; CD69; T cells; CD8+ T cells; Granzyme B / GZMB; MHC class I; Immune-cell infiltration; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4+ T-cell and NK-cell infiltration did not significantly increase in this model", "Controlled_Terms_Unaffected": "CD4; NK cells; T cells; Immune-cell infiltration", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "Increased PD-L1 expression", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2176", "Drug": "AZD0156 + RT + anti-PD-L1", "Drug_category": "others/combination", "Drugbank_ID": "AZD0156", "Target/s_or_mechanism_of_action": "ATM inhibition and RT promote interferon signaling; anti-PD-L1 blocks PD-1/PD-L1 immune-checkpoint signaling", "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Combination", "PMID": "37730275", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Murine HNSCC model", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MOC2", "Dose": "AZD0156: 10 mg/kg orally; RT: 8 Gy; anti-PD-L1: 200 µg intraperitoneally on days 0, 4, 8 and 12", "Technique": "flow cytometry; qPCR; ELISA", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "Increased functional antitumor T-cell responses", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1-mediated immune inhibition targeted pharmacologically", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression induced by IFN-β provides a rationale for checkpoint blockade", "Controlled_Terms_Negative_Regulation": "IFN-γ; PD-L1 / CD274"}, {"ID": "CANIMM/2177", "Drug": "Entinostat (MS-275) + ERAP1 silencing", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibition + loss/silencing of ERAP1, altering antigen processing/presentation", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Combination", "PMID": "39438988", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "9464D murine neuroblastoma", "Animal_Strain_used": "Female C57BL/6 mice, 6–8 weeks", "Cell_line_used_to_induce_tumor_in_mice": "9464D", "Dose": "Entinostat 5 mg/kg/day i.p. ×14 days, ERAP1 genetically silenced", "Technique": "Flow cytometry, IHC, immunofluorescence, immunopeptidomics", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC); Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ and CD4⁺ TILs, CD8⁺ T-cell activation, IFN-γ/granzyme-B-positive T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; T cells; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274"}, {"ID": "CANIMM/2178", "Drug": "Entinostat + anti-PD-1 antibody + ERAP1 silencing", "Drug_category": "others/combination", "Drugbank_ID": "DB11841", "Target/s_or_mechanism_of_action": "HDAC inhibition + PD-1 blockade + altered antigen processing/presentation through ERAP1 silencing", "KEGG_Drug_ID": "D09338", "Drug_Pubchem": "4261", "STR_LINK_(SMILES)": "C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3", "Single/Combination": "Combination", "PMID": "39438988", "Cancer_Type": "Brain Cancer", "Cancer_Type_Description": "9464D murine neuroblastoma", "Animal_Strain_used": "Female C57BL/6 mice, 6–8 weeks", "Cell_line_used_to_induce_tumor_in_mice": "9464D", "Dose": "Entinostat 10 mg/kg oral gavage ×21 days + anti-PD-1 300 mg/mouse i.p. 3 times per week ×21 days + ERAP1 silencing", "Technique": "Flow cytometry, IHC, immunofluorescence", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC); Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "CD8⁺ T-cell infiltration increased", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "PD-1 inhibitory signaling blocked", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-1 / PDCD1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-1 negative regulation inhibited", "Controlled_Terms_Negative_Regulation": "PD-1 / PDCD1"}, {"ID": "CANIMM/1956", "Drug": "Plerixafor (AMD3100)", "Drug_category": "Phenylmethylamines", "Drugbank_ID": "DB06809", "Target/s_or_mechanism_of_action": "Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered.", "KEGG_Drug_ID": "D08971", "Drug_Pubchem": "65015", "STR_LINK_(SMILES)": "C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Single Drug", "PMID": "30700545", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Metastatic Breast Cancer", "Animal_Strain_used": "wild-type FVB", "Cell_line_used_to_induce_tumor_in_mice": "CFP-labeled MCa-M3C cells", "Dose": "AMD3100 10 mg/kg/day", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "αSMA+ cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Alpha-smooth muscle actin (α-SMA)-positive cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1957", "Drug": "Plerixafor (AMD3100)", "Drug_category": "Phenylmethylamines", "Drugbank_ID": "DB06809", "Target/s_or_mechanism_of_action": "Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered.", "KEGG_Drug_ID": "D08971", "Drug_Pubchem": "65015", "STR_LINK_(SMILES)": "C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Single Drug", "PMID": "30700545", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Metastatic Breast Cancer", "Animal_Strain_used": "αSMA-dsRed", "Cell_line_used_to_induce_tumor_in_mice": "CFP-labeled MCa-M3C cells", "Dose": "AMD3100 10 mg/kg/day", "Technique": "QRT-PCR array", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "Ifng and Gzmb", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; Granzyme B / GZMB", "Immune_System-Function_inhibited/numbers_decreased": "Cxcl5 and Cxcr2", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL5", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1958", "Drug": "Plerixafor (AMD3100)", "Drug_category": "Phenylmethylamines", "Drugbank_ID": "DB06809", "Target/s_or_mechanism_of_action": "Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered.", "KEGG_Drug_ID": "D08971", "Drug_Pubchem": "65015", "STR_LINK_(SMILES)": "C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Single Drug", "PMID": "30700545", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Metastatic Breast Cancer", "Animal_Strain_used": "αSMA-dsRed", "Cell_line_used_to_induce_tumor_in_mice": "CFP-labeled MCa-M3C cells", "Dose": "AMD3100 10 mg/kg/day", "Technique": "Immunohistochemistry", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic T lymphocytes (CTLs) infilteration", "Controlled_Terms_Function_enhanced_Number_increased": "T cells; Cytotoxic T lymphocytes / CTLs", "Immune_System-Function_inhibited/numbers_decreased": "cancer-associated fibroblasts (CAFs), αSMA+ cells at both the center and periphery of the tumors, infiltration of FoxP3+ regulatory T cells", "Controlled_Terms_Function_inhibited_Number_decreased": "FOXP3; Regulatory T cells / Tregs; T cells; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1959", "Drug": "Plerixafor (AMD3100)", "Drug_category": "Phenylmethylamines", "Drugbank_ID": "DB06809", "Target/s_or_mechanism_of_action": "Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered.", "KEGG_Drug_ID": "D08971", "Drug_Pubchem": "65015", "STR_LINK_(SMILES)": "C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Single Drug", "PMID": "30700545", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Metastatic Breast Cancer", "Animal_Strain_used": "αSMA-Cre-ERT2/Cxcr4flox/flox", "Cell_line_used_to_induce_tumor_in_mice": "E0771 breast tumors", "Dose": "AMD3100 10 mg/kg/day", "Technique": "Flow cytometry, Q-PCR", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "cytotoxic CD8+ CTLs", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Cytotoxic T lymphocytes / CTLs", "Immune_System-Function_inhibited/numbers_decreased": "Treg cell fractions, 50% reduction in CD11b+ Gr1+ Ly6G+ neutrophils , CD11b+ F4/80+ macrophages CXCR4 in αSMA+ cell populations in the tumors , Cxcr4 and Cxcl12 in the tumors", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL12 / SDF-1; CD11b / ITGAM; Regulatory T cells / Tregs; Macrophages; Neutrophils / granulocytes; CXCR4", "Immune_System_function_unaffected": "CD45+CD11b+Gr1+ myeloid-derived suppressor cells", "Controlled_Terms_Unaffected": "CD11b / ITGAM; CD45; Myeloid-derived suppressor cells / MDSCs", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1967", "Drug": "CXCR4 inhibitor AMD 3100 /\n Plerixafor", "Drug_category": "Phenylmethylamines", "Drugbank_ID": "DB06809", "Target/s_or_mechanism_of_action": "Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered.", "KEGG_Drug_ID": "D08971", "Drug_Pubchem": "65015", "STR_LINK_(SMILES)": "C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "Single/Combination": "Single Drug", "PMID": "30802149", "Cancer_Type": "Ovarian Cancer", "Cancer_Type_Description": "Ovarian Cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "luciferase-expressing syngeneic ID8-luc cells", "Dose": "AMD3100 (3 mg/kg of mouse body weight) 10 times every other day from d 20 post–tumor implantation", "Technique": "ELISA, Flow cytometery", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ and CD4+ T cells intratumoral filteration, FN-γ expressing on CD8+ and CD4+ T cells, forkhead box P3 (FoxP3)+CD25−CD4+ T cells in the tumor, IL-2+CD40L+FoxP3+CD25− cells , PD-L1+ CD38− cells IL-2", "Controlled_Terms_Function_enhanced_Number_increased": "IL-2; CD4; CD8; CD25 / IL2RA; CD40L / CD154; PD-L1 / CD274; FOXP3; T cells; CD4+ T cells; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "CD4+FoxP3+CD25+ Treg cells in tumor CXCL12", "Controlled_Terms_Function_inhibited_Number_decreased": "CXCL12 / SDF-1; CD4; CD25 / IL2RA; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2009", "Drug": "Domatinostat (4SC-202)", "Drug_category": "phenylpyrazoles", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Single Drug", "PMID": "31703604", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c nude ( irradiated with a γ-source (whole-body irradiation, 2 Gy, 60Co) 24 h) and BALB/c immunocompetent", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cell", "Dose": "domatinostat (20 mg/kg twice daily)", "Technique": "Flow cytometry and IHC, gene expression by RNA-seq", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC); Gene expression/sequencing analysis; Gene expression/sequencing analysis", "Immune_System-Function_enhanced/numbers_increased": "CTLs within the tumor core, CD4+ T cells Ifng and IFN-γ APM and MHC-I and -II genes", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; MHC class I; T cells; CD4+ T cells; Cytotoxic T lymphocytes / CTLs; Antigen processing and presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2010", "Drug": "Domatinostat (4SC-202)", "Drug_category": "phenylpyrazoles", "Drugbank_ID": "DB13101", "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": "15985904", "STR_LINK_(SMILES)": "CN1C=C(C=N1)C1=CC=C(C=C1)S(=O)(=O)N1C=CC(\\C=C\\C(=O)NC2=CC=CC=C2N)=C1", "Single/Combination": "Single Drug", "PMID": "31703604", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "C57BL/6 J", "Cell_line_used_to_induce_tumor_in_mice": "C38 tumor fragments", "Dose": "20 mg/kg domatinostat", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CTLs within the tumors (CTLs - effector memory (EM) phenotype (CD44+CD62L−) and expressed the activation markers CD69 and GITR as well as the inhibitory marker PD-1, LAG3 or both ) MHC-I and -II molecules on C38 tumor cells and of MHC-II molecules on M1 macrophages", "Controlled_Terms_Function_enhanced_Number_increased": "CD69; PD-1 / PDCD1; LAG-3; MHC class II; MHC class I; Macrophages; Cytotoxic T lymphocytes / CTLs; M1 macrophage phenotype", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1668", "Drug": "Oxaliplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug_ID": "D01790", "Drug_Pubchem": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": null, "PMID": "19881547", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Animal_Strain_used": "BALB/c (H-2d)", "Cell_line_used_to_induce_tumor_in_mice": "CT26 colon", "Dose": "(250 mg/kg)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "pre-apoptotic exposure of calreticulin (CRT)", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis / caspase activation; Calreticulin / CRT", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1825", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug_ID": "D00275", "Drug_Pubchem": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "26590944", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - A Murine B16 Melanoma Model", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "2.5 - 7.5 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFN-g CD 80, CD 86", "Controlled_Terms_Function_enhanced_Number_increased": "Interferon gamma (IFN-γ); CD80 (B7-1); CD86 (B7-2)", "Immune_System-Function_inhibited/numbers_decreased": "the frequency of MDSC decreased remarkably in regional tumor and spleen in given doses. granzyme 1 expression on MDSC decreased", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD11b and CD3+, CD4+, CD8+ T cells and B cells MHC II", "Controlled_Terms_Unaffected": "CD4; CD8; CD3; CD11b / ITGAM; MHC class II; B cells; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1855", "Drug": "Cisplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug_ID": "D00275", "Drug_Pubchem": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": "Single Drug", "PMID": "27569212", "Cancer_Type": "Hpv16-Expressing Tumors", "Cancer_Type_Description": "Human Papillomavirus (Hpv)-Associated Cancer", "Animal_Strain_used": "C57/BL6", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "Maximum tolerated dose of 10 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor-specific effector and memory CD8+ T cells, and intratumoral phagocytic APCs (cd 11b+) IFNg and TNF, monocyte chemotactic protein 1 (MCP-1/\n CCL2) CD70, CD80, and CD86 b HMGB1 release of tumor cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; TNF-α / TNF; CCL2 / MCP-1; CD8; CD80; CD86; Monocytes; T cells; CD8+ T cells; HMGB1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4+CD25+Foxp3+ T cells and MDSCs OX40L, 4-1BBL, and ICOSL", "Controlled_Terms_Unaffected": "CD4; CD25 / IL2RA; FOXP3; Myeloid-derived suppressor cells / MDSCs; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1986", "Drug": "Cisplatin-based NAC", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00515 (APRD00359)", "Target/s_or_mechanism_of_action": "Formation of DNA cross-links/alkylation", "KEGG_Drug_ID": "D00275", "Drug_Pubchem": "5702198", "STR_LINK_(SMILES)": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "Single/Combination": null, "PMID": "31404614", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "NSCLC", "Animal_Strain_used": "athymic NMRI-Foxn1 nu/nu (Janvier™)", "Cell_line_used_to_induce_tumor_in_mice": "human lung adenocarcinoma cell line (A549)", "Dose": null, "Technique": "RT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "PD-L1 expression on tumor AKT ACTIVATION", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; Immune checkpoint pathway; AKT signaling"}, {"ID": "CANIMM/2027", "Drug": "Oxaliplatin", "Drug_category": "Platinum compounds", "Drugbank_ID": "DB00526", "Target/s_or_mechanism_of_action": "Inhibiting DNA synthesis and transcription", "KEGG_Drug_ID": "D01790", "Drug_Pubchem": "6857599", "STR_LINK_(SMILES)": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "Single/Combination": "Single Drug", "PMID": "32079180", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal Cancer (CRC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26 cells", "Dose": "6 mg/kg,", "Technique": "Immunoblotting,immunohistochemistry,qRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Western blot/immunoblot analysis; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "Ifng, Ifngr1 Cd274 (Pdl1) and Pdcd1lg2 (Pdl2) tumor programmed cell death 1 ligand 1 (PD-L1) level, phosphorylation of STAT1 and its downstream transcription factor IRF1", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; PD-L1 / CD274; PD-L2 / PDCD1LG2; Immune checkpoint pathway; STAT1", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1987", "Drug": "Teniposide", "Drug_category": "Podophyllotoxins", "Drugbank_ID": "DB00444", "Target/s_or_mechanism_of_action": "Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.", "KEGG_Drug_ID": "D02698", "Drug_Pubchem": "452548", "STR_LINK_(SMILES)": "[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1", "Single/Combination": "Single Drug", "PMID": "31408442", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "50 μM teniposide (For the immunization study)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "MHC-I, MHC-II, and antigen presentation machinery gene expression Immunogenic cell death", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class II; MHC class I; Immunogenic cell death; Antigen processing and presentation", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1993", "Drug": "AST 487", "Drug_category": "RET kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Papillary Thyroid Carcinoma", "Animal_Strain_used": "immunodeficient NRG (NOD-Rag1null IL2rgnull)", "Cell_line_used_to_induce_tumor_in_mice": "TPC1", "Dose": "AST 487(10mg/kg-35mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "PD-L1", "Controlled_Terms_Unaffected": "PD-L1 / CD274; Immune checkpoint pathway", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1645", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "12907617", "Cancer_Type": "Adenocarcinoma", "Cancer_Type_Description": "Mammalian Adenocarcinoma", "Animal_Strain_used": "C57BL/6 and BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "DA3-HA", "Dose": "ATRA pellets (21-day release, 5 mg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+CD11b+ ImCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1647", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "12907617", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Fibrosarcoma", "Animal_Strain_used": "C57BL/6 and BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "C3", "Dose": "ATRA pellets (21-day release, 5 mg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+CD11b+ ImCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1885", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "28515123", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "K7M2 WT cells,", "Dose": "a daily treatment of 40 mg/kg ATRA (i.g.) for 1 to 2 consecutive weeks (intravenous injection) or 4 consecutive weeks (intrafemural injection)", "Technique": "Immunohistochemical Staining", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "F4/80+CD209+ (M2-like) TAMs secretion of MMP12 in M2 macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "Tumor-associated macrophages / TAMs; Macrophages; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1984", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single Drug", "PMID": "31296953", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Osteosarcoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "K7M2 WT osteosarcoma cells", "Dose": "Daily for 7 days with 20 mg/kg ATRA before K7M2 WT cell injection; after inoculation, the mice were treated i.g. daily for 7 days for 4 consecutive weeks with 40 mg/kg ATRA", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "F4/80+CD209+ cells", "Controlled_Terms_Function_inhibited_Number_decreased": "F4/80-positive CD209-positive cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2054", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single", "PMID": "12907617", "Cancer_Type": "Adenocarcinoma", "Cancer_Type_Description": "Mammalian Adenocarcinoma", "Animal_Strain_used": "C57BL/6 and BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "DA3-HA", "Dose": "ATRA pellets (21-day release, 5 mg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+CD11b+ ImCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2074", "Drug": "MSU-42011", "Drug_category": "Retinoids", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "Activates retinoid X receptor (RXR), particularly RXRα", "KEGG_Drug_ID": null, "Drug_Pubchem": "154656181", "STR_LINK_(SMILES)": "CC(C)CN(C1=NC=C(C=C1)C(=O)O)C2=CC(=CC(=C2)C(C)(C)C)C(C)(C)C", "Single/Combination": "Single", "PMID": "36901727", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2-positive mammary tumors", "Animal_Strain_used": "MMTV-Neu transgenic mice", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "100 mg/kg/day in diet (approximately 25 mg/kg/day body weight) for 10 days", "Technique": "RNA-seq, qPCR, immunohistochemistry, flow cytometry", "Controlled_Technique": "Gene expression/sequencing analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "increased IL-18, increased H2-AA/MHC-II expression, increased pro-inflammatory CCL6 evidence of macrophage polarization toward an anti-tumor phenotype (M1), Tlr9 and Irf1, Col6a3 and Map9", "Controlled_Terms_Function_enhanced_Number_increased": "IL-18; Macrophages; MHC class II; Antigen presentation", "Immune_System-Function_inhibited/numbers_decreased": "Decreased F4/80⁺CD206⁺ macrophages, decreased IL-13 (immunosuppressive cytokine)", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-13; CD206 / MRC1; Macrophages; Cytokines", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2075", "Drug": "Bexarotene", "Drug_category": "Retinoids", "Drugbank_ID": "DB00307", "Target/s_or_mechanism_of_action": "Selectively binds and activates RXRα, RXRβ and RXRγ", "KEGG_Drug_ID": "D03106", "Drug_Pubchem": "82146", "STR_LINK_(SMILES)": "CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C", "Single/Combination": "Single", "PMID": "36901727", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "HER2-positive mammary tumors", "Animal_Strain_used": "MMTV-Neu transgenic mice", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "100 mg/kg/day in diet (approximately 25 mg/kg/day body weight) for 10 days", "Technique": "RNA-seq, qPCR, immunohistochemistry, flow cytometry", "Controlled_Technique": "Gene expression/sequencing analysis; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC); Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "IL-13 expression decreased in BMDMs treated with bexarotene; however, no significant reduction in F4/80⁺CD206⁺ macrophage proportion was observed", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-13; CD206 / MRC1; Macrophages", "Immune_System_function_unaffected": "F4/80⁺CD206⁺ macrophage proportion, IL-18", "Controlled_Terms_Unaffected": "IL-18; CD206 / MRC1; Macrophages", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2156", "Drug": "All-trans-retinoic acid (ATRA), or Retinoic acid/ Tretinoin", "Drug_category": "Retinoids", "Drugbank_ID": "DB00755", "Target/s_or_mechanism_of_action": "Tretinoin promotes cornified cell detachment and enhances shedding", "KEGG_Drug_ID": "D00094", "Drug_Pubchem": "5538", "STR_LINK_(SMILES)": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O", "Single/Combination": "Single", "PMID": "12907617", "Cancer_Type": "Sarcoma", "Cancer_Type_Description": "Sarcoma - Fibrosarcoma", "Animal_Strain_used": "C57BL/6 and BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "C3", "Dose": "ATRA pellets (21-day release, 5 mg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+CD11b+ ImCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1878", "Drug": "RK20449", "Drug_category": "Src family kinase Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28399411", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Adenocarcinoma", "Animal_Strain_used": "Rag1KO", "Cell_line_used_to_induce_tumor_in_mice": "DLD1", "Dose": "RK20449 (30mg/kg) for 10 days", "Technique": "Quantitative RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD206-expressing CD45+CD11b+F4/80+ macrophages TAMs and Ki67+ proliferating cells AAM genes Il4, Il10, Il13, Arg1, and Ym1", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-4; IL-10; IL-13; CD11b / ITGAM; CD45; CD206 / MRC1; Tumor-associated macrophages / TAMs; Macrophages; Arginase-1 / ARG1; Cell proliferation / Ki-67", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1879", "Drug": "RK20449", "Drug_category": "Src family kinase Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28399411", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Adenocarcinoma", "Animal_Strain_used": "Rag1KO", "Cell_line_used_to_induce_tumor_in_mice": "HCT116", "Dose": "RK20449 (30mg/kg) for 10 days", "Technique": "Quantitative RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD206-expressing CD45+CD11b+F4/80+ macrophages TAMs and Ki67+ proliferating cells AAM genes Il4, Il10, Il13, Arg1, and Ym1", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-4; IL-10; IL-13; CD11b / ITGAM; CD45; CD206 / MRC1; Tumor-associated macrophages / TAMs; Macrophages; Arginase-1 / ARG1; Cell proliferation / Ki-67", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1880", "Drug": "RK20449", "Drug_category": "Src family kinase Inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": null, "KEGG_Drug_ID": null, "Drug_Pubchem": null, "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "28399411", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon - Human Colon Adenocarcinoma", "Animal_Strain_used": "Rag1KO", "Cell_line_used_to_induce_tumor_in_mice": "SW480", "Dose": "RK20449 (30mg/kg) for 10 days", "Technique": "Quantitative RT-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "CD206-expressing CD45+CD11b+F4/80+ macrophages TAMs and Ki67+ proliferating cells AAM genes Il4, Il10, Il13, Arg1, and Ym1", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-4; IL-10; IL-13; CD11b / ITGAM; CD45; CD206 / MRC1; Tumor-associated macrophages / TAMs; Macrophages; Arginase-1 / ARG1; Cell proliferation / Ki-67", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1678", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07866", "Drug_Pubchem": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C2", "Single/Combination": "Single Drug", "PMID": "20702612", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Mammary Tumor", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1-Neu tumor cells (1 × 106) s.c", "Dose": "33 mg/kg body weight", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Gr-1+CD11b+ MDSCs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1679", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07866", "Drug_Pubchem": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C3", "Single/Combination": "Single Drug", "PMID": "20702612", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Mammary Tumor", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1-Neu tumor cells (1 × 106) s.c", "Dose": "33 mg/kg body weight", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ and CD8+ T cells IFN-γ from CD4+ and CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1685", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D00491", "Drug_Pubchem": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "21223350", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "C57BL ⁄ 6", "Cell_line_used_to_induce_tumor_in_mice": "Lewis lung cancer cell line", "Dose": "10 mg ⁄ kg (11.71 micromol ⁄ kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "T reg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": "T-eff", "Controlled_Terms_Unaffected": "T-eff", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1701", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": null, "Drug_Pubchem": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "22039576", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "MMTV-PyMT", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "10 mg/kg) every 5 days", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD3+CD8+ T lymphocytes", "Controlled_Terms_Unaffected": "CD8; CD3; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "infiltration of mammary tumors by CD45+CD11b+Ly6ClowLy6G−F4/80+", "Controlled_Terms_Negative_Regulation": "CD11b / ITGAM; CD45; Immune-cell infiltration"}, {"ID": "CANIMM/1702", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": null, "Drug_Pubchem": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "22039576", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "MMTV-PyMT", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "10 mg/kg) every 5 days", "Technique": "QRT-PCR", "Controlled_Technique": "Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CSF1", "Controlled_Terms_Negative_Regulation": "CSF1 / M-CSF"}, {"ID": "CANIMM/1720", "Drug": "Paclitaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D00491", "Drug_Pubchem": "36314", "STR_LINK_(SMILES)": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "Single/Combination": "Single Drug", "PMID": "23359505", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "ret transgenic", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "(1 mg/kg)", "Technique": "Flow cytometry, ELISA", "Controlled_Technique": "Flow cytometry; Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "CD8 T cell effector", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ MDSCs TGF-β, GM-CSF, IL-1β, IL-10, IL-5, IL-13, TNF-α and IFN-γ in the primary skin tumor microenvironment p38 MAPK, S100A8/A9", "Controlled_Terms_Function_inhibited_Number_decreased": "IFN-γ; IL-1 family; IL-5; IL-10; IL-13; TNF-α / TNF; GM-CSF / CSF2; TGF-β; CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs; MAPK signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1924", "Drug": "Docetaxel", "Drug_category": "Taxanes", "Drugbank_ID": "DB01248 (APRD00932)", "Target/s_or_mechanism_of_action": "Inhibition of tubulin depolymerization", "KEGG_Drug_ID": "D07866", "Drug_Pubchem": "96024562", "STR_LINK_(SMILES)": "[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C0", "Single/Combination": "Single Drug", "PMID": "29500278", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "NSG", "Cell_line_used_to_induce_tumor_in_mice": "MDA-MB-231", "Dose": "(DTX; 25 mg/kg) (n=3)", "Technique": "ELISA", "Controlled_Technique": "Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CCL2 (MCP-1), CCL7 (MCP-3), and CCL8 (MCP-2)-cancer stem-like cell (CSC) phenotype and contributing to tumor relapse", "Controlled_Terms_Negative_Regulation": "CCL2 / MCP-1; CCL7 / MCP-3; CCL8 / MCP-2"}, {"ID": "CANIMM/1867", "Drug": "Topotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB01030", "Target/s_or_mechanism_of_action": "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.", "KEGG_Drug_ID": "D08618", "Drug_Pubchem": "60700", "STR_LINK_(SMILES)": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "Single/Combination": "Single Drug", "PMID": "28069806", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "E0771 cells", "Dose": "20 mg/kg TPT was administered i.p. to the mice every 4 d after the tumor volume reached 100 mm3 (day 0", "Technique": "Flow Cytometry, Immunostaining", "Controlled_Technique": "Flow cytometry; Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "CD3+ T cells, CD8+ T cells, neutrophils (Ly-6G+ F4/802), and DCs (I-A/I-E+ CD11c+ )", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD3; CD11c / ITGAX; Neutrophils / granulocytes; Dendritic cells; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1928", "Drug": "Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a)", "Drug_category": "Topoisomerase I Inhibitor", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29703841", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "(BALB/c)", "Cell_line_used_to_induce_tumor_in_mice": "5 million CT26.WT-hHER2 cells", "Dose": "DS-8201a (10 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells (CD45+CD3+CD8+ cells) and Granzyme B+ CD8+ T cells , ratio of DCs (CD45+CD11c+MHC class II+ cells) to lymphocytes (CD45+ cells) significantly increased , CD86+ cells in DCs CD86 expression on DC , PD-L1 and MHC class I on hHER2+ cells was higher in DS-8201a–treated tumors", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD3; CD86; CD11c / ITGAX; CD45; PD-L1 / CD274; MHC class II; MHC class I; Dendritic cells; T cells; CD8+ T cells; Granzyme B / GZMB; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1929", "Drug": "Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a)", "Drug_category": "Topoisomerase I Inhibitor", "Drugbank_ID": "DB00072", "Target/s_or_mechanism_of_action": "Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene.", "KEGG_Drug_ID": "D03257", "Drug_Pubchem": "46507516", "STR_LINK_(SMILES)": null, "Single/Combination": "Single Drug", "PMID": "29703841", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "(BALB/c)", "Cell_line_used_to_induce_tumor_in_mice": "5 million CT26.WT-hHER2 cells", "Dose": "anti-PD1", "Technique": "Survival Was Analyzed By The Kaplan–Meier Method", "Controlled_Technique": "Survival analysis (Kaplan–Meier)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1939", "Drug": "Irinotecan", "Drug_category": "Topoisomerase I inhibitor", "Drugbank_ID": "DB00762", "Target/s_or_mechanism_of_action": "Irinotecan inhibits the action of topoisomerase I", "KEGG_Drug_ID": "D08086", "Drug_Pubchem": "60838", "STR_LINK_(SMILES)": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "Single/Combination": "Single Drug", "PMID": "30140379", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast Cancer", "Animal_Strain_used": "C3H/HeN", "Cell_line_used_to_induce_tumor_in_mice": "FM3A tumor cells", "Dose": "irinotecan 250 mg/kg", "Technique": "Flow Cytometry, Immunostaining", "Controlled_Technique": "Flow cytometry; Immunostaining/image analysis", "Immune_System-Function_enhanced/numbers_increased": "MHC class I expression but also PD-L1 expression", "Controlled_Terms_Function_enhanced_Number_increased": "PD-L1 / CD274; MHC class I; Immune checkpoint pathway", "Immune_System-Function_inhibited/numbers_decreased": "Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1665", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "19244102", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma (RCC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "Renca cells", "Dose": "10–40 mg/kg daily", "Technique": "Fluorescent Immunohistochemistry And Confocal Laser Scanning Microscopy Of Frozen Tumor Sections, Western Blot", "Controlled_Technique": "Western blot/immunoblot analysis; Immunohistochemistry (IHC); Immunofluorescence assay; Microscopy; Confocal microscopy", "Immune_System-Function_enhanced/numbers_increased": "tumor cell apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs , tumor-infiltrating Tregs p-Stat3 inhibition,Cyclin E and Survivin protein expression ,Stat3 activity in MDSCs and macrophages", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Macrophages; STAT3 signaling; Immune-cell infiltration", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1666", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "19276342", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Tumor", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "MCA26", "Dose": "0.015 mg", "Technique": "Flow cytometry,RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR)", "Immune_System-Function_enhanced/numbers_increased": "T-cell-CD4+ and CD8+ T cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD4; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD4+CD25+Foxp3+ Treg, MDSC IL-10, TGF-β PD-1, CTLA4, and BAFF Foxp3", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; TGF-β; CD4; CD25 / IL2RA; PD-1 / PDCD1; CTLA-4; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1674", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "20406969", "Cancer_Type": "Breast cancer", "Cancer_Type_Description": "Breast - Mammary", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "4T1-mammary", "Dose": "sunitinib (40mg/kg)", "Technique": "Flow cytometry, BrdU assay", "Controlled_Technique": "Flow cytometry; Cell viability/proliferation assay; Cell proliferation assay", "Immune_System-Function_enhanced/numbers_increased": "T-cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ MDSC, intrasplenic proliferation of m-MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs; Monocytic MDSCs / M-MDSCs; Cell proliferation / Ki-67", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1675", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "20406969", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26-colonic", "Dose": "sunitinib (40mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1676", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "20406969", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal Cell Carcinoma", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "RENCA", "Dose": "sunitinib (40mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "T-cells", "Controlled_Terms_Function_enhanced_Number_increased": "T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD11b+Gr1+ MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1690", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "21321535", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "murine cell line 1MEA", "Dose": "Sorafenib (0.6mg/100ul) or solvent (100ul), once daily,", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Tregs and MDSCs.", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD4+ and CD8+ cell", "Controlled_Terms_Unaffected": "CD4; CD8", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1695", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug_ID": "D02368", "Drug_Pubchem": "60750", "STR_LINK_(SMILES)": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "Single/Combination": "Single Drug", "PMID": "21680779", "Cancer_Type": "Adenocarcinoma", "Cancer_Type_Description": "Adenocarcinoma", "Animal_Strain_used": "BALB/c X DBA/2F1 (CD2F1)", "Cell_line_used_to_induce_tumor_in_mice": "Colon 26 (C26) tumor cells", "Dose": "twice weekly i.p. injections of gemcitabine at a dose of 75µg/g of body weight", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "IFN-γ P-STAT1", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; STAT1", "Immune_System-Function_inhibited/numbers_decreased": "MDSC", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1696", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Drug_Pubchem": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "21873989", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "Animal_Strain_used": "(KitV558Δ/+)", "Cell_line_used_to_induce_tumor_in_mice": "spontaneous", "Dose": "1.12 mg i.p. twice daily based on an established dose of 45 mg kg−1", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "T reg apoptosis selectively within the tumor", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Apoptosis / caspase activation", "Immune_System_function_unaffected": "myeloid cells, B cells, NK, or NKT cells IL-4, IL-17, or IFN-γ by CD4+ T cells", "Controlled_Terms_Unaffected": "IFN-γ; IL-4; IL-17 / IL-17A; CD4; NKT cells; B cells; T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1708", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug_ID": "D03218", "Drug_Pubchem": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": "22504156", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MO5 (B16.OVA) tumor cells", "Dose": "axitinib alone (0.5 mg/day provided via oral gavage on days 7–13)", "Technique": "Flow Cytometry, Rt-Pcr And Fluorescence Microscopy", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Microscopy", "Immune_System-Function_enhanced/numbers_increased": "bulk CD8+ T cells IFN-γ,CXCR3,CXCL10 CD31+ Tbet", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CXCL10 / IP-10; CD8; CD31 / PECAM-1; T cells; CD8+ T cells; CXCR3", "Immune_System-Function_inhibited/numbers_decreased": "Treg (CD4+Foxp3+) phenotypes in the TME", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; FOXP3; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1718", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "23108136", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "40 mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Treg", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1721", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23409093", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Hepa1-6", "Dose": "30 mg·kg−1·day−1 sorafenib -60 mg·kg−1·day−1 sorafenib", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "NK cells (CD3− and NK1.1+) CD69", "Controlled_Terms_Negative_Regulation": "CD3; CD69; NK cells"}, {"ID": "CANIMM/1722", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23424039", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "HBV-tg", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "(25 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "hepatic NK cells", "Controlled_Terms_Function_inhibited_Number_decreased": "NK cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1723", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23424039", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "LTa/b-tg", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "(25 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "hepatic NK cells", "Controlled_Terms_Function_inhibited_Number_decreased": "NK cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1737", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23818246", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "BNL cells", "Dose": "(30 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor-infiltrating CD8 T cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "PD-1-expressing CD8(+) T cells and regulatory T cells (Tregs)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD8; PD-1 / PDCD1; Regulatory T cells / Tregs; T cells; CD8+ T cells", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1738", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "23818246", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "ML-1", "Dose": "(30 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "tumor-infiltrating CD8 T cells IFN-γ", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; CD8; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1742", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug_ID": "D03218", "Drug_Pubchem": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": "24135499", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "B16F1 cells", "Dose": "axitinib (25 mg/kg, twice a day)", "Technique": "Hematoxylin and eosin staining,TUNEL assay, Q-PCR, Flow cytometry", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Apoptosis/cell viability assay; Hematoxylin and eosin (H&E)/histology", "Immune_System-Function_enhanced/numbers_increased": "tumor-infiltrating CD8 +, CD45.2 + cells induced the apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD45; Apoptosis / caspase activation; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs IL-6, TNF-a, and IFN-g", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-6; TNF-α / TNF; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD4 + T cells or Treg cells", "Controlled_Terms_Unaffected": "CD4; Regulatory T cells / Tregs; T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1747", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Drug_Pubchem": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "24323358", "Cancer_Type": "Stomach Cancer", "Cancer_Type_Description": "Gastrointestinal Stromal Tumor (GIST)", "Animal_Strain_used": "GIST (KITΔV558/+ on a C57BL/6 (B6) background", "Cell_line_used_to_induce_tumor_in_mice": "spontaneous", "Dose": "600 mg/liter", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "TAMs and TAMs to become M2-like CD11c, MHC class II, CD80, and CD86 were reduced in TAMs", "Controlled_Terms_Function_inhibited_Number_decreased": "CD80; CD86; CD11c / ITGAX; MHC class II; Tumor-associated macrophages / TAMs; M2 macrophage phenotype", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1751", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Drug_Pubchem": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "24734217", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "M05 melanoma cells", "Dose": "0.01–1 mg/day", "Technique": "Immunofluorescence Staining And Fluorescence Microscopy", "Controlled_Technique": "Immunofluorescence assay; Microscopy; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": "CD8+ TIL", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; Tumor-infiltrating lymphocytes / TILs", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1765", "Drug": "Dasatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01254", "Target/s_or_mechanism_of_action": "Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.", "KEGG_Drug_ID": "D03658", "Drug_Pubchem": "3062316", "STR_LINK_(SMILES)": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "Single/Combination": "Single Drug", "PMID": "24994118", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid Cancer - (Anaplastic)", "Animal_Strain_used": "B6129SF1/J syngeneic", "Cell_line_used_to_induce_tumor_in_mice": "105 TBP-3743 cells", "Dose": "orally gavaged with 50 mg/kg dasatinib five days per week", "Technique": "Immunohistochemial Analysis", "Controlled_Technique": "Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD8+ T cells and F4/80+ cells infilateration to tumor tissue, B220+ B cells is observed in tumors, Caspase 3", "Controlled_Terms_Unaffected": "CD8; B cells; T cells; CD8+ T cells; Apoptosis / caspase activation", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1771", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug_ID": "D03218", "Drug_Pubchem": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": "25081318", "Cancer_Type": "Kidney", "Cancer_Type_Description": "Renal - Metastatic Renal Cell Cancer", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "Renca", "Dose": "25 mg/ kg daily via oral administration", "Technique": "Tunel Assay,Flow Cytometry,Western Blotting, Immunohistochemistry", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Immunohistochemistry (IHC); Apoptosis/cell viability assay", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T-cells in TME apoptosis", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; T cells; Apoptosis / caspase activation", "Immune_System-Function_inhibited/numbers_decreased": "MDSC p-STAT3", "Controlled_Terms_Function_inhibited_Number_decreased": "Myeloid-derived suppressor cells / MDSCs; STAT3 signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1779", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug_ID": "D10062", "Drug_Pubchem": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "25388653", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Adenocarcinoma", "Animal_Strain_used": "CEA-Tg C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "cabozantinib-containing diet for 10 or 35 days", "Technique": "Immunohistochemical Analysis, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells,increased infiltration of CD3+ lymphocytes", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD3; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "T regulatory cells (Tregs), myeloid-derived suppressor cells (MDSCs), infiltration of MDSCs,infiltrating tumor-associated macrophages vascular density of MC38-CEA tumors", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Tumor-associated macrophages / TAMs; Macrophages; Immune-cell infiltration", "Immune_System_function_unaffected": "CD4+ T cells in the spleen", "Controlled_Terms_Unaffected": "CD4; T cells; CD4+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1780", "Drug": "Golvatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB11977", "Target/s_or_mechanism_of_action": "An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. Golvatinib binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of various tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.", "KEGG_Drug_ID": null, "Drug_Pubchem": "16118392", "STR_LINK_(SMILES)": "CN1CCN(CC1)C1CCN(CC1)C(=O)NC1=CC(OC2=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C(F)=C2)=CC=N1", "Single/Combination": "Single Drug", "PMID": "25458359", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid -Human Thyroid Cancer", "Animal_Strain_used": "Nude (CAnN.Cg-Foxn1nu/CrlCrlj; female, 5–6 weeks old)", "Cell_line_used_to_induce_tumor_in_mice": "K1/angiopoietin-2 (Ang2)", "Dose": "golvatinib 100 mg/kg", "Technique": "Immunohistochemical Analysis, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "myeloid cells (CD11b+), macrophages (F4/80+ in Flow cytometry, CD11b+F4/80+ in immunohistochemistry)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1782", "Drug": "Lenvatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09078", "Target/s_or_mechanism_of_action": "Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET", "KEGG_Drug_ID": "D09919", "Drug_Pubchem": "9823820", "STR_LINK_(SMILES)": "COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O", "Single/Combination": "Single Drug", "PMID": "25458359", "Cancer_Type": "Head and Neck Cancer", "Cancer_Type_Description": "Thyroid -Human Thyroid Cancer", "Animal_Strain_used": "Nude (CAnN.Cg-Foxn1nu/CrlCrlj; female, 5–6 weeks old)", "Cell_line_used_to_induce_tumor_in_mice": "K1/angiopoietin-2 (Ang2)", "Dose": "lenvatinib 10 mg/kg", "Technique": "Immunohistochemical Analysis, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "myeloid cells (CD11b+)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1783", "Drug": "Golvatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB11977", "Target/s_or_mechanism_of_action": "An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. Golvatinib binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of various tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.", "KEGG_Drug_ID": null, "Drug_Pubchem": "16118392", "STR_LINK_(SMILES)": "CN1CCN(CC1)C1CCN(CC1)C(=O)NC1=CC(OC2=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C(F)=C2)=CC=N1", "Single/Combination": "Single Drug", "PMID": "25458359", "Cancer_Type": "Uterus", "Cancer_Type_Description": "Endometrial - Human Endometrial Cancer", "Animal_Strain_used": "Nude (CAnN.Cg-Foxn1nu/CrlCrlj; female, 5–6 weeks old)", "Cell_line_used_to_induce_tumor_in_mice": "AN3CA tumors", "Dose": "golvatinib 100 mg/kg", "Technique": "Immunohistochemical Analysis, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "macrophage population", "Controlled_Terms_Function_inhibited_Number_decreased": "Macrophages", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1785", "Drug": "Lenvatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB09078", "Target/s_or_mechanism_of_action": "Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET", "KEGG_Drug_ID": "D09919", "Drug_Pubchem": "9823820", "STR_LINK_(SMILES)": "COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O", "Single/Combination": "Single Drug", "PMID": "25458359", "Cancer_Type": "Uterus", "Cancer_Type_Description": "Endometrial - Human Endometrial Cancer", "Animal_Strain_used": "Nude (CAnN.Cg-Foxn1nu/CrlCrlj; female, 5–6 weeks old)", "Cell_line_used_to_induce_tumor_in_mice": "AN3CA tumors", "Dose": "lenvatinib 10 mg/kg", "Technique": "Immunohistochemical Analysis, Flow Cytometry", "Controlled_Technique": "Flow cytometry; Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": "TEM infiltration", "Controlled_Terms_Function_enhanced_Number_increased": "Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1786", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "25529917", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "nude", "Cell_line_used_to_induce_tumor_in_mice": "JHH-7 HCC", "Dose": "sorafenib at a dose of 50mg/kg", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "F4/80+ TAMs, and CD11b+Gr-1+ and CD45+CXCR4+ myeloid cells,", "Controlled_Terms_Negative_Regulation": "CD11b / ITGAM; CD45; Tumor-associated macrophages / TAMs; CXCR4"}, {"ID": "CANIMM/1787", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "25529917", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C3H", "Cell_line_used_to_induce_tumor_in_mice": "HCA-1 tumors", "Dose": "sorafenib at a dose of 50mg/kg", "Technique": "Flow Cytometry, Immunofluorescence Analysis, Western Blot Analysis", "Controlled_Technique": "Flow cytometry; Western blot/immunoblot analysis; Immunofluorescence assay; Immunofluorescence assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "F4/80+ TAMs, and CD11b+Gr-1+ and CD45+CXCR4+ myeloid cells, CD4+CD25+FoxP3+ Tregs in HCA-1 tumors PD-L1 expression, PD-L1 on multiple hematopoietic cells, including on a fraction of Gr-1+ cells, TAMs, dendritic cells and lymphocytes", "Controlled_Terms_Negative_Regulation": "CD4; CD25 / IL2RA; CD11b / ITGAM; CD45; PD-L1 / CD274; FOXP3; Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs; Dendritic cells; Immune checkpoint pathway; CXCR4"}, {"ID": "CANIMM/1808", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "25949902", "Cancer_Type": "Cervical Cancer", "Cancer_Type_Description": "Cervical Cancer", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "TC-1 tumor cells", "Dose": "20, 40 and 60 mg/kg body weight", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells CD69 on the surface of intratumoral and intrasplenic CD8+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD69; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "MDSCs,Tregs", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1813", "Drug": "Gefitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00317", "Target/s_or_mechanism_of_action": "Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme.", "KEGG_Drug_ID": "D01977", "Drug_Pubchem": "123631", "STR_LINK_(SMILES)": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "Single/Combination": "Single Drug", "PMID": "25998384", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Non-Small Cell Lung Cancer (NSCLC))", "Animal_Strain_used": "nude", "Cell_line_used_to_induce_tumor_in_mice": "PC-9 cells", "Dose": "(20 mg/kg, i.g.) every other day", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "PD-L1 expression and NF-κB in tumor cells,", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway; NF-κB signaling", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1816", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug_ID": "D03218", "Drug_Pubchem": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": "26137411", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Subcutaneous And Intracranial Mouse Melanoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MO4 cells", "Dose": "axitinib (25 mg/kg)", "Technique": "Flow Cytometry, Histochemistry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD45+ cells in the spleen of axitinib-treated mice,CD3+ cells, CD8+ T cells,CD4+ T-cell, immune cells within subcutaneous and intracranial tumors, which is mainly due to an increase of CD11b+ cells and more specifically of CD11b+ Ly6ChighLy6G- moMDSCs. CD80 expression on the CD11c+ cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD3; CD80; CD11b / ITGAM; CD11c / ITGAX; CD45; Monocytic MDSCs / M-MDSCs; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD4+CD25+ cells (Tregs), CD11c+ cells (DCs) and CD11b+ cells, MDSC populations", "Controlled_Terms_Unaffected": "CD4; CD25 / IL2RA; CD11b / ITGAM; CD11c / ITGAX; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs; Dendritic cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1839", "Drug": "Cediranib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB04849", "Target/s_or_mechanism_of_action": "Cediranib inhibits vacular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK).", "KEGG_Drug_ID": "D08881", "Drug_Pubchem": "9933475", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1", "Single/Combination": "Single Drug", "PMID": "27044097", "Cancer_Type": "Brain cancer", "Cancer_Type_Description": "Glioblastoma", "Animal_Strain_used": "nude or C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Gl261 cells", "Dose": "cediranib (6 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "TAMs", "Controlled_Terms_Function_inhibited_Number_decreased": "Tumor-associated macrophages / TAMs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1874", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug_ID": "D10062", "Drug_Pubchem": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "Probasin Cre-driven conditional prostate-specific knockout of PTEN and p53 genes (Pb-Cre; PTENfl/lflp53fl/fl)", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "100 mg/kg in water", "Technique": "Flow cytometry,histopathologic evaluation,Quantitative RT-PCR analysis,RNA in situ hybridization (RISH)", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); RNA in situ hybridization (RISH); Hematoxylin and eosin (H&E)/histology", "Immune_System-Function_enhanced/numbers_increased": "Ly6G+, myeloperoxidase+ (MPO+) neutrophil infiltration into the tumor within 24–48 hours,CD11b+GR1+ tumor-infiltrating immune cells , CD11b+CD86+ cells CXCL12 and its receptor CXCR4 within the tumor microenvironment perivascular ICAM-1, intratumoral CD86 expression caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "CXCL12 / SDF-1; CD86; CD11b / ITGAM; Neutrophils / granulocytes; Apoptosis / caspase activation; ICAM-1 / CD54; CXCR4; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "gene expression of CD3, CD4, CD8 (T cell markers) or NKG2D (NK and activated CD8 T cell marker)", "Controlled_Terms_Unaffected": "CD4; CD8; CD3; T cells; CD8+ T cells; NKG2D ligand / receptor pathway", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1875", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug_ID": "D10062", "Drug_Pubchem": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "28274958", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "(Pb-Cre; PTENfl/lflp53fl/fl)", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "100 mg/kg in water", "Technique": "Immunohistochemistry, Flow cytometry, qPCR-based RNA profiling,RISH", "Controlled_Technique": "Flow cytometry; Polymerase chain reaction (PCR/qPCR); Immunohistochemistry (IHC); RNA in situ hybridization (RISH)", "Immune_System-Function_enhanced/numbers_increased": "neutrophil infiltration into the tumor, CD11b+GR1+ tumor-infiltrating immune cells- Ly6GhiLy6Clo, consistent with a granulocytic (and not monocytic) predominance of tumor-infiltrating immune cells, CD11b+CD86+ cells chemokine CXCL12 and its receptor CXCR4 within the tumor microenvironment ICAM-1,CD86 expression caspase-3", "Controlled_Terms_Function_enhanced_Number_increased": "CXCL12 / SDF-1; CD86; CD11b / ITGAM; Neutrophils / granulocytes; Apoptosis / caspase activation; ICAM-1 / CD54; CXCR4; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1893", "Drug": "Regorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08896", "Target/s_or_mechanism_of_action": "Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.", "KEGG_Drug_ID": "D10138", "Drug_Pubchem": "11167602", "STR_LINK_(SMILES)": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1", "Single/Combination": "Single Drug", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "B16-F1", "Dose": "Reg (8 mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "intratumoral CD45+ leukocytes and CD8+ T cells MHC-I", "Controlled_Terms_Function_enhanced_Number_increased": "CD8; CD45; MHC class I; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "CD155, semaphorin 4D, CEACAM1, and galectin-9", "Controlled_Terms_Function_inhibited_Number_decreased": "CD155 / PVR", "Immune_System_function_unaffected": "intratumoral dendritic cells, macrophages, myeloid-derived suppressor cells, or natural killer cells", "Controlled_Terms_Unaffected": "Myeloid-derived suppressor cells / MDSCs; Macrophages; Dendritic cells; NK cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1895", "Drug": "Regorafenib+ anti-CD40 + 50 μg c-di-GMP", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08896", "Target/s_or_mechanism_of_action": "Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.", "KEGG_Drug_ID": "D10138", "Drug_Pubchem": "11167602", "STR_LINK_(SMILES)": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1", "Single/Combination": "Single Drug", "PMID": "28775208", "Cancer_Type": "Skin cancer", "Cancer_Type_Description": "Skin - Melanoma", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "B16-F1", "Dose": "Reg (4 mg/kg), 100 μg of anti-CD40, 50 μg c-di-GMP", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "intratumoral CD45+ leukocytes, CD4+ T cells, and CD8+ T cells, but did not increase CD4+ T cells within the CD45+ population", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; CD8; CD45; T cells; CD8+ T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1909", "Drug": "AG1478", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": null, "Target/s_or_mechanism_of_action": "AG1478 tyrosine kinase inhibitor", "KEGG_Drug_ID": null, "Drug_Pubchem": "2051", "STR_LINK_(SMILES)": "COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC", "Single/Combination": "Single Drug", "PMID": "29056908", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "D122", "Dose": "AG1478 (1 mg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "a strong induction of H-2Kb and H-2Db expression, MHC-I expression", "Controlled_Terms_Function_enhanced_Number_increased": "MHC class I", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1916", "Drug": "Cabozantinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08875", "Target/s_or_mechanism_of_action": "Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.", "KEGG_Drug_ID": "D10062", "Drug_Pubchem": "25102847", "STR_LINK_(SMILES)": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "Single/Combination": "Single Drug", "PMID": "29152128", "Cancer_Type": "Prostate", "Cancer_Type_Description": "Prostate Cancer", "Animal_Strain_used": "severe combined immuno-deficient (beige SCID) male (4- to 10-week-old male )", "Cell_line_used_to_induce_tumor_in_mice": "ARCaPM cells", "Dose": null, "Technique": "FACS", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "M1 macrophage population (F4/80+, MHCII+)", "Controlled_Terms_Function_inhibited_Number_decreased": "MHC class II; Macrophages; M1 macrophage phenotype", "Immune_System_function_unaffected": "M2 macrophages (F4/80+, CD206+)", "Controlled_Terms_Unaffected": "CD206 / MRC1; Macrophages; M2 macrophage phenotype", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1917", "Drug": "Sunitinib+immunization with B6/WT-19 cells", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "29296523", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Cancer (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": null, "Dose": "(40 mg/kg body weight)", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells producing IFN-γ and TNF-α IFN-γ and TNF-α", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; TNF-α / TNF; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": "Treg TGF-β and IL-10", "Controlled_Terms_Function_inhibited_Number_decreased": "IL-10; TGF-β; Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1920", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "29413757", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "hepa1-6 cell", "Dose": "50 mg/kg", "Technique": "Flow Cytometry, Immunohistochemistry And ELISA, RT-PCR", "Controlled_Technique": "Flow cytometry; Reverse transcription PCR (RT-PCR/qRT-PCR); Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA); Immunohistochemistry (IHC)", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "CD4+CD25+Foxp3+ Tregs,expression of PD-L1 in tumor tissue IL-10 and TGF-β", "Controlled_Terms_Negative_Regulation": "IL-10; TGF-β; CD4; CD25 / IL2RA; PD-L1 / CD274; FOXP3; Regulatory T cells / Tregs; Immune checkpoint pathway"}, {"ID": "CANIMM/1923", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug_ID": "D03218", "Drug_Pubchem": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": "29487979", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Carcinoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MC38 tumors", "Dose": "25 mg/kg/day", "Technique": "Flow Cytometry, Depleting Studies By Neutralizing Antibodies", "Controlled_Technique": "Flow cytometry; Immune suppression/blocking/depletion assay", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "intratumoral innate immune cells- tumor-promoting differentiated mast cells\n (CD45+, C117+, FcεR1α+) and TAMs (CD45+, CD11b+,\n F4/80+) , regulatory T cells, monocytes (CD45+,\n CD11b+, Ly-6G−, Ly6C+) and granulocytes (CD45+,\n CD11b+, Ly-6G+, Ly6C−) , HSCs determined as CD45+\n Lin−, CD117+, Sca-1+ cells IN Spleen.", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; CD45; Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs; Monocytes; Neutrophils / granulocytes; T cells", "Immune_System_function_unaffected": "Intratumoral T cells and CD8 T cells", "Controlled_Terms_Unaffected": "CD8; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1936", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "30123861", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MTD2", "Dose": "30 mg/ml", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD4+ T cells", "Controlled_Terms_Function_enhanced_Number_increased": "CD4; T cells; CD4+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": "CD8+ T cells", "Controlled_Terms_Unaffected": "CD8; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1937", "Drug": "Sunitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "30123861", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MTD2", "Dose": "40 mg/kg", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "Tregs (CD4+CD25+FoxP3+) , and MDSCs (CD11b+Gr-1+)", "Controlled_Terms_Function_inhibited_Number_decreased": "CD4; CD25 / IL2RA; CD11b / ITGAM; FOXP3; Regulatory T cells / Tregs; Myeloid-derived suppressor cells / MDSCs", "Immune_System_function_unaffected": "CD8+ T cells", "Controlled_Terms_Unaffected": "CD8; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1938", "Drug": "Sunitinib + immunized with 3 × 107 of B6/WT-19 cells", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB01268", "Target/s_or_mechanism_of_action": "Inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs).", "KEGG_Drug_ID": "D06402", "Drug_Pubchem": "5329102", "STR_LINK_(SMILES)": "CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "Single/Combination": "Single Drug", "PMID": "30123861", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "MTD2", "Dose": "40 mg/kg", "Technique": "Flow cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "CD8+ T cells producing IFN-γ and TNF-α IFN-γ and TNF-α", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; TNF-α / TNF; CD8; T cells; CD8+ T cells", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1976", "Drug": "Sorafenib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00398", "Target/s_or_mechanism_of_action": "Sorafenib exerts its action through inhibition of several kinases involved in both tumour cell proliferation and angiogenesis.", "KEGG_Drug_ID": "D08524", "Drug_Pubchem": "216239", "STR_LINK_(SMILES)": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "Single/Combination": "Single Drug", "PMID": "31078430", "Cancer_Type": "Hepatocellular Cancer", "Cancer_Type_Description": "Hepatocellular Carcinoma (HCC)", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "Hepa1-6-chGPC3 cells", "Dose": "7.5 mg/kg sorafenib for 5 days after eight days of Hepa1-6-chGPC3 tumor implantation", "Technique": "QPCR, ELISA", "Controlled_Technique": "Polymerase chain reaction (PCR/qPCR); Enzyme-linked immunosorbent assay (ELISA)", "Immune_System-Function_enhanced/numbers_increased": "IL12 mRNA in TAMs", "Controlled_Terms_Function_enhanced_Number_increased": "IL-12; Tumor-associated macrophages / TAMs", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1983", "Drug": "Erlotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00530", "Target/s_or_mechanism_of_action": "Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR).", "KEGG_Drug_ID": "D07907", "Drug_Pubchem": "176870", "STR_LINK_(SMILES)": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "Single/Combination": "Single Drug", "PMID": "31291990", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung Cancer", "Animal_Strain_used": "CCSP-rtTA; TetO-EGFRL858R bitransgenic", "Cell_line_used_to_induce_tumor_in_mice": "doxycycline diet", "Dose": "25 mg/kg, 5 days a week", "Technique": "Flow Cytometry,Bio-Plex Cytokine Assay", "Controlled_Technique": "Flow cytometry; Cytokine/multiplex immunoassay", "Immune_System-Function_enhanced/numbers_increased": "CD45+ immune cells and the absolute number of CD4+ and CD8+ T cells,infiltration of T cells into the lungs,CD103+ dendritic cells CCL2 and CCL5 ,IFN-γ, IL-12p40, Irf5 expression CD86 on Aleveolar macrophages-inflammatory response in AMs.", "Controlled_Terms_Function_enhanced_Number_increased": "IFN-γ; IL-12; CCL2 / MCP-1; CCL5 / RANTES; CD4; CD8; CD86; CD45; Macrophages; Dendritic cells; T cells; CD8+ T cells; Immune-cell infiltration", "Immune_System-Function_inhibited/numbers_decreased": "CCL3 and chemokine CXCL1", "Controlled_Terms_Function_inhibited_Number_decreased": "CCL3 / MIP-1α; CXCL1", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": "increased Cd274 (the gene encoding Pd-l1) expression and Pd-l1 protein on AMs", "Controlled_Terms_Negative_Regulation": "PD-L1 / CD274; Immune checkpoint pathway"}, {"ID": "CANIMM/1994", "Drug": "Alectinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB11363", "Target/s_or_mechanism_of_action": "Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase.", "KEGG_Drug_ID": "D10542", "Drug_Pubchem": "49806720", "STR_LINK_(SMILES)": "CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O", "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Anaplastic Large Cell Lymphoma (ALCL)", "Animal_Strain_used": "NSG", "Cell_line_used_to_induce_tumor_in_mice": "Karpas 299 cells", "Dose": "alectinib ((20mg/kg -35mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/1995", "Drug": "Crizotinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB08865", "Target/s_or_mechanism_of_action": "Crizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d'Origine Nantais (RON). Abnormalities in the ALK gene caused by mutations or translocations may lead to expression of oncogenic fusion proteins. In patients with NSCLC, they have the EML4-ALK gene. Crizotinib inhibits ALK tyrosine kinase which ultimately results in decreased proliferation of cells that carry the genetic mutation and tumour survivability.", "KEGG_Drug_ID": "D09731", "Drug_Pubchem": "11626560", "STR_LINK_(SMILES)": "C[C@@H]OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl", "Single/Combination": "Single Drug", "PMID": "31540894", "Cancer_Type": "Lymphoma", "Cancer_Type_Description": "Lymphoma - Anaplastic Large Cell Lymphoma (ALCL)", "Animal_Strain_used": "NSG", "Cell_line_used_to_induce_tumor_in_mice": "Karpas 299 cells", "Dose": "crizotinib(10mg/kg -25mg/kg)", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": "HLA-A,B,C", "Controlled_Terms_Function_enhanced_Number_increased": "HLA class I antigen", "Immune_System-Function_inhibited/numbers_decreased": "PD-L1", "Controlled_Terms_Function_inhibited_Number_decreased": "PD-L1 / CD274; Immune checkpoint pathway", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2015", "Drug": "Imatinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB00619", "Target/s_or_mechanism_of_action": "It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia.", "KEGG_Drug_ID": "D01441", "Drug_Pubchem": "5291", "STR_LINK_(SMILES)": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "Single/Combination": "Single Drug", "PMID": "31704808", "Cancer_Type": "Colon Cancer", "Cancer_Type_Description": "Colon Tumor", "Animal_Strain_used": "BALB/c", "Cell_line_used_to_induce_tumor_in_mice": "CT26", "Dose": "Imatinib (0, 10, or 50 mg/kg)", "Technique": null, "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "T reg cells", "Controlled_Terms_Function_inhibited_Number_decreased": "Regulatory T cells / Tregs", "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2050", "Drug": "Axitinib", "Drug_category": "Tyrosine kinase inhibitor", "Drugbank_ID": "DB06626", "Target/s_or_mechanism_of_action": "Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.", "KEGG_Drug_ID": "D03218", "Drug_Pubchem": "6450551", "STR_LINK_(SMILES)": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1", "Single/Combination": "Single Drug", "PMID": null, "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Lung - Lewis Lung Carcinoma", "Animal_Strain_used": "C57BL/6", "Cell_line_used_to_induce_tumor_in_mice": "LLC1", "Dose": "25 mg/kg/day", "Technique": "Flow Cytometry", "Controlled_Technique": "Flow cytometry", "Immune_System-Function_enhanced/numbers_increased": null, "Controlled_Terms_Function_enhanced_Number_increased": null, "Immune_System-Function_inhibited/numbers_decreased": "intratumoral innate immune cells- tumor-promoting differentiated mast cells\n (CD45+, C117+, FcεR1α+) and TAMs (CD45+, CD11b+,\n F4/80+) , regulatory T cells,Monocytes and\n granulocytes", "Controlled_Terms_Function_inhibited_Number_decreased": "CD11b / ITGAM; CD45; Regulatory T cells / Tregs; Tumor-associated macrophages / TAMs; Monocytes; Neutrophils / granulocytes; T cells", "Immune_System_function_unaffected": "Intratumoral T cells and CD8 T cells", "Controlled_Terms_Unaffected": "CD8; T cells; CD8+ T cells", "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2102", "Drug": "Vinblastine (VBL)", "Drug_category": "Vinca alkaloids", "Drugbank_ID": "DB00570", "Target/s_or_mechanism_of_action": "Binds tubulin/microtubules and inhibits microtubule polymerization.", "KEGG_Drug_ID": "D08675", "Drug_Pubchem": "241903", "STR_LINK_(SMILES)": "CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1", "Single/Combination": "Single", "PMID": "37652576", "Cancer_Type": "Colorectal Cancer", "Cancer_Type_Description": "Colorectal cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "MC38", "Dose": "VBL 1.25 mg/kg", "Technique": "M1-like TAM polarization, macrophage phagocytosis, CD8⁺ T-cell activation/infiltration", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "M2-like TAM phenotype/function; TAM-mediated immunosuppression", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; Tumor-associated macrophages / TAMs", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}, {"ID": "CANIMM/2133", "Drug": "Vinblastine (VBL)", "Drug_category": "Vinca alkaloids", "Drugbank_ID": "DB00570", "Target/s_or_mechanism_of_action": "Binds tubulin/microtubules and inhibits microtubule polymerization.", "KEGG_Drug_ID": "D08675", "Drug_Pubchem": "241903", "STR_LINK_(SMILES)": "CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1", "Single/Combination": "Single", "PMID": "37652576", "Cancer_Type": "Lung Cancer", "Cancer_Type_Description": "Pulmonary/lung cancer", "Animal_Strain_used": "C57BL/6J", "Cell_line_used_to_induce_tumor_in_mice": "LLC (Lewis lung carcinoma)", "Dose": "VBL 1.25 mg/kg", "Technique": "M1-like TAM polarization", "Controlled_Technique": null, "Immune_System-Function_enhanced/numbers_increased": "M2-like TAM-associated immunosuppression", "Controlled_Terms_Function_enhanced_Number_increased": "Macrophages; Tumor-associated macrophages / TAMs", "Immune_System-Function_inhibited/numbers_decreased": null, "Controlled_Terms_Function_inhibited_Number_decreased": null, "Immune_System_function_unaffected": null, "Controlled_Terms_Unaffected": null, "Negative_Immune_System_regulation_-Function_enhanced/numbers_in": null, "Controlled_Terms_Negative_Regulation": null}]